

JAMES R. BERENSON, M.D.

Curriculum Vitae

July 2025

Business Addresses:

- (Non-Profit) Institute for Myeloma & Bone Cancer Research (IMBCR)
9201 Sunset Blvd., Suite 300
W. Hollywood, CA 90069
(310) 623-1214 tel
(310) 623-1120 fax
<http://www.imbcr.org>
- (Practice) Berenson Cancer Center
9201 W. Sunset Blvd., Suite 310
W. Hollywood, CA 90069
(310) 623-1222 tel
(310) 623-1122 fax
<http://www.berensoncancercenter.com>
- (Clinical Trials) ONCOtherapeutics, Inc.
9201 W. Sunset Blvd., Suite 307
W. Hollywood, CA 90069
(310) 623-1200 tel
(310) 623-1121 fax
<http://www.ONCOtherapeutics.com>
- (Biotech group) ONCOtracker, Inc.
9201 Sunset Blvd., Suite 307
W. Hollywood, CA 90069
(424) 204-0726
(310) 623-1120 fax
<http://www.ONCOtracker.com>
- Titles:** Medical & Scientific Director
President & Chief Executive Officer
- Cell:** (310) 420-9649
- IMBCR e-mail:** jberenson@imbcr.org
Business e-mail: jberenson@berensoncancercenter.com

EDUCATION

1970-1971	Cornell University Ithaca, NY
1971-1973	Stanford University (B.S. with Distinction in Biology) Palo Alto, CA
1973-1977	University of California, San Diego (M.D.) 9500 Gilman Drive (campus) 200 W. Arbor Drive (medical center) San Diego, CA 92093

POSTGRADUATE TRAINING, EXPERIENCE AND APPOINTMENTS

2014-Present	President & Chief Executive Officer ONCOtracker 9201 West Sunset Blvd., Suite 307 West Hollywood, CA 90069
2003-Present	Medical & Scientific Director President & Chief Executive Officer Institute for Myeloma & Bone Cancer Research (IMBCR) 9201 West Sunset Blvd., Suite 300 W. Hollywood, CA 90069
2003-Present	Medical & Scientific Director President & Chief Executive Officer James R. Berenson, M.D., Inc./Berenson Cancer Center 9201 West Sunset Blvd., Suite 310 W. Hollywood, CA 90069
2003-Present	Medical & Scientific Director President & Chief Executive Officer ONCOtherapeutics 9201 West Sunset Blvd., Suite 317 W. Hollywood, CA 90069

2003-2004	Physician Synergy Hematology/Oncology Medical Group 5901 W. Olympic Blvd., Suite 407 Los Angeles, CA 90036
2000-2003	Director Multiple Myeloma and Bone Metastasis Programs, Dept. of Medicine / Div. of Hematology-Oncology Cedars-Sinai Medical Center 8700 Beverly Blvd., Rm. 5416 Los Angeles, CA 90048
1998-2000	Chief of Cancer Research Associate Director of Research VA Greater Los Angeles Healthcare System (VAGLAHS) 11301 Wilshire Blvd. Los Angeles, CA 90073
1997-2003	Professor of Medicine Dept. of Medicine / Div. of Hematology-Oncology UCLA School of Medicine Los Angeles, CA 90095
1992-1998	Chief of Medical Oncology Dept. of Hematology/Oncology West Los Angeles Veterans Administration Medical Center 11301 Wilshire Blvd. Los Angeles, CA 90073
1991-1997	Associate Professor of Medicine in Residence Medicine/Hematology-Oncology UCLA School of Medicine 10833 Le Conte Ave. Los Angeles, CA 90095 Staff Physician Dept. of Hematology-Oncology Dept. of Veterans Affairs Medical Center 11301 Wilshire Blvd. Los Angeles, CA 90073
1983-1991	Assistant Professor of Medicine in Residence Medicine/Hematology-Oncology UCLA School of Medicine 10833 Le Conte Ave. Los Angeles, CA 90095

	Staff Physician Division of Hematology-Oncology Department of Medicine Veterans Affairs Medical Center West Los Angeles, CA
1982-1983	Adjunct Assistant Professor of Medicine Medicine/Hematology-Oncology, UCLA School of Medicine Los Angeles, CA
1981-1983	Researcher in the Laboratory of Dr. K. Calame Department of Biological Chemistry UCLA School of Medicine March of Dimes, NIH NSRA, and Damon-Runyon- Walter Winchell Fellowship Support
1980-1983	Fellowship Training in Hematology-Oncology Dept. of Medicine UCLA School of Medicine William Hocking, MD Center for Health Sciences Los Angeles, CA 90095
1977-1980	Internship and Residency Straight Internal Medicine University of Utah Medical Center James Williams, MD 50 N. Medical Drive Salt Lake City, UT 84132
1974-1977	Medical Student Research Assistant (Advisor: Dr. Alex Fefer) Medicine, Hematology-Oncology University of Washington
1973-1974	Medical Student Research Assistant (Advisor: Dr. Nathan Kaplan) Department of Biochemistry University of California at San Diego San Diego, CA
1972	Research Assistant Department of Psychology Stanford University Stanford, CA

1970-1971	Research Assistant (Advisor: Dr. Carl Sagan) Department of Astronomy Cornell University Ithaca, NY
1969-1970	NSF Summer Fellow (Advisor: Dr. E.A. Mirand), Department of Medicine Roswell Park Memorial Institute Buffalo, NY

MEDICAL LICENSES AND CERTIFICATION

1977-Present	Diplomate, National Board of Medical Examiners
1980-Present	California Board of Medical Examiners (G042018)
1980-Present	Diplomate in Internal Medicine, American Board of Internal Medicine
1985-Present	Diplomate in Medical Oncology, American Board of Internal Medicine

HONORS AND AWARDS

1964-1970	Gold Medals, Northwest Science Fair
1965	Eagle Scout
1974	Phi Beta Kappa
1982	March of Dimes Special Fellowship in Postgraduate Medicine
1982	Who's Who in California
1982-1984	Damon Runyon-Walter Winchell Fellow
1983	Outstanding Young Men of America
1989	Ralph Goldman Research Award
1990	Who's Who Among Rising Young Americans
1991	Who's Who in Health and Medical Services
1991	Ralph Goldman Research Award (Sponsor of award recipient: Jin Cao, M.D.)

1992	Man of the Year
1995	Sterling Who's Who
1999	2000 Outstanding Scientists of the 20 th Century
2006	Madison Who's Who
2009-2010	Emerald Who's Who
2009	Distinguished Professionals Who's Who
2019	Doctors: Best of West Hollywood 2019
2021	2021 Southern California Super Doctors
2022	2022 Southern California Super Doctors
2022	2022 Hero in Healthcare for Blood Cancer Awareness Month
2023	2023 Southern California Super Doctors
2023	2023 Castle Connolly Top Doctor of Los Angeles
2024	20 th Anniversary of the IMBCR Honoree

SOCIETIES, MEMBERSHIPS AND COMMITTEES

1973-1977	American Medical Student Association (President) University of California, San Diego
1980-Present	American College of Physicians (ACM)
1984-2000	American Federation for Clinical Research
1984-Present	American Society of Clinical Oncology (ASCO)
1984-Present	Physicians for Social Responsibility
1988-Present	American Association for Cancer Research (AACR)
1990-Present	Scientific Board, International Myeloma Foundation
1990-1993	Executive Board, International Myeloma Foundation

1990-2003	Myeloma Committee, Southwest Oncology Group
1992-Present	American Society of Hematology (ASH)
1993	Judge, California State Science Fair
1993-2000	Medical Advisory Board, Lymphoma Research Foundation
1993-Present	American Association for the Advancement of Science (AAAS)
1993-1999	Principal Investigator, Southwest Oncology Group DVA Medical Center, West Los Angeles
1994-1999	Associate Director, Hematologic Malignancies, Jonsson Comprehensive Cancer Center
1994-1995	Chairman, Scientific Review Committee, Lymphoma Research Foundation
1994-1999	Member, Finance and Planning Committee and Executive Board, BACRA, Inc.
1994-2000	Member, Jonsson Comprehensive Cancer Center Trials Editorial Board
1994-2000	Executive Board, BBRI, Inc.
1995-Present	Member, ABMTR (Autologous Blood & Marrow Transplant Registry) Multiple Myeloma Working Committee
1995-1998	Member, Scientific Subcommittee on Neoplasia, ASH
1995-1997	Scientific Organizing Committee, Vth International Workshop on Multiple Myeloma
1996-Present	Multiple Myeloma Working Committee, Autologous Blood & Marrow Transplant Registry
1997-Present	Member, Editorial Board, Cancer, Research, Therapy and Control
1997-Present	Editorial Board, Current Drugs Group
1997-2010	Internet Conference Moderator, Strategic Implications International
1997-2005	Co-Chair, ASCO Committee to Formulate Bisphosphonate Guidelines
1997-Present	Member, Multiple Myeloma Research Foundation - Scientific Advisory Board, Kathy Giusti Myeloma Research Foundation

1998-2000	Deficit Spending Committee, BBRI, Inc.
1998-2000	Vice Chair, Myeloma Committee, Southwest Oncology Group
1998-1999	Member, Scientific Organizing Committee of International Myeloma Workshop VI
1998-1999	Member, Scientific Organizing Committee of International Society Hematology Meeting, 1999
1998-Present	Member, Myeloma International Prognostic Index Working Group
1999-2000	Executive Director Search Committee, BBRI, Inc.
1998	Founding Board of Directors, International Society for Bone Metastases, ISBM
1999-2000	Member, IMF Clinical Conference 2000
1999	Co-Chair, The First International Workshop on Virus in Myeloma
1999	Board of Directors, California Institute of Molecular Medicine
1999-2000	Membership Board, BBRI, Inc.
1999	American Society for Blood and Marrow Transplantation (ASBMT)
1999	Scientific Advisor, VIIIth International Myeloma Workshop
2000	Member, Scientific Review Committee, Concern Foundation
2001	Judge, California State Science Fair
2002-2004	Translational Grant Review Committee, Leukemia & Lymphoma Society
2004-Present	Clinical Advisory Board, Auxeris Therapeutics
2004-2012	SCOR Review Committee, Leukemia & Lymphoma Society
2004-2007	Study Section, National Institute of Health, Clinical Oncology
2005-Present	Member, IBMTR Working Group, Amyloid Study
2005-Present	Member, IBMTR Working Group, Myeloma Committee
2006-Present	Foundation Board of Directors, Leukemia, Lymphoma & Myeloma Society

10/8/2007-Present	***Member, International Myeloma Working Group on the Role of Vertebral Augmentation in Multiple Myeloma
2008–Present	Member, Myeloma Workshop 12, Guidelines, Panel 2, for Prognostic Factors and Staging Systems
2008-Present	Member, Myeloma Workshop, Panel 3, Guidelines for Standard Investigative Workshop
2009	Co-Chair, Medicom, Mastery of Myeloma Lectures
2009	Co-Chair, PER Myeloma Advisory Board, Orlando, Florida
2009	Co-Chair, MGUS Roundtable meeting in Washington, DC
2010-2018	Member, Bioethics Colloquium, Academy for Jewish Religion, Los Angeles
2012-Present	Member, Scientific Advisory Committee, International Waldenstrom's Macroglobulinemia Foundation
2015-2019	Member, American Association for Clinical Chemistry
11/2017	Co-Chair, Multiple Myeloma Research Foundation Patient Summit, Pasadena, CA
6/21-Present	Medical Advisory Board, Carakit
11/2022-Present	Scientific Advisory Board, Telo Genomics
2023-Present	Medical Advisor, MyeloMates Myeloma Support Group
2024-Present	Medical Advisory Board, mQOL

CURRENT RESEARCH INTERESTS:

Antibodies, T-cell receptors, cytokines, oncogenes, viruses, bone disease, immune therapy, and stem cell transplants in human lymphoid malignancies; treatment of metastatic bone disease and lymphoid malignancies.

IMBCR PRE-CLINICAL RESEARCH GRANTS- PRINCIPAL INVESTIGATOR

7/2023-Present	Company:	Sumitomo Pharma Oncology, Inc., Marlborough, MA
	Title:	Evaluation of Anti-Myeloma Effects of TP-3654 (PIM-1 kinase inhibitor) Alone and in Combination with Other Active Anti-Myeloma Agents <i>In Vitro</i> and <i>In Vivo</i>
12/2021-12/2022	Company:	Turning Point Therapeutics, San Diego, CA
	Title:	Evaluation of Anti-Myeloma Effects of Repotrectinib Alone and in Combination with Anti-Myeloma Agents <i>In Vitro</i> and <i>In Vivo</i> (under ONCOtracker)
9/21-8/2022	Company:	Leeds University, Leeds, England
	Title:	Evaluation of Anti-Myeloma Effects of PARP Inhibitors PJ34 and GeA-69 Alone and in Combination with the Proteasome Inhibitor Carfilzomib <i>In Vitro</i> and <i>Ex Vivo</i> (under ONCOtracker)
5/2021-8/2022	Company:	Precision Biosciences, Durham, North Carolina
	Title:	Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma (under ONCOtracker)
5/2020-Present	Company:	Compugen, Holon, Israel
	Title:	Anti-Myeloma Effects of the PVRIG and TIGIT in Combination with Anti-Myeloma Agents <i>in vitro</i> (Step I- Expression of PVRIG and TIGIT in Multiple Myeloma Bone Marrow)
4/2020-6/2022	Company:	Oncopeptides
	Title:	Evaluation of Anti-Myeloma Effects of Melflufen in Combination with Standard of Care Therapies <i>In Vivo</i> Using Human MM Xenograft Models
9/2019-Present	Company:	Karyopharm, Cambridge, MA
	Title:	Determination of the Optimal Dose and Schedule of Selinexor <i>In Vivo</i> in MM Xenograft Models
8/2014-8/2016	Company:	Sunesis Biopharmaceutical
	Title:	Assessing the Anti-Myeloma Effects of Vosaroxin <i>In Vitro</i> and <i>In Vivo</i>
7/2014-7/2016	Company:	Onyx Pharmaceutical
	Title:	Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice

7/2014-1/2018	Company: Incyte Biopharmaceutical Title: <i>In Vitro</i> and <i>In Vivo</i> Anti-Myeloma Effects of JAK1 Inhibitor (INC39110) Alone and in Combination with Immunomodulatory Drugs, Proteasome Inhibitors, Steroids, and Chemotherapeutic Agents
2/2014-2/2016	Company: Bio-Cancer Treatment International Title: <i>In Vitro</i> and <i>In Vivo</i> Anti-Myeloma Effect of PEG-BCT-100, a Recombinant Preparation of Human Enzyme Arginase 1
12/2013-12/2016	Company: Pfizer Pharmaceuticals Title: Determination of Apoptotic Effect of CXCR4 Antibody in Myeloma Tumor Cells Co-Cultured with Bone Marrow Stromal Cells Alone and in Combination with Other Anti-Myeloma Agents
2/2012-2/2014	Company: Gilead Title: Anti-Myeloma Effects of CAL-101 <i>In Vitro</i> and CAL-120 <i>In Vivo</i>
11/2010-11/2015	Company: Cephalon/Teva Title: Anti-Myeloma Effects of IFN α Administered at Five Dose Levels Using the Human Multiple Myeloma Xenograft LAG κ -1A
9/2010-11/2010	Company: Compugen Title: Evaluation of the Anti-Myeloma Effects of the TM22 Antibody <i>In Vitro</i>
8/2010-8/2012	Company: CytRx Title: Evaluation of the Anti-Myeloma Effects of the Synthetic Retinoid INNO-507 Alone and in Combination Treatment <i>In Vitro</i> and <i>In Vivo</i>
7/2010-7/2012	Company: Cephalon/Teva Title: <i>In Vivo</i> Anti-Myeloma Effects of IFN α Using Human Multiple Myeloma Xenografts
7/2010-7/2012	Company: CytRx Title: Effects of the Lyn Kinase Inhibitor INNO-406 on Osteoclast Formation and Bone Resorption
7/2010-9/2010	Company: MannKind Title: Preliminary Study to Evaluate XBP-1 Splicing in Human Multiple Myeloma Xenograft Models
6/2010-6/2012	Company: CytRx

	Title:	<i>In Vivo</i> Anti-Myeloma Effects of INNO-206 Using a Human Multiple Myeloma Xenograft
6/2010-6/2013	Company: Title:	Onyx Anti-Angiogenic Effects of Carfilzomib and ONYX 0912 Using the CAM and CAM/FB Models
6/2010-6/2012	Company: Title:	Onyx Effects of Carfilzomib in Combination with Anti-Myeloma Agents Using Human Multiple Myeloma Tumors Growing in SCID Mice
5/2010-11/2010	Company: Title:	CytRx <i>In Vivo</i> Anti-Myeloma Effects of INNO-406 Using a Human Multiple Myeloma Xenograft
4/2010-4/2012	Company: Title:	Igenica Identification of a New Membrane Target to Treat Multiple Myeloma
3/2010-3/2012	Company: Title:	Cephalon Efficacy and Tolerability of CEP-18770 in Combination with Dexamethasone and Lenalidomide Using SCID-hu Models of Multiple Myeloma
3/2010-3/2012	Company: Title:	CytRx Expression, Activation, Inactivation of Lyn in Myeloma Cells and <i>In Vitro</i> Anti-Myeloma Effects of Lyn Inhibitor INNO-406
3/2010-6/2010	Company: Title:	Compugen Determination of Expression of TM21 in Multiple Myeloma (MM) Cells <i>In Vitro</i> and in MM Xenografts and Anti-MM Effects of TM21 <i>In Vitro</i>
2/2010-5/2010	Company: Title:	Qwell <i>In Vitro</i> Anti-Myeloma Effects of Avicin D
2/2010-5/2010	Company: Title:	CytRx <i>In Vivo</i> Anti-Myeloma Effects of INNO-206 Using a Human Multiple Myeloma Xenograft
1/2010-5/2010	Company: Title:	Compugen Supplement of TM21 <i>In Vitro</i> Proposal
12/2009-4/2010	Company: Title:	CompuGen RNA from MM Patients and Tumors

11/2009-11/2012	Company: Title:	Novartis Evaluation of the Anti-MM Efficacy of LBH589 in Combination with Melphalan and Bortezomib
9/2009-12/2009	Company: Title:	Qwell CAM/FB model for screening anti-angiogenic drugs
9/2009-3/2010	Company: Title:	Celgene Evaluation of Lenalidomide and Pomalidomide Using SCID-hu Models of Multiple Myeloma
4/2009-9/2009	Company: Title:	Compugen Assessment of TM21 Serum Levels in Multiple Myeloma Patients
2/2009-7/2009	Company: Title:	Cephalon <i>In Vivo</i> Efficacy and Tolerability of Chronic Oral Dosing of CEP-18770 in Pre-clinical Models of Human Multiple Myeloma
1/2009-4/2010	Company: Title:	Millennium Bortezomib Platform Study Using SCID-hu Models of Multiple Myeloma and Plasma Cell Leukemia
11/2008-11/2010	Company: Title:	OncoGenex <i>In Vivo</i> Anti-Myeloma Effects of OGX-427
9/2008-11/2009	Company: Title:	Amgen Evaluation of the Effects of AMG 458 on Myeloma Growth <i>In Vivo</i> Using SCID-Hu Models
8/2008-3/2009	Company: Title:	PharmaMar Use of Human Multiple Myeloma Tumors Growing in SCID Mice to Determine the <i>In Vivo</i> Effects of Aplidin® (APLD) in Combination with Dexamethasone
7/2008-12/2008	Company: Title:	Cephalon <i>In Vivo</i> Effects of CEP-18770 in Combination with Anti-Myeloma Agents Using Human Multiple Myeloma Tumors Growing in SCID Mice
7/2008-9/2008	Company: Title:	Hana Bioscience Anti-tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in SCID-hu Models of Multiple Myeloma
1/2008-7/2008	Company:	Cephalon

	Title:	<i>In Vitro</i> and <i>In Vivo</i> Effects of Treanda® (Bendamistine HCl) Alone and in Combination with Arsenic Trioxide and Ascorbic Acid
7/2007-12/2007	Company:	Merck
	Title:	<i>In Vivo</i> Effects of Vorinostat in Combination with Melphalan Using a Human Multiple Myeloma Tumor, LAGκ-1B, Growing in SCID Mice
	Company:	Cephalon
	Title:	CEP-18770 + Treanda
5/2007-10/2007	Company:	Novartis
	Title:	Using <i>In Vitro</i> and <i>In Vivo</i> Studies to Optimize the Anti-tumor Effects of the HDAC Inhibitor LBH589 in Multiple Myeloma (MM)
2/2007-9/2007	Company:	ZioPharm
	Title:	Effects of the Novel Organic Arsenic Compound ZIO-101 on the Animal Model of Human MM LAGλ-1
4/2006-10/2006	Company:	Genentech
	Title:	Study on the Effects of Anti-VEGF Mab and Met Inhibitors Alone, in Combination, and in Combination with the Proteasome Inhibitor Bortezomib
4/2006-10/2006	Company:	Novartis
	Title:	RAD001
12/2005-5/2006	Company:	CuraGen
	Title:	Study on the <i>In Vivo</i> Effects of PXD101, a Novel Histone Deacetylase Inhibitor, on Human Multiple Myeloma Using the Animal Model of Human MM LAGλ-1
2/2005-8/2005	Company:	Pfizer
	Title:	Study of Celecoxib in Inhibition of Multiple Myeloma Cell Growth in Xenograft Mice

ONCOTHERAPEUTICS CLINICAL RESEARCH GRANTS- PRINCIPAL INVESTIGATOR

12/2022-Present	Company:	Incyte
	Title:	Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in Serum B-Cell Maturation

Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Disease Progression in Order to Add Lenalidomide to those Failing the Ruxolitinib/Methylprednisolone Combination

4/2022-12/2022	Company: Title:	Abbvie Efficacy of Venetoclax in Combination with Other Multiple Myeloma Medications for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
4/2022-Present	Company: Title:	Abbvie The Incidence of Translocation t(11;14) among Patients with Multiple Myeloma
5/2020-Present	Company: Title:	Karyopharm A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-Containing Therapy
11/2018-Present	Company: Title:	Takeda Oncology A Phase 2, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients
2017-Present	Company: Title:	Bio-Cancer Treatment International Ltd. Recombinant Human Arginase 1 (rhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD
2016-Present	Company: Title:	Bristol-Myers Squibb A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone among High Risk Relapsed/Refractory Multiple Myeloma Patients
2016-Present	Company: Title:	Incyte Corporation A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
2014-Present	Company: Title:	Celgene A Phase 2 Study of Pomalidomide, as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen
2014-Present	Company:	Millennium/Takeda

	Title:	A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their last Combination Regimen Containing Either Bortezomib or Carfilzomib
2014-2018	Company: Title:	Onyx Pharmaceuticals/Amgen, Inc. A Phase 2 Study of Weekly 70 mg/m ² Carfilzomib with or without Steroids for Multiple Myeloma Patients Refractory to 27 mg/m ² Carfilzomib with or without Steroids
2014-2018	Company: Title:	Bristol-Myers Squibb A Phase 2 Single Arm Study of Safety of Elotuzumab Administered over Approximately 60 Minutes in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
2013-2017	Company: Title:	Onyx Pharmaceuticals/Amgen, Inc. CHAMPION 2 trial: A Multicenter, Open-label, Phase 1/2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone Induction Followed by Randomization to Carfilzomib Maintenance versus Observation in New Diagnosed Multiple Myeloma Patients
2012-2018	Company: Title:	Onyx Pharmaceuticals/Amgen, Inc. CHAMPION 1 trial: A Phase 1/2 Study of Weekly Carfilzomib in Combination with Dexamethasone for Progressive Multiple Myeloma
2012-2017	Company: Title:	Onyx Pharmaceuticals/Amgen, Inc. A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
2011-2017	Company: Title:	Celgene Corporation A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
2011-2016	Company: Title:	Millennium Pharmaceuticals, Inc. A Phase II Study of Subcutaneous Bortezomib-Regimens for Patients with Relapsed/Refractory Multiple Myeloma Failing Prior Intravenous Bortezomib-Containing Regimens
2011-2016	Company: Title:	Millennium Pharmaceuticals, Inc. Correlation Between Serum Vitamin D Levels and the Incidence and Severity of Peripheral Neuropathy among Multiple Myeloma

Patients who have Previously Received Treatment with
Bortezomib or Thalidomide

2011-2015	Company:	Millennium Pharmaceuticals, Inc.
	Title:	A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy in Relapsed/Refractory Multiple Myeloma Patients Retreated with Bortezomib
2011-2015	Company:	Onyx Pharmaceuticals
	Title:	A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Failing Bortezomib-Containing Regimens
2010-2015	Collaborator:	David Geffen School of Medicine, University of California at Los Angeles
	Title:	Evaluation of the Risk of Skin Cancer in Multiple Myeloma (MM) Patients
2010-2015	Company:	Cephalon, Inc.
	Title:	A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma (C10953/6270)
2010-2011	Company:	CytRx Corporation
	Title:	A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Pacitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-Small Lung Cancer
2009-2011	Company:	Millennium Pharmaceuticals, Inc.
	Title:	An Open-Label, Dose-Escalation, Phase 1 study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma (C16004)
2009-2015	Company:	Celgene Corporation
	Title:	A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory Multiple Myeloma (MM) (RV-MM-PI-0533)
2008-2015	Company:	Cephalon, Inc.
	Title:	An Open-Label Study of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma (C18083/1063/MM/US)

2008-2011	Company: Title:	Vidacare Corporation A Trial of a New Powered Bone Marrow Core Biopsy System (OnControl™ by Vidacare) Compared to Traditional Manual Devices
2008-2011	Company: Title:	Millennium Pharmaceuticals, Inc. and Centocor Ortho Biotech Services, LLC A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Newly Diagnosed Multiple Myeloma (MM) (X05272, DOXILMMY2010)
2008-2016	Company: Title:	Novartis Pharmaceuticals, Corp. A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM) (CLBH589BUS15T)
2008-2011	Company: Title:	Medtronic Spine, LLC A Retrospective Study to Evaluate Bone Loss and Disease in Patients with MGUS
2008-2010	Company: Title:	Gloucester Pharmaceuticals, Inc. A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients with Relapsed or Refractory Disease (GPI-08-0006)
2007-2008	Company: Title:	National Institute of Health (NIH) RADAR: Novel Multiple Myeloma Drugs (R01)
2007-2010	Company: Title:	Novartis Pharmaceuticals, Corp. Factors that Determine Overall Survival among Patients with Multiple Myeloma Treated with Zoledronic Acid (CZOL446GU5A35T)
2007-2008	Company: Title:	CuraGen Corporation A Phase II Study of Belinostat in Combination with Bortezomib in Patients with Relapsed, Refractory Multiple Myeloma (PXD101-CLN16)
2006-2009	Company: Title:	Attenuon, LLC A Randomized phase II trial of ATN-224 in Combination with Temozolomide or Temozolomide followed by ATN-224 in Patients with Advanced Melanoma (ATN-224-008)

2006-2009	Company: Title:	Attenuon, LLC A Phase I/II Study of ATN-224 and Bortezomib in Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib (ATN-224-007)
2006-2009	Company: Title:	ZioPharm Oncology, Inc. A Phase II Trial of Zio-101 in Advanced Multiple Myeloma (SGL2001b)
2006-2009	Company: Title:	ZioPharm Oncology, Inc. A Phase I/II Trial of Zio-101 in Advanced Multiple Myeloma (SGL2001)
2005-2008	Company: Title:	Novartis Pharmaceuticals, Corp. A Prospective, Randomized, Double-blind, Multi-center Comparative 3-arm Trial on Efficacy and Safety of Zoledronic Acid 4 mg (Monthly vs. 3-monthly vs. placebo) beyond 1 Year of Treatment with Zoledronic Acid in Patients with Bone Lesions from Multiple Myeloma or Breast Cancer (CZOL446E2105)
2005-2008	Company: Title:	Millennium Pharmaceuticals, Inc. A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma
2005-2008	Company: Title:	Cytogen Corporation A Phase I Study of Samarium Sm-153 Lexidronam Combined with Bortezomib for Patients with Relapsed or Refractory Multiple Myeloma (Velsam)
2005-2006	Company: Title:	CuraGen Corporation A Phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma (PXD-101-301G)
2005-2006	Company: Title:	Attenuon, LLC An Open Label, Dose Escalation Phase I Study of the Safety, Pharmacodynamics, Pharmacokinetics of ATN-224 Capsules in Patients with Advanced Hematologic Malignancies (ATN-224-001)
2004-2008	Company: Title:	Novartis Pharmaceuticals, Inc. A Phase I/II Trial of Zometa in Patients with Monoclonal Gammopathy of Undetermined Significance (ZOMGUS-001)
2004-2016	Company:	Pfizer

	Title:	A Prospective Phase I/II Open-label, Safety & Efficacy Study of Celecoxib Treatment in Patients with Smoldering or Early Stage (I/II) Multiple Myeloma (COXAON 0509-056)
2004-2005	Company:	Kyphon, Inc.
	Title:	A Multicenter, Prospective, Randomized, Controlled Study to Evaluate the Safety & Effectiveness of KyphX HV-R as a Fixation Material in Kyphoplasty Procedures in Patients with painful Vertebral Body Compression Fractures Due to Multiple Myeloma of Osteolytic Metastatic Breast Cancer (SP0401)
2004-2006	Company:	Cell Therapeutics, Inc. and Millennium Pharmaceuticals, Inc.
	Title:	A Phase I/II Trial of Arsenic Trioxide / Bortezomib Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma (AB-001)
2003-2004	Company:	Cell Therapeutics Inc.
	Title:	A Phase I/II Study of Arsenic Trioxide Twice-Weekly Dosing in Patients with Multiple Myeloma (CTI 1063)
2003-2004	Company:	Cell Therapeutics, Inc.
	Title:	A Prospective, Open Label, Safety & Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma (MAC 001)
2003-2004	Company:	Genoptix, Inc.
	Title:	Research Protocol for a Study on the Optical Analysis of Multiple Myeloma Cells for their Drug Response Profile (Genoptix 001)

**JAMES R BERENSON, MD CLINICAL AND PRE-CLINICAL RESEARCH GRANTS-
PRINCIPAL INVESTIGATOR**

1/2025-Present	Company:	mQOL
	Title:	A Prospective Observational Study to Deploy mQOL into Multiple Myeloma Patient Population to Assess the Accessibility, Completion Rate, Time Burden, and Utility of Capturing, Aggregating and Reporting Symptom & Quality of Life (QoL) Data
7/2023-2025	Company:	Bristol Myers Squibb

	Title:	A Phase 3, Two-Stage, Randomized , Multicenter, Open-Label study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma
7/2023-2024	Company:	Pfizer
	Title:	MagnetisMM-RW Study/ Protocol Number: C1071013- A Multi-National, Prospective, Non-Interventional Study of Standard of Care in Participants with Multiple Myeloma who are Refractory to at Least 1 Proteasome Inhibitor, 1 Immunomodulatory Agent, and 1 Anti-CD38 Monoclonal Antibody
4/2023-Present	Company:	Janssen Research & Development
	Title:	HALO Study: 54767414NAP4001- A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
4/2022-2024	Company:	Takeda
	Title:	TAK-573-1501, A Phase 1/2 Open-Label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 as a Single Agent in Patients with Refractory Multiple Myeloma
2/2022-Present	Company:	EMN
	Title:	A Phase 3 Randomized, Open-Label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma
1/2022-Present	Company:	ORIC
	Title:	An Open-label Phase 1b Study of Oric-533 in Patients with Relapsed or Refractory Multiple Myeloma
2020	Company:	Ceracor
	Title:	A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects with Relapsed or Refractory Multiple Myeloma
2018-19	Company:	Aduro Biotech
	Title:	A Phase 1/2 Dose Escalation, Safety and Tolerability Study of BION-1301 Adults with Relapsed or Refractory Multiple Myeloma
2015-2018	Company:	Amgen, Inc.

	Title:	A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma
2015-2017	Company: Title:	Incyte Corporation A Phase 1a/1b Open-Label, Dose-Escalation, Safety, and Tolerability Study of INCB052793 in Subjects with Advanced Malignancies
2015-2016	Company: Title:	Karyopharm Therapeutics, Inc. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with a Proteasome Inhibitor and an Immunomodulatory Drug
2014-Present	Company: Title:	Onyx Pharmaceuticals/Amgen, Inc. Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Patients
2011-2013	Company: Title:	Millennium Pharmaceuticals An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma
2004-2007	Company: Title:	Seattle Genetics, Inc. A Phase I Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma (SG040-0001)
2003-2004	Company: Title:	Xcyte Therapies, Inc. A Randomized Phase II Study of Xcellerated T-Cells with or without Prior Fludarabine Therapy in Patients with Multiple Myeloma (XT005)
2003-2004	Company: Title:	Celgene Corporation A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Combination Thalidomide Plus Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma (THAL-MM-003)
2003-2004	Company:	Celgene Corporation

	Title:	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety & Efficacy of Single Agent CC-5013 in Subjects with Relapsed / Refractory Multiple Myeloma (CC-5013-MM-014)
2003-2004	Company:	Millennium Pharmaceuticals, Inc.
	Title:	Prospective, Open Label, Safety & Efficacy Study of Combination Treatment with PS-341 & Melphalan in Patients with Relapsed or Refractory Multiple Myeloma (I34101-009)
2003-2004	Company:	Millennium Pharmaceuticals, Inc.
	Title:	A Phase II, Open-Label, Extension Study to Provide PS-341 to Patients Who Previously Participated in a PS-341 Clinical Study & Who May Benefit from Re-treatment with Continuation of PS-341 Therapy (M34101-029)
2003-2004	Company:	Millennium Pharmaceuticals, Inc.
	Title:	A Randomized, Open-Label, Phase II Study of 2 Doses of PS-341 Alone or in Combination with Dexamethasone in Patients with Multiple Myeloma Who Have Failed to Respond to or Relapsed Following Front-line Therapy (M34100-24)
2003-2004	Company:	Millennium Pharmaceuticals, Inc.
	Title:	An Open-Label Phase II Study of PS-341 Alone or in Combination with Multiple Myeloma Who Have Relapsed Following Front-line Therapy & are Refractory to Their Most Recent Therapy (M34100-025)
2003-2004	Company:	Novartis Pharmaceuticals, Inc.
	Title:	The Effect of Zoledronic Acid Infusion Rate on Pharmacokinetics, Pharmacodynamics, & Renal Function in Patients with Multiple Myeloma or Prostate Cancer & Bone Metastases (CZOL 446E-510)
2003-2004	Company:	Chugai
	Title:	A Phase I/II, 24-week, Multicenter, Double-blinded, Randomized, Dose-ranging Study to Evaluate the Safety & Efficacy of a Humanized Monoclonal Antibody to PTHrP Versus Zoledronic Acid in patients with Breast Cancer Metastatic to Bone (CAL 03)
2002-2003	Company:	Ariad
	Title:	Animal Study of Src Inhibitors (AP-23451 and AP-22317) in Multiple Myeloma
2002-2003	Company:	Multiple Myeloma Research Foundation
	Title:	Multiple Myeloma Plasma Cells Express RANKL and Induce the Formation of Bone-Resorbing Osteoclasts

2002-2003	Company: Grant	NORD
2002-2003	Company: Product: Title:	Pharmacia Celecoxib A Prospective, Open-label, Efficacy Study of Celecoxib Treatment in Patients with Smoldering or Early Stage (grade I and II) Multiple Myeloma
2002-2003	Company: Product: Title:	Novartis Gleevec A Phase II Study of Safety and Efficacy of Gleevec in Patients with Multiple Myeloma
2002-2003	Company: Product: Title:	Millennium PS-341 A Prospective, Open-Label, Safety and Efficacy Study of Combination Treatment with PS-341 and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma, STUDY# 134101-009
2002-2003	Company: Title:	Pharmacia, A Phase I/II Study of the Safety and Efficacy of PNU-166196A in Adult Patients with Multiple Myeloma that Has Progressed on Prior Chemotherapy
2002-2003	Company: Title:	Ariad Pharmaceuticals Pre-clinical Studies of a Src Inhibitor in Myeloma and Bone Metastasis
2002-2003	Company: Title:	Kramer Foundation Studies on the Biology of Myeloma
2001-2002	Company: Title:	AMGEN OPG-990746 – A Randomized, Double-Blind, Active-Controlled, Single-Dose Phase I Study to Evaluate the Safety and Tolerability of AMGN-0007 in Patients with Lytic Bone Metastases
2001-2002	Company: Title:	AMGEN A Randomized, Double-Blind, Active-Controlled, Single-Dose Phase I Study to Evaluate the Safety and Tolerability of AMG162 in Patients with Cancer-Related Bone Metastases
2001-2002	Company:	Celgene Corporation

	Title:	Thalidomide and Prednisone for Primary Amyloidosis: A Phase II Study
2001-2002	Company:	Cell Therapeutics, Inc.
	Title:	Phase I/II Study of Arsenic Trioxide Twice-Weekly Dosing in Patients with Multiple Myeloma
2001-2002	Company:	Chugai Biopharmaceuticals, Inc.
	Title:	CAL-02 – An Open-Label, Ascending, Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Humanized Monoclonal Antibody, CAL, Administered Intravenously to Patients with Lytic or Mixed Lytic/Blastic Bone Metastases
2001-2002	Company:	Kramer Foundation
	Title:	Studies on the Biology of Myeloma
2001-2002	Company:	Millennium Pharmaceuticals
	Title:	M34100-025 – An Open-Label Phase II study of PS-341 Alone or in Combination with Dexamethasone in Patients with Multiple Myeloma who have Relapsed
2001-2002	Company:	Millennium Pharmaceuticals
	Title:	Protocol 029 – A Phase II, Open-Label, Extension Study to Provide PS-341 to Patients who Previously Participated in a PS-341 Clinical Study Who May Benefit from Re-Treatment with or Continuation of PS-341 Therapy
2001-2003	Company:	Peninsula Community Foundation
	Title:	Novel Therapeutic Approaches to Multiple Myeloma
2000-2001	Company:	Kramer Foundation
	Title:	Studies on the Biology of Myeloma
2000-2001	Company:	Novartis Pharmaceuticals, Inc
	Title:	Protocol 506: The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function
2000-2001	Company:	Pharmacia Corporation
	Title:	A Phase I Study of SD 7784, a Small Molecule Inhibitor of the $\alpha V\beta 3$ Integrin in Patients with Multiple Myeloma Who Failed Prior Chemotherapy
Have		
2000-2001	Company:	Ortho Biotech

	Title:	The Effects of PROCRIT (Epoetin alfa) on Hemoglobin, Symptom Distress and Quality of Life during Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients with Mild to Moderate Anemia
2000-2001	Company:	AMGEN
	Title:	The role of OPG, RANK, and RANKL in the Pathogenesis of Multiple Myeloma
2000-2001	Company:	Novartis Pharmaceuticals, Inc.
	Title:	Inhibitory Effects of Bisphosphonates in Multiple Myeloma - a Laboratory Study
2000-2001	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Evaluating Zoledronate plus Standard Therapy versus Placebo plus Standard Therapy in Patients with Recurrent Carcinoma of the Prostate Who are Asymptomatic with Castrate Levels of Testosterone and Having Rising PSA levels without Radiologically Evident Metastatic Disease
2000-2001	Company:	Novartis Pharmaceuticals, Inc.
	Title:	An Open-Label, Single Intravenous Infusion Dose Study to Determine the Pharmacokinetics and Pharmacodynamics of Zoledronate in Cancer Patients with Bone Metastases
2000-2001	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Phase II Dose-Ranging Trial of Single-Agent Zoledronate for Relapse/Refractory Multiple Myeloma – US01
2000-2001	Company:	Novartis Pharmaceuticals, Inc.
	Title:	An Open-label, Randomized, Multicenter Clinical Study to Investigate the Efficacy and Tolerability of Intravenous Zometa (zoledronate) 8 mg in Patients with Metastatic Bone Lesions Due to Breast Cancer or Multiple Myeloma – INT-ARE 03,
1999-2000	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Evaluating Zoledronate plus Standard Therapy versus Placebo Plus Standard Therapy in Patients with Recurrent Carcinoma of the Prostate who are Asymptomatic with Castrate Levels of Testosterone and have Rising PSA Levels without Radiologically-Evident Metastatic Disease
1999-2000	Company:	Kramer Foundation
	Title:	Molecular Mechanisms Leading to Multiple Myeloma

1999-2000	Company: Title:	Novartis Pharmaceuticals, Inc. An Open-Label, Single Intravenous Infusion Dose Study to Determine the Pharmacokinetics and Pharmacodynamics of Zoledronate in Cancer Patients with Bone Metastases
1999-2001	Company: Title:	Novartis Pharmaceuticals, Inc. A Randomized, Double-Blind, Multicenter Comparative Trial of IV Zoledronate (4 mg & 8 mg) versus IV Aredia (90 mg) as an Adjunct to Standard Therapies, in the Treatment of Multiple Myeloma and Breast Cancer Patients with Cancer-Related Bone Lesions
1998-2001	Company: Title:	Novartis Pharmaceuticals, Inc. Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 mg & 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients with Any Cancer with Bone Metastases Other than Breast Cancer, Multiple Myeloma or Prostate Cancer
1999-2001	Company: Title:	Novartis Pharmaceuticals, Inc. A Double-Blind, Multi-Centered, Randomized Safety and Efficacy Trial of Intravenous Aredia (90 mg) versus Placebo for the Palliation of Bone Pain in the Patient with Advanced Prostate Cancer
1999-Present	Company: Title:	Novartis Pharmaceuticals, Inc. An Open-label, Randomized, Multicenter Evaluation of the Safety and Tolerability of Pamidronate 90 mg Administered as an Intravenous Infusion over 4, 2, or 1 hour
1999-Present	Company: Title:	Novartis Pharmaceuticals, Inc. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Comparative Safety and Efficacy Study of IV Zoledronate (4 mg & 8 mg) in Prostate Cancer Patients with Metastatic Bone Lesions Receiving Antineoplastic Therapy
1999-Present	Company: Title:	Novartis Pharmaceuticals, Inc. Open-Label, Fixed Ascending, Dose Ranging, Safety Trial of Intravenous Injection Bolus of Zoledronate in Non-Small Cell Lung and Prostate Cancer Patients with Bone Metastases
1998-2000	Company: Title:	Novartis Pharmaceuticals, Inc. A Double-Blind, Multi-Centered, Randomized Safety and Efficacy Trial of Intravenous Zoledronate (4 mg) versus Placebo

James R. Berenson, MD

for the Palliation of Bone Pain in the Patient with Advanced Prostate Cancer

1998-2000	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Double-Blind, Multi-centered, Randomized Safety and Efficacy trial of Intravenous Aredia (90 mg) versus Placebo for the Palliation of Bone Pain in the Patient with Advanced Prostate Cancer
1998-1999	Company:	Kramer Foundation
	Title:	Studies on the Biology of Myeloma
1997-1999	Company:	Women's Cancer Epidemiology Study Group
	Title:	A Statewide Case Control Study of Myeloma
1997-1999	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Randomized, Double-Blind Study of Two Doses of Zoledronate and Aredia 90 mg in the Treatment of Tumor-Induced Hypercalcemia Protocol
1997-1999	Company:	Novartis Pharmaceuticals, Inc.
	Title:	An Open-Label, Randomized, Multi-Center Evaluation of the Safety and Tolerability of Pamidronate (90 mg) Administered as an Intravenous Infusion over 4, 2, or 1 Hour
1997-1999	Company:	Novartis Pharmaceuticals, Inc.
	Title:	A Phase II Dose-Ranging Trial of Single-Agent Aredia for Relapsed / Refractory Multiple Myeloma
1997-1999	Company:	Amgen, Inc.
	Title:	Assessment of Minimal Residual Disease in Autografts and Peripheral Blood of G-CSF and Stem Cell Factor Mobilized Myeloma Patients Undergoing Autologous Transplants
1997-1998	Company:	Novartis Pharmaceuticals, Inc.
	Title:	An Open Label, Fixed Descending, Dose Ranging, Safety trial of Intravenous Injection Bolus of Zoledronate in Non-Small Cell Lung and Prostate Cancer Patients with Bone Metastases
1997-1998	Company:	Kramer Foundation
	Title:	Studies on the Biology of Myeloma
1996-1998	Company:	CIBA-Geigy
	Title:	Phase II Double-blind, Randomized, Dose ranging, Dose Regimen, Safety and Efficacy Trial of Rapid Intravenous Infusion

James R. Berenson, MD
of Zoledronate vs. Aredia in Cancer Patients with Osteolytic Bone Metastases

1996-1997	Company: Title:	Chiron Therapeutics Phase I/II Trial of Interleukin-2 in Maintenance Phase Multiple Myeloma
1995-1997	Company: Title:	Solopak Pharmaceutical Inc. A Randomized, Double-Blind, Multi-Center Study of Low-Dose Gallium Nitrate for Treatment of Bone Involvement Due to Multiple Myeloma
1995-1999	Company: Title:	CellPro A Multi-Center, Randomized, Controlled Phase III Study Evaluating CD34+ Selected vs Unselected, Autologous Peripheral Blood Progenitor Cell Transplantation in Patients with Multiple Myeloma
1995-1997	Company: Title:	CellPro CD34 Mobilization Kinetics Study
1995-1998	Company: Title:	CIBA-GEIGY Phase I / CGP-42446: Open-Label, Fixed Ascending, Dose Ranging, Safety Trial of Rapid Intravenous Infusion of CGP-42446 in Cancer Patients with Osteolytic Bone Metastases
1995-1996	Company: Title:	CellPro Salary Support for Stem Cell Processing Technician and Clinical Research Nurse
1994-1995	Company: Title:	CellPro Laboratory Verification and Equipment Grants
1994	Company: Title:	CellPro Clinical Trials Development in Multiple Myeloma
1992-1994	Company: Title:	Schering CD34 Stem Cell Transplants in Multiple Myeloma
1992-1994	Company: Title:	Roche Laboratories All Trans-Retinoic Acid and InterferonAlpha-2a in Drug Resistant Multiple Myeloma and Waldenstrom's Macroglobulinemia
1993-1994	Company: Title:	CIBA-GEIGY Pharmacokinetics of Pamidronate Disodium in Cancer Patients

James R. Berenson, MD
with Various degrees of Hepatic Dysfunction (Protocol 28)

1992-1993	Company: Title:	CIBA-GIEGY Pharmacokinetics of Pamidronate Disodium in Cancer Patients With Various Degrees of Renal Dysfunction (Protocol 27)
1991-1992	Company: Title:	Schering Interferon in Myeloma - Mechanism of Anti- Tumor Activity
1990-1993	Company: Title:	VA Merit Review Idiotypic-Bearing Peripheral Blood Lymphocytes in Multiple Myeloma
1990-1995	Company: Title:	CIBA-GEIGY APD Myeloma Study
1990-1991	Company: Title:	Margaret Early Foundation Molecular Basis of Cervical Carcinogenesis
1990-1991	Company: Title:	California Institute for Cancer Research Idiotypic-Bearing Peripheral Blood Lymphocytes in Multiple Myeloma
1990-1991	Company: Title:	Academic Senate, UCLA Regulatory Cells in the Peripheral Blood of Multiple Myeloma
1989-1990	Company: Title:	California Institute for Cancer Research Chromosome 11 Abnormalities in Head and Neck Cancer
1988-1989	Company: Title:	Academic Senate, UCLA Oncogenes in Head and Neck Cancer Patients
1988-1989	Company: Title:	California Cancer Research Coordinating Committee Analysis of int-2 and bcl-1 genes in Squamous Cell carcinomas
1986-1989	Company: Title:	Veterans Administration Merit Review Molecular Mechanisms Leading to the Development of Multiple Myeloma
1987-1988	Company: Title:	California Institute for Cancer Research Oncogenes in Head and Neck Cancer Patients
1987-1988	Company: Title:	Academic Senate, UCLA Analysis of Antibody and T-cell Receptor Genes in Chronic Myelogenous Leukemia

1986-1987	Company:	Academic Senate, UCLA
	Title:	Molecular Mechanism in the Development of Multiple Myeloma
1985-1986	Company:	California Cancer Research Coordinating Committee
	Title:	Analysis of Antibody Genes and Oncogenes in Multiple Myeloma
1985-1986	Company:	Academic Senate, UCLA
	Title:	Analysis of Antibody Genes and Oncogenes in Multiple Myeloma
1984-1985	Company:	Veterans Administration Regional Advisory Group (RAG) Award
	Title:	Analysis of Antibody Genes and Oncogenes in Multiple Myeloma
1983-1984	Company:	California Institute for Cancer Research
	Title:	Analysis of Immunoglobulin Genes in Chronic Myelogenous Leukemia
1982-1984	Company:	Damon Runyon-Walter Winchell Fellowship
	Title:	Analysis of Heavy Chain Promoter Regions
1982-1983	Company:	National Research Service Award
	Title:	Analysis of Immunoglobulin Heavy Chain Promoter Regions
1982	Company:	March of Dimes
	Title:	Special Fellowship in Postgraduate Medicine

PATENTS (under ONCOtracker and Institute for Myeloma & Bone Cancer Research)

US Patent No. 12174189- BCMA- Improved Diagnostic, Prognostic, and Monitoring Methods for Chronic Lymphocytic Leukemia

BCMA- Improved Methods for Monitoring Immune Status of a Subject: Granted in Belgium, Czechia, Denmark, European Patent Application, Finland, France, Germany, Hong Kong, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, and United Kingdom

BAFF- Improved Methods for Monitoring Immune Status of a Subject: Granted in Germany and United Kingdom

Improved Diagnostic, Prognostic, and Monitoring Methods for Multiple Myeloma, Chronic Lymphocytic Leukemia, and B- cell Non-Hodgkin: Granted in United States

Gamma Secretase Modulators for the Treatment of Immune System Dysfunction: Registered in China, Europe, Hong Kong, Japan, South Korea, Russia, and United States

Anti-Cancer Effects of JAK2 Inhibitors in Combination with Thalidomide Derivatives and Glucocorticoids- Granted in United States, European Patent Application

CONSULTING, ADVISORY & PEER REVIEW ACTIVITIES

Section Editor

(Muscular/Skeletal): Supportive Cancer Therapy

Editorial Board:

Annals of Hematology

Annals of Oncology

British Journal of Haematology (retired from Board in 2022)

Clinical Advances in Hematology & Oncology

Clinical Cancer Research

Clinical Lymphoma & Myeloma

Critical Reviews in Oncogenesis

Current Opinion in Supportive and Palliative Care

Supportive Cancer Therapy

Targeted Oncology

Reviewer:

Acta Biochimica et Biophysica Sinica

Adis – Wolter Kluwer Health

Advances in Hematology

Aging Health

AIDS

American Journal of Cancer

American Journal of Hematology

American Journal of Medicine

American Journal of Pathology

American Society of Clinical Oncology website – <http://www.oncology.com>

Annals of Hematology

Annals of Oncology

Advanced in Therapy

Baylor University Medical Center Proceedings

Biochemical Journal

BioScience Reports

Biochemical Society Transactions

Biologics: Targets & Therapy

Biology of Blood & Marrow Transplantation

Biomarkers and Prevention

BioMed Central

Biomolecules

Bioscience Reports

[Blood](#)
[Blood Cancer Journal](#)
[Blood Global Hematology](#)
[Blood Reviews](#)
[Bone Marrow Transplantation](#)
[British Journal of Haematology](#)
[British Journal of Cancer](#)
[Calcified Tissue International](#)
[Cancer](#)
[Cancer Biomarkers](#)
[Cancer Epidemiology](#)
[Cancer Management and Research](#)
[Cancer Reports](#)
[Cancer Research](#)
[Cancer Research Communications](#)
[Cancer Research Therapy and Control](#)
[Cancer Treatment Reviews](#)
[Cancers](#)
[Case Reports in Medicine](#)
[Cellular Immunology](#)
[Clinical Advances in Hematology & Oncology](#)
[Clinical Cancer Research](#)
[Clinical Interventions in Aging](#)
[Clinical Lymphoma, Myeloma and Leukemia](#)
[Clinical Medicine Insights: Oncology](#)
[Clinical Pharmacology: Advances and Applications](#)
[Clinical Therapeutics](#)
[Clinical Transplantation](#)
[ClinicoEconomics and Outcomes Research](#)
[Computational and Structural Biotechnology Journal](#)
[Coping with Cancer](#)
[Current Cancer Therapy Reviews](#)
[Current Opinion in Supportive and Palliative Care](#)
[Cytokine](#)
[DNA & Cell Biology](#)
[Dove Medical Press: Peer-reviewed Journals for Professionals](#)
[Dovepress](#)
[Dove Medical Press](#)
[Drug Design, Development and Therapy](#)
[Drugs \(Wolters Kluwer\)](#)
[Drugs and Aging](#)
[Drug Delivery](#)
[European Journal of Clinical & Medical Oncology](#)
[European Journal of Haematology](#)
[European Journal of Pharmacology](#)
[Experimental Cell Research](#)

Experimental Hematology
Expert Opinion on Emerging Drugs
Expert Opinion on Investigational Drugs – Informa Healthcare
Expert Opinion on Therapeutic Targets
Expert Opinion on Pharmacotherapy
Expert Review of Hematology
Expert Review of Molecular Diagnostics
Expert Review of Anticancer Therapy
Frontiers Pharmacology
Future Medicine
Future Oncology
Gene
Haematologica
Heliyon
Hematological Oncology
Hematology
HemaSphere
Hospital Practice
International Journal of Biochemistry & Cell Biology
International Journal of Cancer
International Journal of Experimental & Clinical Chemotherapy
International Journal of Medical Sciences
International Immunopharmacology
International Myeloma Foundation Scientific Advisory Board
Journal of American Medical Association
Journal of Cellular Biochemistry
Journal of Cellular and Molecular Medicine
Journal of Chemotherapy
Journal of Clinical Investigation
Journal of Clinical Oncology
Journal of Community and Supportive Oncology
Journal of Comparative Effectiveness Research
Journal of Computational and Structural Biotechnology Journal
Journal of Hematology
Journal of International Medical Research
Journal of the Royal Society Interface
Journal of Supportive Care in Cancer
Lancet
Lancet Haematology
Lancet Oncology
Leukemia
Leukemia and Lymphoma
Leukemia & Lymphoma Society
Leukemia Research
Mayo Clinic Proceedings
Medical Oncology

Mediterranean Journal of Hematology and Infectious Diseases
Microvascular Research
Molecular Cancer Research
Molecular Cancer Therapeutics
Molecular Medicine
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation website –
<http://www.multiplemyeloma.org>
Multiple Myeloma Research Foundation Senior Grant Awards
Nature
Nature Reviews – Clinical Oncology
Nature Clinical Practice Oncology
Nature Reviews
Netherlands Journal of Medicine– <http://mc.manuscriptcentral.com/nethjmed>
New England Journal of Medicine
npj vaccines
Oncogene
Oncology
Oncology Letters
Oncology and Therapy
Oncotarget
OncoTargets and Therapy
Osteoporosis International
PloS One
PNAS (Proceedings of the National Academy of Sciences of the USA)
Practical Laboratory Medicine
Radiation Oncology
Science
Science Translational Medicine
Seminars in Oncology
Skeletal Wellness Institute for Cancer
Skeletal Wellness Institute for Cancer website – www.swicancer.org
Supportive Cancer Therapy
Supportive Care in Cancer
Targeted Oncology
The Oncologist
Therapeutic Advances in Musculoskeletal Disease
Therapeutic Advances in Hematology
Toxicology
Toxicology in Vitro
Translational Cancer Research
Viruses
Yonsei Medical Journal - <http://journal.eymj.org>

Internet Database : www.MMSupport.net – Patient Support Website

OTHER PROFESSIONAL ACTIVITIES

1983	Leukemia Society of America, Los Angeles Chapter
1983	Performing Artists Against Cancer (Professional Representative)
1984-1994	Associate Editor, <u>Cancer Update</u>
1993-1994	Member, Executive Board of Directors, Temple Shalom
1995	Reviewer of grants, <u>American Federation for Clinical Research</u>
1997-1998	Editor, Cancer Research, Therapy and Control
1997	Expert Columnist, <u>Salud (i) Ciencia</u>
1997-2001	Mayo Clinic Scientific Advisory Board, “Studies on Monoclonal Gammopathies”
1997	Contributing Author, A Monograph for Continuing Medical Education, The Role of Tumor Purging in Autologous Transplantation
1998	Editorial Board, American Journal of Drugs in Cancer, Adis International Publications
1998	Global Advisory Board for Zometa, Novartis Pharmaceuticals, Inc.
1998-2001	Associate and Consultant, Anchor Center for Humanistic Oncology
1998-2000	Mentor, Amgen Oncology Fellows Mentoring Program, ASCO Annual Meeting in Los Angeles
1998-2000	Safety Monitoring Board ARE 03 Trial.
1999	Reviewer of abstracts, VII International Conference on Malignant Lymphoma
1999	Advisory Board for Thalomid, Celgene
1999	Advisory Panel for Anti-PTHrP Antibodies, Chugai Pharmaceuticals
1999	Advisory Panel for OPG in Bone Metastasis, AMGEN
1999	Section Editor, <i>Supportive Cancer Therapy</i> , Jeffrey Crawford, MD, Editor-in-

Chief, Baylor Health – Cancer Information Group, Dallas, TX

1999-2000	Chair, ASCO Annual Meeting by an ASCO Program Committee Member
1999	Research Board of Advisors, American Biographical Institute, Inc.
1999	Reviewer, UCLA AIDS Institute Grants (Basic, Clinical and Social/Behavioral Studies)
10/1999	Visiting Professor and Guest Lecturer on Multiple Myeloma, Australia and New Zealand Haematology Annual Meeting, Hobart, Tasmania
10/1999	Visiting Professor and Guest Lecturer on Multiple Myeloma, Australia and New Zealand Haematology Annual Meeting, Hobart, Tasmania
12/1999	Symposium on Multiple Myeloma at the Annual American Society of Hematology Meeting, New Orleans, Louisiana
12/1999	Symposium on Multiple Myeloma at the Annual American Society of Hematology Meeting, New Orleans, Louisiana
12/9/99	Berenson, JR, “Advances in Lymphoma / Leukemia,” Israeli Cancer Research Fund Seminar.
12/11/99	Berenson, JR and Vescio, R, “Multiple Myeloma: New Advances in Biology & Treatment,” S. CA Support Groups of The International Myeloma Foundation and Leukemia Society of America, Newport Beach, CA.
12/9/99	Berenson, JR, “Advances in Lymphoma / Leukemia,” Israeli Cancer Research Fund Seminar.
12/11/99	Berenson, JR and Vescio, R, “Multiple Myeloma: New Advances in Biology & Treatment,” S. CA Support Groups of The International Myeloma Foundation and Leukemia Society of America, Newport Beach, CA.
1/29/00	Berenson, JR, “Multiple Myeloma: Diagnosis and Treatment of the Bone Disease,” International Myeloma Foundation Patient and Family Seminar.
3/2000	Annual Meeting of the International Bone Marrow Transplant Registry, Transplants for Myeloma, Anaheim, California
3/2000	European Society of Hematology, Biology and Treatment of Myeloma Bone Disease, Barcelona, Spain
3/2000	Annual Meeting of the International Bone Marrow Transplant Registry, Transplants for Myeloma, Anaheim, California

3/2000	European Society of Hematology, Biology and Treatment of Myeloma Bone Disease, Barcelona, Spain
4/2000	2 nd International Conference on Cancer-Induced Bone Diseases, Early Clinical Trials with Zometa, Davos, Switzerland
2000-Present	National Institutes of Health – Grant Reviewer
1998-Present	Expert Panel, Stem Cell Transplants in Myeloma for the American Society for Blood and Marrow Transplantation
1998-Present	Reviewer of Grants, National Institutes of Health, Center for Scientific Review, Clinical Oncology Study Section
6/2000	The International Myeloma Foundation Patient Support Meeting, Tyson’s Corner, VA.
12/9/2000	Berenson, JR and Vescio, R, “Multiple Myeloma: New Advances in Biology & Treatment,” S. CA Support Groups of The International Myeloma Foundation and Leukemia Society of America, Newport Beach, CA.
12/2000	ASBMT Expert Panel Reviewer, ASH Annual Meeting, San Francisco, CA
12/2000	National Institutes of Health/National Cancer Institute’s Leukemia, Lymphoma and Myeloma Progress Review Group, Chantilly, VA
12/2000	ASBMT Expert Panel Reviewer, ASH Annual Meeting, San Francisco, CA
12/2000	National Institutes of Health/National Cancer Institute’s Leukemia, Lymphoma and Myeloma Progress Review Group, Chantilly, VA
2/2001	Course Director: “Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma” Symposium, Cedars-Sinai Medical Center, Los Angeles, CA
1998-Present	Celgene Speaker Corps, Renal Cell Carcinoma and Other Solid Tumors and Multiple Myeloma and Other Hematologic Malignancies.
2001-Present	Academic Senate Committee, Cedars-Sinai Medical Center
2001-Present	Center for Biomedical Continuing Education Board
2001-2011	Leukemia & Lymphoma Society – SCOR Grant Reviewer

2/2001	Course Director: “Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma” Symposium, Cedars-Sinai Medical Center, Los Angeles, CA
4/2001	Reviewer of grants, Associazione Italiana per la ricerca sul Cancro (AIRC)
6/9/2001	International Myeloma Foundation, Patient Support Group, Community Workshop, “Bone Involvement & Complications,” Studio City, CA
6/2001	Leukemia & Lymphoma Society Translational Research Program Grant Review Subcommittee, New York, NY
6/9/2001	International Myeloma Foundation, Patient Support Group, Community Workshop, “Bone Involvement & Complications,” Studio City, CA
2002-Present	Advisory Board for Enable Healthcare Communications
2002	Multiple Myeloma Research Foundation 2002 Senior Research Award reviewer
2002-Present	Editorial Board, <i>American Journal of Cancer</i> , Adis International Publishers
1998-Present	Anemia and Cancer: Treatment Information for Oncologists and Nurses (ACTION) Speakers Bureau, DesignWrite Corp. for Ortho Biotech
1998-Present	American Association for the Advancement of Science (AAAS)
2002-Present	Specialized Program of Research Excellence (SPORE) Review Committee, Leukemia & Myeloma Group, National Cancer Institute (NCI).
1/12/2002	International Myeloma Foundation & Leukemia & Lymphoma Society, Patient Support Group 2002, Community Workshop, “Multiple Myeloma: New Advances in Biology & Treatment,” Newport Beach, CA
4/25-27/02	Program Committee, Third North American Symposium on Skeletal Complications of Malignancy, Paget Foundation, Bethesda, MD, April 25-27, 2002.
10/25-27/02	Educational Forum on Lymphoma, The Lymphoma Research Foundation
11/02	Titan Pharmaceuticals, Inc. Clinical Experts Advisory Meeting on Gallium Maltolate, Chicago, IL
12/2002	Expert Advisor, Titan Pharmaceuticals – Gallium Maltolate investigational drug, San Francisco, CA

2006-2011	Specialized Center of Research (SCOR),” The Leukemia & Lymphoma Society Program Grant Review Subcommittee
2004-Present	Executive Planning Committee, Skeletal Wellness Institute for Cancer
2006-Present	Foundation Board of the Leukemia & Lymphoma Society
2007-Present	Development Committee, American Society of Hematology (ASH)
2007-Present	Research and Therapeutics Committee, Georgia Cancer Specialists
2007-Present	Expert Advisor, Multiple Myeloma Research Foundation Patient Brochure
2008-Present	Cancer Research UK – Translational Research in Clinical Trials Committee – Grant Reviewer
2011-Present	National Institutes of Health- SPORE Grant Reviewer
2012- Present	Expert Reviewer, McKesson Specialty Health, Multiple Myeloma Treatment Guidelines for Multiple Myeloma
2012- Present	Expert Reviewer, McKesson Specialty Health, Bone Health Treatment Guidelines
5/2014	Expert Reviewer, Association for Value-Based Cancer Care, Multiple Myeloma Roundtable, Hollywood, CA
5/2014	Co-Chair, Multiple Myeloma Research Foundation Clinical Insights in Multiple Myeloma Patient Symposium, Los Angeles, CA
5/2014	Guest Faculty, Celgene Multiple Myeloma Speaker Training, Celgene Corporation, Chicago, IL
7/2014	Expert Faculty for Celgene Advisory Board, Celgene Corporation, San Diego, CA
2014-Present	Business Advisory Board, SYNERGEN Health LLC
11/2014	Keynote Speaker, “What’s New in Myeloma,” Sri Lanka Medical Association of North America Western Region meeting, Skirball Center, Los Angeles, CA
2016-2017	International Myeloma Working Consensus Panel 1, Recommendations Diagnostic Work up, Risk Stratification and Disease Monitoring for MGUS and MM
2016-2017	International Myeloma Working Consensus Panel 2, Recommendations for Management of Special Populations and High-Risk Myeloma

5/2017	Invited Speaker, “The Role of Serum BCMA in Monitoring, Predicting Outcomes and Immune Deficiency of Multiple Myeloma,” at the Third Annual Immuno-Therapy in Myeloma Scientific Workshop, Philadelphia, PA
7/2018	Invited Speaker, “Multiple Myeloma: Induction, Consolidation and Maintenance Therapy,” New Orleans Summer Cancer Meeting, New Orleans, LA
1/2020	Invited Speaker, “Serum B-cell Maturation Antigen (sBCMA): A New Precision Biomarker to Predict Outcomes for Multiple Myeloma and Chronic Lymphocytic Leukemia Patients,” Precision Medicine World Conference, Santa Clara, CA
9/2021	Invited Speaker, “Myeloma: It’s Complicated,” West Hawaii Cancer Symposium, Kona, Hawaii
9/23-Present	Study Steering Committee (SSC), A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (480Vd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
10/23	Invited Speaker, “MRD Does Not Reflect the Biology and Clinical Complexities of the Disease,” Lymphoma, Leukemia and Myeloma Congress, New York City, NY
9/24	Invited Speaker, “New Advances in the Monitoring and Treatment of Multiple Myeloma.” Hematology Grand Rounds, University of Southern California

MEDIA INTERVIEWS & PRESS ARTICLES

02/2001	Bankhead C, “Treating Bone Disease May Benefit Myeloma,” Oncology Times: Meeting Reporter, <i>The American Society of Hematology – 42nd Annual Meeting & Exposition</i> , The Moscone Center, San Francisco, CA 12/1-5/2000
03/2001	Focus on Pain Section, “High-Potency Bisphosphonate is Effective for Bone Mets,” in <i>Oncology News International (ONI)</i> , 10:3:17, March (2001)
07/2001	Berenson, JR , “Novartis Zometa Bone Metastases NDA Submission Expected by August,” commentary on Zometa’s effectiveness as compared to pamidronate, 6:7 July (2001)
02/2002	Berenson JR , <i>Cure Magazine</i>
04/2002	Berenson JR , <i>Prevention Magazine</i>

- 07/2003 Veronica's View by Veronica Hendrix, "New Hope for Fatal Blood Disease Targeting African Americans," *Los Angeles Sentinel*
- 07/2003 Denise Dador, KABC-TV interview for Channel 7 News. Air date
- 07/2003 Pat Prescott, KTWV interview. Air date
- 09/2003 **Berenson JR**, "New Currents in Treatment of Bone Metastases: A Case-Based Approach," TxReporter - Ask the Experts - Audio Edition
- 06/2004 Heather Lindsey, "James Berenson Starts Independent Institute for Multiple Myeloma Research," *Oncology Times*, 26:12:28
- 07/2004 Heather Lindsey, "Bone Metastases: New Approaches of Attack," *Oncology Times*, 26:25:16
- 01/2004 Cathy Dunn, "Matching Wits with Multiple Myeloma: New Drug Therapies Offer Choices to Challenge this Complex Disease," *Cure*, 48-52, (2004)
- 02/2006 Mark Palacio, Managing Editor, Hematology/Oncology Today. Low-dose bortezomib and melphalan benefits patients with relapsed multiple myeloma: Low-dose option prolongs progression-free survival and improves quality of life compared with high-dose chemotherapy and transplant."
- 08/2006 Mark L. Fuerst, "ASCO Annual Meeting: Zoledronic Acid Extends Survival in Lung Cancer & Multiple Myeloma Patients with High Levels of Bone Metabolism," *Oncology Times*, 28:16:37 & 40 (2006)
- 09/2021 "COVID-19 mRNA Vaccines in Immune Compromised Patients," KNBC, KCBS, KTLA, KABC, FOX NEWS, KNX RADIO, KCAL, AND CHANNEL 34

NEWS COLUMNS WRITTEN

- 01/2000, Volume II, Issue VII Multiple Myeloma Research Foundations' *Myeloma Focus*, "Ask the Expert" column
- 06/2001, Volume 4, Number 5 International Myeloma Foundation's *Myeloma Today*, "Ask the Experts: Essentials of Hypercalcemia."
- 06/2002 Hematology Oncology Newslink, *SuperGen, the Key to Life*, "More is Better."

- 08/2004 Multiple Myeloma Research Foundation's *Myeloma Focus*,
"Ask the Expert" column
- 02/2004 **Berenson JR**, "Low-Dose Melphalan, Arsenic Trioxide, Ascorbic Acid Appears
Effective for Refractory Myeloma," *Oncology News International*
- Fall/2021 **Berenson JR**, "Response to mRNA COVID-19 Vaccine in MM Patients,"
Multiple Myeloma TODAY

BIBLIOGRAPHY

RESEARCH PAPERS - Published - Peer Reviewed

1. Underwood W, Gutleben D, Berenson R, Cheng K, **Berenson J**, Kulik J, and Wenzel G, "Mood, Attention and Generosity," *Personality and Soc Psych Bull*, 1:402-403 (1974).
2. **Berenson JR**, Einstein AB, and Fefer A, "Syngeneic Adoptive Immunotherapy and Chemoimmunotherapy of a Friend Leukemia: Requirements for T-cells," *J Immunol*, 115:234-238 (1975).
3. Clarke C, **Berenson J**, Gorman J, Boyer PD, Crews S, Siu G, and Calame K, "An Immunoglobulin Promoter Region is Unaltered by DNA Rearrangement and Somatic Mutation During B-cell Development," *Nucleic Acid Res*, 10:7731-7749 (1982).
4. Brown N, Liu C, **Berenson J**, Garcia C, Wang R, and Calame K, "Immunoglobulin Gene Rearrangements in B-Cells Clonally Transformed by Epstein-Barr Virus," *Proc Natl. Acad Sci*, 82:556-559 (1985).
5. **Berenson J**, Wong R, Kim K, Brown N, and Lichtenstein A, "Evidence for Peripheral Blood B Lymphocyte but not T Lymphocyte Involvement in Multiple Myeloma," *Blood*, 70:1550-1553 (1987).
6. **Berenson J** and Lichtenstein A, "Clonal Rearrangement of the Beta-T Cell Receptor Gene in Multiple Myeloma," *Leukemia*, 3:133-136 (1989).
7. Munker R, Miller CW, **Berenson J**, Dresden O, and Koeffler HP, "A PH¹ Chromosome Positive B Cell Line Expresses the Fusion Protein P210," *Nouvelle Revue Francaise D'Hematologie*, 31:39-43 (1989).
8. **Berenson J**, Yang J, and Mickel R, "Frequent Amplification of the Bcl-1 Locus in Head and Neck Squamous Carcinomas," *Oncogene*, 4:1111-1116 (1989).
9. **Berenson J** and Koeffler HP, "Rearrangement and Expression of Beta-T Cell Receptor and Antibody Genes in Established Ph¹ Chronic Myelogenous Leukemia Cell Lines," *Hematologic Pathology*, 3:125-132 (1989).
10. Lichtenstein A, **Berenson J**, Norman D, Chang MP, and Carlile A, "Production of Cytokines by Bone Marrow Cells Obtained from Patients with Multiple Myeloma," *Blood*, 74:1266-1273 (1989).
11. **Berenson J** and Lichtenstein A, "Clonal Rearrangement of Immunoglobulin Genes in the Peripheral Blood of Multiple Myeloma Patients," *Br J Haematol*, 73:425-427 (1989).

12. Kimata H, **Berenson J**, Kagan J, and Saxon A, "The Human T Cell-B Cell Responsive Hybridomas Established by the Fusion Between Normal T Cells with an EBV Transformed Plasmacytoma B Cell Line," Clin Immunol Immunopath, 54:134-147 (1990).
13. **Berenson JR**, Lichtenstein A, Hart S, Palomares D, and Miller RA, "Expression of Shared Idiotypes by Paraproteins from Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance," Blood, 75:2107-2111 (1990).
14. Barath P, Fishbein M, Cao J, **Berenson J**, Helfant R, and Forrester J, "Detection and Localization of Tumor Necrosis Factor in Human Atheroma," Amer J Cardiol, 65:297-302 (1990).
15. **Berenson JR**, Koga H, Yang J, Pearl J, Holmes EC, and Figlin R, "Frequent Amplification of the Bcl-1 Locus in Poorly Differentiated Squamous Cell Carcinoma of the Lung," Oncogene, 5:1343-1348 (1990).
16. Barath P, Fishbein MC, Cao J, **Berenson J**, Helfant RH, and Forrester JS, "Tumor Necrosis Factor Gene Expression in Human Vascular Intimal Smooth Muscle Cells Detected by In Situ Hybridization," Amer J Pathol, 137:503-509 (1990).
17. Lichtenstein A, **Berenson J**, Gera JF, Waldburger K, Martinez-Maza O, and Berek JS, "Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor and Lymphokine-Activated Killer cells: Correlation with Expression of HER2/neu Oncogenes," Cancer Research, 50:7364-7370 (1990).
18. Paquette R, **Berenson J**, Lichtenstein A, McCormick F, and Koeffler HP, "N-RAS Mutations in Multiple Myeloma Bone Marrow," Oncogene, 5:1659-1663 (1990).
19. Lichtenstein AK, Gera JF, Andrews J, **Berenson J**, and Ware CF, "Inhibitors of ADP-ribose Polymerase Decrease the Resistance of HER2/neu-Expressing Cancer Cells to the Cytotoxic Effects of Tumor Necrosis Factor," J Immunol, 146:2052-2058 (1991).
20. Jensen GS, Mant MJ, **Berenson JR**, Ruether BA, and Pilarski LM, "Selective Expression of CD45 Isoforms Defines CALLA⁺ Monoclonal B Lineage Cells in Peripheral Blood from Myeloma Patients as Late Stage B Cells," Blood, 78:711-719 (1991).
21. Lichtenstein A, Fady C, Gera JF, Gardner A, Chazin VR, Kelley D, and **Berenson J**, "Effects of Beta-2 Microglobulin Anti-Sense Oligonucleotides on Sensitivity of HER2/neu Oncogene-expressing and Non-expressing Target Cells to Lymphocyte-mediated Lysis," Cellular Immunol, 141:219-232 (1992).
22. Sawicki MP, Wan Y-JY, Johnson CL, **Berenson J**, Gatti R, and Passaro E, Jr., "Loss of Heterozygosity on Chromosome 11 in Sporadic Gastrinomas," Human Genetics, 89:445-449 (1992).
23. Lyn D, Cherney BW, Lalande M, Gause B, **Berenson JR**, and Smulson M, "A Duplicated Region is Responsible for the Poly(ADP-Ribose) Polymerase Polymorphism on Chromosome 13 Associated with a Predisposition to Cancer," American J. Human Genetics, 52:124-134 (1993).

24. Hudnall D and **Berenson J**, “Evidence of a Clonal Isotype Switch Within the Pseudofollicular Proliferation Centers of Small Lymphocytic Lymphoma: Implications Regarding the Origin of Proliferation Centers,” *Human Pathol*, 24:796-801 (1993).
25. King BL, Lichtenstein A, **Berenson J**, and Kacinski BM, “A Polymerase Chain Reaction-Based Microsatellite Typing Assay Used for Tumor Cell Line Identification,” *American Journal of Pathology*, 144:486-491 (1994).
26. Schiller G, Nimer S, Vescio R, Lieb G, Lee M, Gajewski J, Territo M, and **Berenson J**, “A Phase I-II Study of Busulfan and Cyclophosphamide Conditioning Followed by the Transplantation of Autologous Hematopoietic Progenitor Cells or Allogeneic Bone Marrow as Treatment for Advanced Multiple Myeloma,” *Bone Marrow Transplantation*, 14:131-136 (1994).
27. Kampe CE, Hart S, Miller RA, Lichtenstein A, Kyle RA, and **Berenson JR**, “Expression of Shared Idiotypes by Paraproteins from Patients with Monoclonal Gammopathy of Undetermined Significance,” *Br J Haematol*, 87:719-724 (1994).
28. Vescio RA, Hong CH, Cao J, Kim A, Schiller G, Lichtenstein AK, Berenson R, and **Berenson JR**, “The Hematopoietic Stem Cell Antigen, CD34, is not Expressed on the Malignant Cells in Multiple Myeloma,” *Blood*, 84:3283-3290 (1994).
29. Schiller G, Vescio R., Lee M., Spitzer G., Freytes C, Bearman S, Lill M, Berenson R, and **Berenson JR**, “CD34 Selection of Autologous Peripheral Blood Progenitor Cells for Transplantation in Patients with Multiple Myeloma,” Presenting in the American Association of Blood Banks in November, reproduced for publication in *Transfusion*, 34 (Suppl. 10S):58S (1994).
30. Cao J, Vescio RA, Hong CH, Kim A, Lichtenstein AK, and **Berenson JR**, “Identification of Malignant Cells in Multiple Myeloma Bone Marrow with Immunoglobulin VH Gene Probes by Fluorescent in situ Hybridization and Flow Cytometry,” *J Clinical Investigation*, 95:964-972 (1995).
31. Kampe CE, Vovan T, Alim A, and **Berenson JR**, “Streptococcus Sanguis Bacteremia and Colorectal Cancer: A Case Report,” *Medical and Pediatric Oncology*, 24:67-68 (1995).
32. Lichtenstein, A, Tu, Y, Fady, C, Vescio R, and **Berenson JR**, “Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells by BCL-2-Independent Mechanisms,” *Cellular Immunology*, 162:248-255 (1995).
33. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee J, Hong C, Lichtenstein A, Lill M, Hall J, Berenson R, and **Berenson JR**, “Transplantation of CD34-Positive Peripheral Blood Progenitor Cells Following High-Dose Chemotherapy for Patients with Advanced Multiple Myeloma,” *Blood*, 86:390-397 (1995).
34. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, DerDanielian M, Wu V, Newman R, Lichtenstein, AK, and **Berenson JR**, “Myeloma Ig Heavy Chain V Region Sequences Reveal Prior Antigenic Selection and Marked Somatic Mutation But No Intracлонаl Diversity,” *Journal of Immunology*, 155:2487-2497 (1995).

35. Cao J, Vescio RA, Rettig MB, Hong CH, Kim A, Lee JC, Lichtenstein AK, and **Berenson JR**, “A CD10-Positive Subset of Malignant Cells is Identified in Multiple Myeloma Using PCR with Patient-Specific Immunoglobulin Gene Primers,” *Leukemia*, 9:1948-1953 (1995).
36. Cao J, Hong C, Rosen L, Vescio RA, Smulson M, Lichtenstein AK, and **Berenson JR**, “Deletion of Genetic Material from a Poly (ADP-Ribose) Polymerase-like gene on Chromosome 13 Occurs Frequently in Patients with Monoclonal Gammopathies,” *Cancer Epidemiology, Biomarkers & Prevention*, 4:759-763 (1995).
37. **Berenson JR**, Lichtenstein A, Porter L, Dimopoulos A, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma JD, Heffernan M, Seaman J, and Knight RD, “Efficacy of Pamidronate Disodium in Reducing Skeletal-Related Events in Patients with Advanced Multiple Myeloma,” *New England Journal of Medicine*, 334:488-493 (1996).
38. Rettig MB, Vescio RA, Cao J, Wu CH, Lee JC, Han E, DerDanielian M, Newman R, Hong C, Lichtenstein AK, and **Berenson JR**, “VH Gene Usage in Multiple Myeloma: Complete Absence of the VH4.21 (VH4-34) Gene,” *Blood*, 87:2846-2852 (1996).
39. Centola M, Lin K, Sutton C, **Berenson JR**, Kunkel LA, Rosen L, Hahn BH, and Robinson RR, “Production of Anti-erythrocyte Antibodies by Leukemic and Nonleukemic B Cells in Chronic Lymphocytic Leukemia Patients”, *Leukemia and Lymphoma*, 20:465-469 (1996).
40. Tu Y, Xu FH, Liu J, Vescio R, **Berenson JR**, Fady C, and Lichtenstein A, “Upregulated Expression of BCL-2 in Multiple Myeloma Cells Induced by Exposure to Doxorubicin, Etoposide and Hydrogen Peroxide,” *Blood*, 88:1805-1812 (1996).
41. Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, and **Berenson JR**, “Quantitative Comparison of Multiple Myeloma Tumor Contamination in Bone Marrow Harvest and Leukaphereses Autografts,” *Bone Marrow Transplantation*, 18:103-110 (1996).
42. Tasaka T, **Berenson JR**, Vescio R, Hiramata T, Miller CW, Nagai M, Takahara J, and Koeffler HP, “Analysis of the p16^{INK4A}, p15^{INK4B} and p18^{INK4C} Genes in Multiple Myeloma”, *British J of Haematology*, 96:98-102 (1997).
43. **Berenson JR**, Rosen L, Vescio R, Lau H, Woo M, Sioufi A, Kowalski M, Knight R, Heffernan M, and Seaman J, “Pharmacokinetics of Pamidronate Disodium in Cancer Patients with Normal or Impaired Renal Function,” *J Clin Pharmacol*, 37:285-290 (1997).
44. Thompson AA, Talley JA, Do HN, Kagan HL, Kunkel L, **Berenson JR**, Cooper MD, Saxon A, and Wall R, “Aberrations of the B cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia,” *Blood*, 90:1387-1394 (1997).

45. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, and **Berenson JR**: “Kaposi’s Sarcoma-Associated Herpesvirus Infection of Bone Marrow Dendritic Cells from Multiple Myeloma Patients”, *Science* 276:1851-1854 (1997).
46. Said JW, Rettig M, Heppner K, Vescio RA, Schiller G, Belson D, Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, and **Berenson JR**, “Localization of Kaposi’s sarcoma Associated Herpesvirus (KSHV) in bone marrow biopsies from patients with multiple myeloma,” *Blood*, 90:4278-4282 (1997).
47. Rettig M, Said JW, Sun R, Vescio RA, and **Berenson JR**, “Kaposi’s Sarcoma-Associated Herpesvirus Infection and Multiple Myeloma,” *Science*, 278:1969-1973 (1997).
48. Rettig M, Said J and **Berenson JR**, “Multiple Myeloma and Kaposi’s Sarcoma-Associated Herpesvirus-A Paracrine Model of Tumorigenesis?” *Trends in Microbiology*, 5:425-426 (1997).
49. **Berenson JR**, Lau HS, Woo M, von Teichert J, Hamilton PB, Kowalski MO, Schaffer V, and Seaman JJ, “Pharmacokinetics of Pamidronate Disodium in Cancer Patients with Normal or Impaired Hepatic Dysfunction” *J Clin Pharmacol.* 37(4): 285-90 (April 1997).
50. **Berenson JR**, Vescio RA, and Said J, “Multiple Myeloma: The Cells of Origin-A Two Way Street” *Leukemia* 12:121-127 (1998).
51. Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, Cao J, Lee JC, Lichtenstein A, Lill M, Berenson R, and **Berenson JR**, “Autologous CD34-Selected Blood Progenitor Cell Transplants for Patients with Advanced Multiple Myeloma”, *Bone Marrow Transplantation*, 21:141-145 (1998).
52. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, **Berenson JR**, Krajewski S, Reed JC, and Lichtenstein A, “BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance,” *Cancer Research*, 58:256-262 (1998).
53. **Berenson JR**, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, and Knight R, “Long-term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events,” *J Clin Oncol*, 16:593-602 (1998).
54. Aparicio A, Gardner A, Tu Y, Savage A, **Berenson JR**, and Lichtenstein A, “In Vitro Cytoreductive Effects on Multiple Myeloma Cells Induced by Bisphosphonates,” *Leukemia*, 12:220-229 (1998).
55. Tasaka T, Asou H, Munker R, Said JW, Vescio R, **Berenson JR**, Nagai M, Takahara J, and Koeffler HP, “Methylation of the p16^{INK4A} Gene in Multiple Myeloma,” *Br J of Haematol*, 101:558-564 (1998).
56. **Berenson JR** and Vescio RA, “HHV-8 is Present in Multiple Myeloma Patients,” *Blood*, 93:3157-3166 (1999).

57. Vescio R, Schiller G, Stewart K, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, and **Berenson JR**, “Multicenter Phase III Trial to Evaluate CD34+ Selected vs. Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma,” *Blood*, 93:1858-1868 (1999).
58. Pold M, Zhou J, Chen GL, Hall JM, Vescio RA, and **Berenson JR**, “Identification of a New, Unorthodox Member of the MAGE Gene Family,” *Genomics*, 59:161-167 (1999).
59. Sjak-Shie NN, Vescio RA, and **Berenson JR**, “HHV-8 Infection and Multiple Myeloma,” *J of Leukocyte Biology*, 66:357-360 (1999).
60. Krieger MS, Schiller G, **Berenson JR**, Stewart K, Noga SJ, Ballester O, Tarantolo S, Stiff P, Kuhn D, Scherzo B, Jacobs C, White JM, and DiPersio J, “Collection of Peripheral Blood Progenitor Cells (PBPC) Based on a Rising WBC Significantly Increases the Number of CD34+ Cells”, *Bone Marrow Transplantation*, 24:25-8 (1999).
61. Major P, Lipton A, **Berenson JR**, and Hortobagyi G, “Oral Bisphosphonates: A Review of Clinical Use in Metastatic Bone Disease,” *Cancer*, 88:6-14 (2000).
62. Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, and **Berenson JR**, “Human Herpesvirus 8 (KSHV) Contamination of Peripheral Blood and Autograft Products from Multiple Myeloma Patients,” *Bone Marrow Transplantation*, 25:153-160 (2000).
63. Dilworth D, Liu L, Stewart K, **Berenson JR**, Lassam N, and Hogg D, “Germline *CDKN2A* Mutation Implicated in Predisposition to Multiple Myeloma,” *Blood*, 95:1869-1871 (2000).
64. Hillner BE, Ingle JN, **Berenson JR**, Janjan NA, Albain KS, Lipton A, Yee G, Biermann, and Chlebowski JS, “ASCO Guideline on the Role of Bisphosphonates in Breast Cancer,” *Journal of Clinical Oncology*, 18:1378-1391 (2000).
65. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, **Berenson JR**, Collins RH, and Koup RA, “Assessment of Thymic Output in Adults After Haematopoietic Stem Cell Transplantation and Prediction of T-cell Reconstitution,” *Lancet*, 355:1875-81 (2000).
66. Pold M, Pold A, Ma HJ, Sjak-Shie NN, Vescio RA, and **Berenson JR**, “Cloning of the First Invertebrate MAGE Parologue: An Epitope that Activates T-cells in Humans is Highly Conserved in Evolution,” *Developmental and Comparative Immunology*, 4:1-13 (2000).
67. Ablashi DV, Chatlynne L, Thomas D, Bourboulia D, Rettig MB, Vescio RA, Viza D, Gill P, Kyle R, **Berenson JR**, and Whitman JE, Jr, “Lack of Serological Association of HHV-8 (KSHV) in MGUS Patients with and without Progression to Multiple Myeloma,” *Blood*, 96:6:2304-06 (2000).

68. Ma HJ Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M, Belson D, Moss TJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, and **Berenson JR**, “Human Herpes Virus 8 DNA Sequences from ORF26 and ORF65 in Multiple Myeloma Patients Show a Disease Specific Pattern,” *Clinical Cancer Research*, 6:4226-4233 (2000).
69. **Berenson JR**, “Zoledronic Acid in Cancer Patients with Bone Metastases: Results of Phase I and II Trials,” *Seminars in Oncology*, (Suppl 6) 28:2:25-34 April (2001).
70. **Berenson JR**, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, and Von Teichert JM, “A Phase I, Open Label, Dose-Ranging Trial of Intravenous-Bolus Zoledronic Acid, a Novel Bisphosphonate, in Cancer Patients With Metastatic Bone Disease, *Cancer*, 91:1:144-154, (2001).
71. **Berenson JR**, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, and Seaman JJ, “Zoledronic Acid Reduces Skeletal Related Events in Patients with Osteolytic Metastases: A Double-blind Randomized Dose Response Study,” *Cancer*, 91:1191-1200 (2001).
72. **Berenson JR**, “Advances in the Biology and Treatment of Myeloma Bone Disease,” *American Society of Health-System Pharmacists, Inc.*, 58:S4:S1-S13 (2001).
73. **Berenson JR**, Ma HM, and Vescio R, “The Role of Nuclear Factor- κ B in the Biology and Treatment of Multiple Myeloma,” *Sem Onc*, 28:6:626-633 (2001).
74. Beksac M, Ma M, DerDanielian M, Zhang L, Liu J, Arat M, Erekul S, Konuk N, Koc H, Vescio R, and **Berenson JR**, “Frequent Demonstration of Human Herpes Virus 8 (HHV-8) in Bone Marrow Biopsy Samples from Turkish Patients with Multiple Myeloma (MM),” *Leukemia*, 15:1268-1273 (2001).
75. **Berenson JR**, “Advances in the Biology and Treatment of Myeloma Bone Disease,” *Am J Health-Syst Pharm*, 58:3:S16-20 (2001).
76. Stewart KA, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, Dipersio J, Anderson KC, and **Berenson JR**, “Purging of Autologous Peripheral Blood Stem Cells in Multiple Myeloma By CD34+ Selection Does Not Improve Overall or Progression Free Survival Following High Dose Chemotherapy: Results of a Multi-Center Randomized Controlled Trial,” *J Clin Oncol*, 19:17:3771-3779 (2001).
77. **Berenson JR**, Vescio R, Rosen L, Von Teichert J, Woo M, Swift R, Savage A, and Lipton A, “A Phase I Dose-Ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases,” *Clin Cancer Res*, 7:478-485 (2001).
78. Menke DM, Chadburn A, Cesarman E, Green D, **Berenson JR**, Said J, Tiemann M, Parwaresch R, and Thome SD, “Analysis of the Human Herpesvirus 8 (HHV-8) Genome and HHV-8 vIL-6 Expression in Archival Cases of Castleman Disease at Low Risk for HIV Infection,” *Amer J Clin Path*, 117:2:268-275 (2002).

79. **Berenson JR**, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, and Salmon SE, “Maintenance Therapy with Alternate-day Prednisone Improves Survival in Multiple Myeloma Patients,” *Blood*, 99(9):3163-3168 May (2002).
80. Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, Mikail A, Roussos E, Sjak-Shie N, Vescio R, and **Berenson JR**, “Identification of Polymorphisms of the IκBα Gene Associated with an Increased Risk of Multiple Myeloma,” *Cancer Genet Cytogenet*, 137(1):43-48 Aug (2002).
81. **Berenson JR**, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, and Biermann JS. “American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma.” *J Clin Oncol*, 20(17):3719-3736 Sep (2002).
82. **Berenson JR**, “Treatment of Hypercalcemia of Malignancy with Bisphosphonates,” *Semin Oncol*, 29(6: Suppl 21):12-18 Dec (2002).
83. **Berenson JR**, “Advances in the Biology and Treatment of Myeloma Bone Disease,” *Semin Oncol*, 29(6 Suppl 17) 11-16 Review Dec (2002).
84. Chen T, **Berenson JR**, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma M, Ravera C, Deckert F, Schran H, Seaman J, and Skerjanec A, “Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases,” *J Clin Pharmacol*, 42(11):1228-36, November (2002).
85. Hahn T, Wingard JR, Anderson KC, Bensinger WI, **Berenson JR**, Brozeit G, Carver JR, Kyle RA, and McCarthy PL, Jr., “The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Multiple Myeloma: An Evidence-Based Review,” *Biol Blood Marrow Transplant*, 9(1):4-37 Review (January 2003).
86. Ma HM, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, and **Berenson JR**, “The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Cells to Chemotherapeutic Agents,” *Clin Cancer Res* 9(3):1136-1144 Mar (2003).
87. Hahn T, **Berenson JR**, Leahigh A, Cohoon C, O’Rourke D, Brozeit G, Wingard J, Carver J, Anderson K, McCarthy P, Kyle R, and Bensinger W, “ASBMT Guidelines,” *Biol Blood Marrow Transplant*, 9:1:4-37 (2003).
88. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee G, Janjan N, Cauley JA, Blumenstein BA, Albain KS, Lipton A, and **Berenson JR**. “2003 Update of the Role of Bisphosphonates and Bone Health Issues in Women with Breast Cancer,” *J Clin Oncol* (2003).
89. Yang HH, Vescio R, Schenkein D, and **Berenson JR**, “A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma,” *Clin Lymphoma* 4(2):119-122 Sep (2003).

90. Yang H, Ma MH, Vescio RA, and **Berenson JR**, “Overcoming Drug Resistance in Multiple Myeloma – The Emergence of Therapeutic Approaches to Induce Apoptosis,” *J Clin Oncol*, 21(22):4239-4247 (Nov 2003).
91. **Berenson JR**, “Treatment Strategies for Myeloma Bone Disease,” *Oncology*, 17(12):1678, 1681-1682 (Dec 2003).
92. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orłowski RZ, Kuter D, Limentani SA, Lee S, Esseltine D-L, Kauffman M, Adams J, Schenkein DP and Anderson KC. “A Phase 2 Study of Bortezomib in Relapsed, Refractory Multiple Myeloma,” *New Engl J Med* 348:26:2609-2617 (June 26, 2003).
93. Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, **Berenson JR**, List AF, Peters WA 3rd, Flanigan RC, MacDonald JS, Al-Sarraf M, Thompson IM, and Coltman CA Jr, “Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture,” *J Clin Oncol*, 21(23 Suppl):246s-252s Dec (2003).
94. Skerjanec A, **Berenson JR**, Hsu C, Major P, Miller WH Jr, Ravera C, Schran H, Seaman J, and Waldmeier F, “The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function,” *J Clin Pharmacol*, 43:2:154-162 (2003).
95. **Berenson JR**, “Arsenic Trioxide (Trisenox ®) in Multiple Myeloma: Current Clinical Trials and Future Directions,” *Haematologica*, 4:1:S1 (2003).
96. **Berenson JR**, “Pathophysiology of Myeloma Bone Disease and Management of Skeletal Complications,” *Haematologica*, 4:1:S8 (2003).
97. **Berenson JR**, “PS-341: Prospecting a New Hope for Myeloma,” *Blood: Inside Blood* 101:4:15 February (2003).
98. Anderson KC, Barlogie B, **Berenson JR**, Dalton WS, Adams J, Alsina M, Bekker P, Bergsagel PL, Boise L, Chan K, Chanan-Khan AA, Comenzo R, Congdon D, Croucher P, Epstein J, Fenton R, Fonseca R, Gallant G, Hussein MA, Jagannath S, Pearse RN, Roodman DG, Sausville E, Shaughnessy JD, Stewart K, Stirling DI, Trudel S, Ness BV, and Witzig TE, “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma: Research Roundtable,” *Eur J Haematol*. 70:263-272 (2003).
99. Yang H.H., Vescio R., and **Berenson JR**, “A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with relapsed or Refractory Multiple Myeloma,” *Clin Lymphoma*. 4:119-122 (2003).

100. Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, **Berenson JR**, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, and Coltman CA, “Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture,” *J Clin Oncol.* 21: 23s:246s-252s (December 1, 2003 Supplement).
101. Yang HH, Ma MH, Vescio RA, and **Berenson JR**, “Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis,” *J Clin Oncol.* 21:22:4239-4247 (November 15, 2003).
102. **Berenson JR** and Hirschberg R, “Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid,” *Oncologist.* 9:3:319-29 (2004).
103. Jagannath S, Barlogie B, **Berenson JR**, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine D-L, Schenkein DP, and Anderson KC, “A Phase 2 Study of Two Doses of Bortezomib in Relapsed or Refractory Myeloma,” *Blackwell Br J of Haematol.* 127:165-172 (2004).
104. Feinman R, Siegel DS, and **Berenson JR**, “Regulation of NF- κ B in Multiple Myeloma: Therapeutic Implications,” *Clinical Advances in Hematology & Oncology.* 2:3 March (2004).
105. **Berenson JR** and Hirschberg R, “Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid,” *The Oncologist.* 9:319-329 (2004).
106. **Berenson JR**, “Potential Antitumor Effects of Bisphosphonates,” *Emerging Treatment Paradigms in Multiple Myeloma.* July (2004).
107. Richardson PG, Barlogie B, and **Berenson JR**, “Survival, Duration of Response, and Time to Progression with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma: An Update with Additional Follow-up,” *Hematol J*, 5 (suppl 2): s103, (2004).
108. **Berenson JR**, Swift RA, Ferretti D, and Purner MB, “A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma,” *Clin Lymphoma*, 5(2):130-134 Sep (2004).
109. **Berenson JR**, “Biology and Management of Multiple Myeloma,” *Current Clinical Oncology (Cancer Research Oncology/Hematology)*, 1:385, May (2004).
110. **Berenson JR**, “Myeloma, a Malignant Proliferation of Plasma Cells,” *Cure*, 3:4, Winter (2004).
111. Ingo JD and Bergner R, **Berenson JR**, and Hirschberg R, “Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid,” *The Oncologist*, 10:82-83 (2005).
112. **Berenson JR.**, “Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases.” *Oncologist*, 10(1):52-62 Review (2005).

113. Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Alexanian R, Srkalovic G, Orlowski R, Richardson P, Anderson J, Nix DL, Esseltine DL and Anderson KC, “Bortezomib in Recurrent and/or Refractory Multiple Myeloma,” *Cancer*, 103(6):1195-1200 Mar (2005).
114. **Berenson JR**, “Safety of Prolonged Therapy with Bortezomib in Relapsed/Refractory Multiple Myeloma,” *Cancer*, 24: 937 (2005).
115. **Berenson JR**, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, and Anderson K, “Safety of Prolonged Therapy with Bortezomib in Relapsed or Refractory Multiple Myeloma,” *Cancer*, 104(10):2141-2148 (2005).
116. Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, and Anderson KC, “Bortezomib in Relapsed and/or Refractory Multiple Myeloma: Initial Clinical Experience in Patients with Impaired Renal Function. (Bortezomib in Myeloma and Renal Disease),” *Cancer*, 103(6):1195-1200 (March 15, 2005).
117. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, **Berenson JR**, Hussain MM, Klueppelberg U, Norin AJ, Akman HO, Ozcelik T, and Batuman OA, “Circulating Endothelial Progenitor Cells in Multiple Myeloma: Implications and Significance,” *Blood* 105(8):3286-3294 Apr (2005).
118. **Berenson JR**, “Supportive Care in Myeloma,” *Clin Adv Hematol Oncol*, 2(9):569-571 Nov (2005).
119. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, **Berenson JR**, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC, and SUMMIT/CREST Investigators, “Risk Factors and Kinetics of Thrombocytopenia Associated with Bortezomib for Relapsed, Refractory Multiple Myeloma,” *Blood*, 106(12): 3777-3784 Dec (2005).
120. Zheng J, Xie Y, Campbell R, Chen H, Arasteh A, Chen ISY, **Berenson JR**, and Pang S,* “Involvement of Claudin-7 in HIV Infection of CD4(-) cells” *Retrovirology*. 2005 Dec 20;2:79.
121. **Berenson JR**, “Myeloma Bone Disease,” *Best Pract Res Clin Haematol*, 18(4):653-672 Review (2005).
122. Zheng J, Xie Y, Campbell R, Song J, Massachi S, Razi M, Chiu R, **Berenson J**, Yang OO, Chen IS, and Pang S. “Involvement of Claudin-7 in HIV Infection of CD4(-) Cells.” *Retrovirology* 2: 79, 2005.
123. Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, and **Berenson JR**, “LAG Lambda-1: A Clinically Relevant Drug Resistant Human Multiple Myeloma Tumor Murine Model That Enables Rapid Evaluation of Treatments for Multiple Myeloma,” *Int J Oncol*, 28(6):1409-1417 (2006).

124. Yeh H, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, and **Berenson JR**, “Serum Pleiotrophin Levels Are Elevated in Multiple Myeloma Patients and Correlate with Disease Status,” *British Journal of Haematology*, 133: 526-529 (2006).
125. **Berenson JR**, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, and Swift R, “Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma,” *J Clin Oncol*, 24: 937-944 (2006).
126. **Berenson JR**, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Pomeroy JT, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong S-F, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, and Swift RA, “Efficacy and Safety of Melphalan, Arsenic Trioxide and Ascorbic Acid Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Prospective, Multicentre, Phase II Single-Arm Study,” *Br J Haematol* 135:174-183 (2006).
127. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, **Berenson JR**, Singhal S, Siegel DS, Kayd E, Irwin D, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Collins D, Anderson KC, and Amato AA, “Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma with Bortezomib,” *J Clin Oncol*, 24(19):3113-3120 (July 1, 2006).
128. Lipton A, **Berenson JR**, Body J-J, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisey DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, and King L, “Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference,” *Clin Cancer Res* 12(20Suppl):6209s-6212s (October 15, 2006).
129. Yeh HS and **Berenson JR**, “Treatment for Myeloma Bone Disease,” *Clin Cancer Res* (October) 12(20Suppl):6279s-6284s (2006).
130. Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, and **Berenson JR**, “Interference with Nuclear Factor Kappa B and c-Jun NH₂-terminal Kinase Signaling by TRAF6C Small Interfering RNA Inhibits Myeloma Cell Proliferation and Enhances Apoptosis,” *Oncogene*, 25:6520-6527 (2006).
131. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Limentani SA, Kuter D, Hideshima T, Esseltine DL, Schenkein D, and Anderson KC, “Extended Follow-up of a Phase 2 Trial in Relapsed, Refractory Multiple Myeloma: Final Time-to-Event Parameters from the SUMMIT Trial,” *Cancer*, 106(6):1316-1319 (March 15, 2006).
132. **Berenson JR**, Rajdev L and Broder M, “Pathophysiology of Bone Metastases,” *Cancer Biol Ther*, 5(9):1078-1081 Review Sep (2006).

133. **Berenson JR**, Rajdev L and Broder M, “Managing Bone Complications of Solid Tumors,” *Cancer Biol Ther*, 5(9):1086-1089 Review Sep (2006).
134. **Berenson JR**, Rajdev L and Broder M, “Bone Complications in Multiple Myeloma,” *Cancer Biol Ther*, 5(9):1082-1085 Review Sep (2006).
135. **Berenson JR**, Rajdev L and Broder M, “Treatment Strategies for Skeletal Complications of Cancer,” *Cancer Biol Ther*, 5(9):1074-1077 Sep (2006).
136. Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, and **Berenson JR**, “Serum Pleiotrophin Levels are Elevated in Multiple Myeloma Patients and Correlate with Disease Status,” *Br J Haematol*, 133(5):526-529 (2006).
137. Chang Y, **Berenson JR**, Wang Z, and Deuel TF, “Dominant Negative Pleiotrophin Induces Tetraploidy and Aneuploidy in U87MG Human Glioblastoma Cells,” *Biochem Biophys Res Commun*, 351(2):336-339 Dec (2006).
138. Yeh HS and **Berenson JR**, “Myeloma Bone Disease and Treatment Options,” *Eur J Cancer*, 42:1554-1563 (2006).
139. Zheng J, Xie Y, Campbell R, Song J, Wang RQ, Chiu R, **Berenson JR**, Razi M, Massachi S, Yang OO, Chen I, and Pang S, “gp120-Independent HIV Infection of Cells Derived from the Female Reproductive Tract, Brain, and Colon,” *Acqui Immune Defic Syndr* 1-10 (2006).
140. Unger JM, LeBlanc M, Crowley JJ, Grossman B, Natale RB, Wozniak AJ, **Berenson JR**, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, and Coltman CA, “Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture,” *J Clin Oncol*, 21:23s:246s-252s (2006).
141. **Berenson JR** and Yeh HS, “Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy,” *Clinical Lymphoma & Myeloma*, 7:3:192-198 (2006).
142. Jagannath S, Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC, and SUMMIT/CREST Investigators, “Bortezomib in Combination with Dexamethasone for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma with Less Than Optimal Response to Bortezomib Alone,” *Haematologica*, 91(7):929-34 July (2006).
143. **Berenson JR**, Rajev L, and Broder M, “Managing Bone Complications of Solid Tumors,” *Cancer Biol Ther*, 5(9):1086-1089 (September 2006).
144. **Berenson JR**, Rajdev L, and Broder M, “Bone Complications in Multiple Myeloma,” *Cancer Biol Ther*, 5(9):1082-1085 (September 2006).
145. **Berenson JR**, Rajdev L, and Broder M, “Treatment Strategies for Skeletal Complications of Cancer,” *Cancer Biol Ther.*, 5(9):1074-1077 (September 2006).

146. **Berenson JR**, Rajdev L, and Broder M, “Pathophysiology of Bone Metastases,” *Cancer Biol Ther.*, 5(9):1078-1081 (September 2006)
147. Zheng J, Xie Y, Campbell R, Song J, Wang RQ, Chiu R, **Berenson J**, Razi M, Massachi S, Yang OO, Chen IS, and Pang S. “Gp120-independent HIV Infection of Cells Derived from the Female Reproductive Tract, Brain, and Colon.” *Journal of Acquired Immune Deficiency Syndromes* 43:127-36 (2006).
148. **Berenson JR**, “Future Directions in Metastatic Bone Disease: Survival – Where do we go from here?” *Johns Hopkins Adv Stud Med*, 6(10E):S1070-S1075 (2006).
149. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon MS, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, and **Berenson JR**, “Antimyeloma Effects of Arsenic Trioxide Are Enhanced by Melphalan, Bortezomib and Ascorbic acid,” *Br J Haematol*, 138: 467-478 (2007).
150. Chang Y, Zuka M, Perez-Pinera P, Mortimer J, **Berenson JR**, and Deuel TF, “Secretion of Pleiotrophin Stimulates Breast Cancer Progression through Remodeling of the Tumor Microenvironment” *Proc Nat Acad of Sciences*, 104:26:10888-10893 (2007).
151. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, and **Berenson JR**, “Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma,” *Clinical Lymphoma & Myeloma* (2007).
152. **Berenson JR**, “Current Issues, Trends and Advances in Oncology,” CD Pharma Interactive Medical Productions (2007).
153. **Berenson JR**, Matous J, Swift RA, Mapes R, Morrison B, and Yeh HS, “A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” *Clin Cancer Res*, 13(6):1762-1768 (March 15, 2007).
154. Anderson P, **Berenson JR** and Brufsky AM, “New Options in Managing Metastatic Bone Disease,” *Journal Plus*, Annenberg Center for Health Sciences (April 20, 2007).
155. **Berenson JR**, “Editorial for Clinical Lymphoma and Myeloma.” (June 2007).
156. Chen H, Gordon MS, Campbell RA, Li, M Wang, C, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, and **Berenson JR**, “Pleiotrophin is Highly Expressed by Myeloma Cells and Promotes Myeloma Tumor Growth,” *Blood*, 110:287-295 July (2007).
157. **Berenson JR**, Vescio RA, “Pathogenesis of multiple myeloma-I,” *UpToDate*, (September 2007).
158. Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, and **Berenson JR**, “Pleiotrophin is

Highly Expressed by Myeloma Cells and Promotes Myeloma Tumor Growth.” *Blood*, 110(1):287-295 (2007).

159. Campbell RA, and **Berenson JR**, “Animal Models of Multiple Myeloma and Their Utility in Drug Discovery,” *Curr Protocols in Pharmacology*. 14.9.1-14.9.22 (March 2008).

160. **Berenson JR**, and Yellin O, “New Drugs in Multiple Myeloma,” *Curr Opin Support Palliat Care*, 2:204-210 (2008).

161. Hussein MA, Vrionis FD, Allison R, **Berenson JR**, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall L, Roodman D, Siegel D, Vescio R, Zonder J, and Durie BGM, “Keynote Address: The Role of Vertebral Augmentation in Multiple Myeloma: International Myeloma Working Group Consensus Statement,” *Leukemia*, 22:1479-1484 (2008).

162. Perez-Pinera P, Chang Y, **Berenson JR**, and Deuel TF, “Pleiotrophin, a Multifunctional Angiogenic Factor: Mechanisms and Pathways in Normal and Pathological Angiogenesis,” *Curr Opinion in Hematol* 15(3):210-214, May 2008. doi: 10.1097/MOH.0b013e3282fdc69e.

163. Baritaki S, Suzuki E, Umezawa K, Spandidos D, **Berenson JR**, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, and Bonavida B, “Inhibition of Yin Yang 1-dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-enhanced Apoptosis in Cancer Cells,” *J Immunol*, 180(9):6199-6210 (May 1, 2008).

164. **Berenson JR**, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee S-P, Wilson J, Yellin O, Morrison B, Hilger J, and Swift RA, “Safety and Efficacy of Bortezomib and Melphalan Combination in Patients with Relapsed or Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study After Longer Follow-up,” *Annals of Hematol*, 87:623-631 (2008).

165. Li ZW, Chen H, Campbell RA, Bonavida B, and **Berenson JR**, “NF- κ B in the Pathogenesis and Treatment of Multiple Myeloma,” *Curr Opinion in Hematol* 15(4):391-399 (July 2008).

166. **Berenson JR**, Yellin O, Boccia RV, Flam M, Wong S-F, Batuman O, Moezi MM, Woytowicz D, Duivivier H, Nassir Y, and Swift RA, “Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss,” *Clin Cancer Res*, 14(19):6289-6295 (October 1, 2008).

167. Bashey A, Perez WS, Zhang M-J, Anderson KC, Ballen K, **Berenson JR**, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, and Hari P on behalf of the Plasma Cell Disorders Working Committee, “Comparison of Twin and Autologous Transplants for Multiple Myeloma,” *Biol Blood Marrow Transplant*, 14:1118-1124 (2008).

168. Coleman RE, Guise TA, Lipton A, Roodman GD, **Berenson JR**, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Vessella RL, and Weilbaecher KN, “Advancing Treatment for Metastatic Bone

Cancer: Consensus Recommendations from the Second Cambridge Conference,” Clin Cancer Res, 14(20):6387-6395 (October 15, 2008)

169. Jagannath S, Barlogie B, **Berenson JR**, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine D-L, and Anderson KC, “Short Report: Updated Survival Analyses After Prolonged Follow-up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma,” Br J Haematol., 143(4):537-540 (November 2008).

170. **Berenson JR**, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, and Swift RA, “A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” Clin Cancer Res, 15(3):1069-1075 (2009).

171. **Berenson JR**, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: An Effective and Well-Tolerated Frontline Regimen,” Eur J Haematol, 82:432-439 (2009).

172. **Berenson JR** and Yellin O, “Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeleton is Important,” Clinical Lymphoma & Myeloma, 9(4):311-315 (August 2009).

173. **Berenson JR**, “Bortezomib in Newly Diagnosed Multiple Myeloma,” Nature Reviews 6:1-2 (May 2009).

174. Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, Shalitin D, Zeng Z, Gui D, Perez-Pinera P, Berenson RJ, Said F, Bonavida B, Deuel, and **Berenson JR**, “Tumor-Produced Pleiotrophin Induces Transdifferentiation of Monocytes into Vascular Endothelial Cells: A Novel Mechanism of Tumor-Induced Vasculogenesis,” Blood, 113:1992-2002 (2009). **Cover Paper & Cover Photograph.**

175. Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, Campbell RA, Xie Y, Chiu R, **Berenson JR**, Shi W, Chen IS, and Pang S, “Regulation of Prostate-Specific Antigen Expression by the Junctional Adhesion Molecule A,” Urology, 73(5):1119-1125 (2009).

176. Richardson P, Jagannath S, Hussein M, **Berenson JR**, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, and Anderson KC, “Safety and Efficacy of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma,” Blood, 114(4):772-778 (23 July 2009).

177. Baritaki S, Yeung K, Palladino M, **Berenson JR**, and Bonavida B, “Pivotal Role of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization,” Cancer Res, 69(21):8376-8385 (November 1, 2009).

178. Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li Z-W, Chen H, and **Berenson JR**, “The Proteasome Inhibitor CEP-18770 Enhances the Anti-Myeloma Activity of Bortezomib and Melphalan,” Br J Haematol, 148(4):569-581 (February, 2010).

179. Campbell R, Sanchez E, Steinberg J, Shalitin D, Li Z-W, Chen H, and **Berenson JR**, “Vorinostat Enhances the Anti-Myeloma Effects of Melphalan and Bortezomib,” *Eur J Hematol*, 84:201-211 (March 2010).
180. Huerta-Yepe, Militello L, Baritaki S, Pzaos CMR, Cabrera-Munoz MdL, Vega MI, Libra M, Malaponte G, Canevari S, Castellano G, Chen H, and **Berenson JR**, “Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies,” *Forum on Immunopathological Diseases and Therapeutics*, 1(1-2):127-139 (2010).
181. Chen H, Wang C, Li M, Sanchez E, Li J, Berenson AM, Steinberg JA, Wang J, Shen J, Li ZW, Bonavida B, and **Berenson JR**, “A Novel Angiogenesis Model for Screening Anti-Angiogenic Compounds: The Chorioallantoic Membrane/Feather Bud Assay,” *Int J Oncol*, 37:71-79 (2010).
182. Hussein M, **Berenson JR**, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, and Whiting N, “A Phase I Multidose Study of Dacetuzumab (SGN-40; Humanized Anti-CD40 mAb) in Patients with Multiple Myeloma,” *Haematologica*, 95:845-848 (2010).
183. Terpos E, **Berenson JR**, Cook RJ, Lipton A, and Coleman RE, “Prognostic Variables for Survival and Skeletal Complications in Patients with Multiple Myeloma Osteolytic Bone Disease,” *Leukemia*, 24:1043-1049 (2010).
184. **Berenson JR**, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau J-L, Joshua D, Lonial D, Niesvizky R, Palumbo A, Roodman GD, San-Miguel J, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, and Kyle RA, “Monoclonal Gammopathy of Undetermined Significance: A Consensus Statement,” *Br J Haematol*, 150 (1): 28-38 (2010).
185. **Berenson JR**, “Therapeutic Options in the Management of Myeloma Bone Disease,” *Semin. Oncol* 37, (suppl 1):S20-S29 (2010)
186. Epstein MS, Wicknick F, Epstein JB, **Berenson JR**, and Gorsky M, “Management of Bisphosphonate-Associated Osteonecrosis: Pentoxifylline and α -Tocopherol, an Initial Case Series,” *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 110:593-596 (2010).
187. **Berenson JR**, Yellin O, Crowley J, Makary A, Gravenor D, Yang H, Upadhyaya G, Flinn I, Staszewski H, Tiffany N, Sanani S, Farber C, Morganstein N, Bolejack V, Nassir Y, Sefaradi A, Shamouelian A, and Swift R, “Prognostic Factors and Jaw and Renal Complications Among Multiple Myeloma Patients Treated with Zoledronic Acid,” *Am J Hematol*, 110:25-30 (2011).
188. **Berenson JR**, Boccia R, Lopez T, Warsi GM, Argonza-Aviles E, Lake S, Ericson SG, and Collins R, “Results of a Multicenter Open-Label Randomized Trail Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (The ZMAX Trial),” *J Supportive Oncol*, 9:32-40 (2011).
189. Waterman G, Yellin O, Swift R, Mapes R, and **Berenson JR**, “A Retrospective Review of Pegylated Liposomal Doxorubicin (PLD), Bortezomib and Dexamethasone (DVD) for Relapsed and Refractory (R/R) Multiple Myeloma (MM) Patients,” *Ann Hematol*, 90:193-200 (2011).

190. **Berenson JR**, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Ashraf T, and Vrionis F, “A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty to Nonsurgical Fracture Management in the Treatment of Painful, Acute Vertebral Compression Fractures in Cancer Patients,” *Lancet Oncology*, 12:225-235 (2011).
191. **Berenson JR**, Yellin O, Blumenstein B, Bojanower D, Croopnick J, Aboulafia G, and Spadaccini C, “Using a Powered Bone Marrow Biopsy System Results in Shorter Procedures, Causes Less Residual Pain to Adult Patients and Yields Larger Specimens,” *Diagnostic Pathology* 6:23-29 (2011).
192. **Berenson JR**, Yellin O, Quiery A, Brady J, Patel R, Wong S-F, Colbourn D, Gravenor D, Tiffany N, Shamasunder HK, and Wirtschafter E, “A Retrospective Study to Evaluate the Work up and Follow up of Patients with Monoclonal Gammopathy of Undetermined Significance,” *Clinical Lymphoma, Myeloma and Leukemia* 11:336-341 (2011).
193. Migliorati CA, Epstein JE, Abt E, and **Berenson JR**, “Osteonecrosis of the Jaw and Bisphosphonates in Cancer: A Narrative Review,” *Nature Rev Endocrinol*, 7:34-42 (2011).
194. Sanchez E, Shen J, Steinberg J, Campbell RA, Li M, Wang C, Bonavida B, Chen H, Li Z-W, and **Berenson JR**, “LBH589 Enhances the Anti-Myeloma Effects of Chemotherapy *In Vitro* and *In Vivo*,” *Leukemia Res*, 35(3):373-379 (2011).
195. Terpos E, Dimopoulos MA, and **Berenson JR**, “Established Role of Bisphosphonate Therapy for Prevention of Skeletal Complications from Myeloma Bone Disease,” *Crit Rev Oncol Hematol*, 77(Suppl 1):S13-S23 (2011).
196. **Berenson JR**, “Anti-tumor Effects of Bisphosphonates: From the Laboratory to the Clinic,” *Current Opinion Supportive and Palliative Care*, 5:233-240 (2011)
197. Waterman G, Yellin O, Jamshidia K, Swift R, Tamkin J, Audell R, and **Berenson JR**, “Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates: A Report of Six Cases,” *J Bone and Joint Surg Am*, 93:e106 (1-9) (2011).
198. **Berenson JR**, Yellin O, Chen C-S, Patel R, Bessudo A, Boccia RV, Yang HH, Vescio R, Wirtschafter E, Hilger JD, and Swift RA, “A Modified Regimen of Pegylated Liposomal Doxorubicin, Bortezomib, and Dexamethasone is Effective and Well Tolerated in Frontline Treatment of Multiple Myeloma,” *Brit J Haematol*, 155:580-587 (2011).
199. Bonavida B, Huerta-Y S, Baritaki S, Vega M, Liu H, Chen H, and **Berenson JR**, “Overexpression of Yin Yang 1 in the Pathogenesis of Human Hematopoietic Malignancies,” *Critical Reviews in Oncogenesis*, 16(3-4):261-267 (2011).
200. **Berenson JR**, “The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients with Multiple Myeloma,” *Clinical Lymphoma, Myeloma and Leukemia*, 12:2-4 (2012).

201. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, **Berenson JR**, and Bonavida B, "TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target," *Clinical Lymphoma, Myeloma and Leukemia*, 12:155-63 (2012).
202. Sanchez E, Ji M, Wang C, Nichols CM, Li J, Chen H, and **Berenson JR**, "Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206," *Clinical Cancer Res*, 18(14):3856-3867 (2012).
203. Papanastassiou J, Phillips F, Meirhaege JV, **Berenson J**, Andersson G, Chung G, Danilov CM, Small BJ, and Vrionis F, "Comparing Effects of Kyphoplasty, Vertebroplasty, and Non-Surgical Management in a Grouped and Meta-Analysis of Randomized and Non-Randomized Controlled Trials," *European Spine J*. 21:1826-1843 (2012).
204. Sanchez E, Li M, Li J, Wang C, Chen H, and **Berenson JR**, "CEP-18770 (Delanzomib) in Combination with Dexamethasone and Lenalidomide Inhibits the Growth of Multiple Myeloma," *Leukemia Res*, 36:1422-1427 (2012).
205. Eshagian S and **Berenson JR**, "Multiple Myeloma: Improved Outcomes with New Therapeutic Approaches," *Current Opinion Supportive and Palliative Care*, 6:330-336 (2012).
206. **Berenson JR**, "The Future of Treatment for Multiple Myeloma," *Commun Oncol*, 9:S47-S51 (2012).
207. **Berenson JR**, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, and Swift RA, "A Phase 2 Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma," *Leukemia*, 26(7):1675-80 (2012).
208. Papanastassiou JD, Aghayev K, **Berenson JR**, Schmidt M, and Vrionis FD, "Is Vertebral Augmentation the Right Choice for Cancer Patients with Painful Vertebral Compression Fractures?" *JNCCN*, 12:715-719 (2012).
209. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Okhovat J-P, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, and **Berenson JR**, "Serum BCMA is Elevated in Multiple Myeloma and Correlates with Disease Status and Survival," *Brit J Haematol*, 158 (6):727-738 (2012).
210. Papanastassiou J, Phillips F, Van Meirhaeghe J, **Berenson JR**, Anderson G, Chung G, Small B, Aghyev K, and Vrionis F, "Comparing Effects of Kyphoplasty, Vertebroplasty and Nonsurgical Management in a Meta-Analysis of Randomized and Non-Randomized Controlled Studies," *European Spine Journal*, 21:1826-1843 (2012).

211. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang M-J, Li P, **Berenson JR**, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, and Hari P, “Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research,” *Leukemia*. 26:1091-1097 (2012).
212. **Berenson JR**, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnellly D, Siegel RS, Kewalramani T, Gorak EJ Swift RA, and Mayo D, “Phase I/II Trial Assessing Bendamustine Plus Bortezomib Combination Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma,” *Brit J Haematol*, 160:321-330 (2013).
213. **Berenson JR**, Hilger JD, Yellin O, Boccia R, Matous J, Dressler K, Ghazal H, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, and Vescio R, “A Phase 1/2 Study of Oral Panobinostat Combined with Melphalan for Patients with Relapsed or Refractory Multiple Myeloma,” *Ann Hematol*, 93:89-98 (2014).
214. Mulligan G, Lichter D, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyah N, Bolen J, Dorner A, Van de Velde H, Ricci D, Lonial S, Richardson P, Jagannath S, **Berenson JR**, Irwin DH, Stadtmauer E, Traynor AM, Orłowski RZ, Mavromatis B, Hedewisch-Becker S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine D, and Schu M, “Mutation of NRAS but Not KRAS Significantly Reduces Myeloma Sensitivity to Single-Agent Bortezomib Therapy,” *Blood*, 123:632-639 (2014).
215. Sanchez E, Chen S, and **Berenson JR**, “*In Vivo* Models of Multiple Myeloma,” *Biochemical Pharmacology*, 89:313-320 (2014).
216. Terpos E, **Berenson JR**, Raje N, and Roodman D, “Management of Bone Disease in Multiple Myeloma,” *Expert Rev Hematol* 7(1):113-25 (2014).
217. **Berenson JR** and Giralt S, “To Transplant or Not to Transplant in Multiple Myeloma,” *Clinical Advances in Hematology & Oncology*, 12:319-323 May (2014).
218. Kumar S, Bensinger W, Zimmerman T, Reeder C, **Berenson JR**, Berg D, Hui A, Gupta N, Yu J, Shou Y, and Niesvizky R, “Weekly Dosing of the Investigational Oral Proteasome Inhibitor Ixazomib Citrate in Relapsed/Refractory Multiple Myeloma,” *Blood*, 124:1047-1055 (2014).
219. **Berenson JR**, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman, Gravenor D, Eshaghian S, Nassir Y, Swift RA, and Vescio RA, “Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy,” *Leukemia*, 28(7):1529-1536 (2014).
220. Huerta-Yepez S, Liu H, Baritaki S, De Loides Cabrera-Hernandez M, Rivera-Pazos C, Maldonado-Valenzuela, Valencia-Hipolito A, Vega MI, Chen H, **Berenson JR**, and Bonavida B, “Overexpression of Yin Yang 1 in Bone Marrow-Derived Human Multiple Myeloma and Its Clinical Significance,” *Int J Oncol* 45 (3):1184-1192 (2014).

221. Andrea-Vieyra C and **Berenson JR**, “Carfilzomib in Multiple Myeloma,” Expert Opinion on Biological Therapy, e-published August 29, 2014.
222. Andreu-Vieyra C and **Berenson JR**, “The Potential of Panobinostat as a Treatment Option for Multiple Myeloma,” Therapeutic Adv in Hematol, e-published October 17, 2014.
223. Gillespie A, Sanchez E, Tang G, Chen H, and **Berenson J**, “TNFRSF17,” Atlas Genet Cytogenet Oncol Haematol. October (2014).
224. **Berenson JR**, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Shlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, and Vescio R, “A Phase 3 Trial of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma,” Supportive Care Cancer, 23:1503-1512 (2015).
225. **Berenson JR**, Vesole D, and Seigel D, “Do Patients with Multiple Myeloma Need Maintenance Treatment?” Clinical Advances in Hematology & Oncology, 13:163-166 March (2015).
226. Wang Y, Yang F, Shen Y, Zhang W, Kothari N, Chang VT, Guan X, Champlin R, **Berenson JR**, and Wang ML, “Maintenance Therapy with Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis of Phase 3 Randomized Controlled Trials,” J Natl Cancer Inst, 108(3):djv342 November (2015).
227. Wang J, Udd KA, Vedisheva A, Swift RA, Spektor T, Bravin E, Schneiderman E, Ibrahim E, Treisman J, Masri M, and **Berenson JR**, “Low Serum Vitamin D Occurs Commonly among Multiple Myeloma Patients Treated with Bortezomib and/or Thalidomide and is Associated with Severe Neuropathy,” Support Care Cancer, 24:3105-3110 February (2016).
228. Xiang J, Leung C, Hu C, Geng C, Liu L, Jiang C, Yi L, Li Z, **Berenson J**, and Bai X, “Synthesis and Evaluation of 2-alkylthio-4-(N-substituted sulfonamide) Pyrimidine Hydroxamic Acids as Anti-Myeloma Agents,” Chem Biol Drug Des. 87(3): 472-477 (2016).
229. **Berenson JR**, Spektor TM, and Wang J, “Advances in the Management of Multiple Myeloma,” Journal of Community and Supportive Oncology, 14(5):232-235 May (2016).
230. Harutyunyan NM, Vardanyan S, Ghermezi M, Jillian Gottlieb J, Berenson A, Andreu-Vieyra C, Udd K, and **Berenson JR**, “Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients,” Br J Haematol, 174(1):81-87 July (2016).
231. Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang C, Finlay J, Chen H, and **Berenson JR**, “Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma,” Clin Cancer Res, 22(13):3383-97 July (2016).

232. **Berenson JR**, Cartmell A, Bessudo A, Lyons R, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, and Berdeja JG, “Results of CHAMPION-1: A Phase 1/2 Study of Weekly Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma,” *Blood*, 127(26):3360-68 July (2016).
233. Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, **Berenson JR**, Doyle A, Nock S, and Wilson DS, “Targeting Attenuated IFN α to Myeloma Cells with an a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity,” *PLOS ONE*, 11(9): Sept (2016).
234. Robinson A, Wang J, Vardanya S, Madden E, Hebroni F, Udd K, Spektor T, Nosrati J, Kitto A, Zahab M, Cheema S, Fors D, Norber A, Diehl J, Waterman G, Swift RA, Crowley J, and **Berenson JR**, “Risk of Skin Cancer in Multiple Myeloma Patients: A Retrospective Cohort Study,” *Eur J Haematol*, 97(5):439-444 November (2016).
235. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, and **Berenson JR**, “Improved Clinical Outcomes for Multiple Myeloma Patients Treated at a Single Specialty Clinic,” *Annals of Hematol*. 96:441-448 (2017).
236. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, and **Berenson JR**, “Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib,” *Annals of Hematol*. 96:449-459 (2017).
237. Ghermezi M, Li M, Vardanyan S, Harutyunyan N, Gottlieb J, Berenson A, Spektor T, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang C, Swift RA, Chen H, and **Berenson JR**, “Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients,” *Haematologica*. 102(4):785-795 (2017).
238. **Berenson JR**, Manges R, Badarinath S, Cartmel A, Macintyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, and Rifkin R, “A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma,” *American J Hematol*. 92:460-466 (2017).
239. Chen H, Li M, Sanchez E, Wang C, Lee T, Soof CM, Casas C, Jasmin Cao J, Tang GY, and **Berenson JR**, “TRAF6 Is Over-Expressed in Multiple Myeloma and Blocking Its Intracellular Signaling Shows Both Anti-Myeloma and Anti-Bone Resorptive Effects,” *Molecular Cancer Res*. 15:598-609 (2017).
240. Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, and **Berenson JR**, “Anti-Angiogenic and Anti-Multiple Myeloma Effects of Oprozomib (OPZ) Alone and in Combination with Pomalidomide (Pom) and/or Dexamethasone,” *Leukemia Res*. 57:45-54 (2017).

241. Boccia RV, Bessudo A, Agajanian A, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, and **Berenson JR**, “A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2),” *Clinical Lymphoma, Myeloma and Leukemia* 17:433-437 (2017).
242. Udd K, Spektor T, **Berenson JR**, “Monitoring Multiple Myeloma,” *Clinical Advances in Hematology & Oncology*. 15(12):951-961 (2017).
243. Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, and **Berenson JR**, “Manifestation of Peripheral Neuropathy in Multiple Myeloma Patients with Bortezomib Retreatment,” *Support Care Cancer*. 25:3217-3224 (2017).
244. Cohen A, Spektor TM, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Swift RA, Vescio R, and **Berenson JR**, “Safety and Efficacy of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed and Refractory Multiple Myeloma,” *Brit J Haematol*. 180:60-70 (2018).
245. Sanchez E, Smith E, Yachar M, Patil S, Mingjie L, Porter AL, Tenenbaum EJ, Schlossberg R, Soof C, Hekmati T, Tang G, Wang C, Chen H, and **Berenson JR**, “The Role of BCMA in Biology, Management, and as a Potential Therapeutic Target in Multiple Myeloma,” *Targeted Oncology*. 13:39-47 (2018).
246. Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Hekmati T, Tang G, Wang CS, Chen H, and **Berenson JR**, “The Clinical Significance of BCMA as a Therapeutic Target and Biomarker,” *Expert Review of Molecular Diagnostics*. 18(4):319-329 (2018).
247. Moreau P, Mateos MV, **Berenson JR**, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang, M, Zahlten-Kumeli A, Stewart AK, “Once Weekly vs Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Interim Analysis Results of a Randomized, Phase 3 Study,” *The Lancet Oncology*. 19(7):953-964 (2018).
248. Gross Z, Rahbari A, Wirtschafter E, Spektor T, Udd K, Bujarski S, Ghermezi M, Nosrati J, Vidisheva A, Eades B, Cecchi G, Maluso T, Swift R, and **Berenson JR**, “Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study,” *European Journal of Haematol*. 100(6):621-623 (2018).
249. Rahbari KJ, Nosrati JD, Spektor TM, and **Berenson JR**, “Venetoclax in Combination with Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma,” *Clinical Lymphoma, Myeloma and Leukemia*. 18(9):e339-e343 (2018).
250. Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, Schlossberg RE, Vidisheva AP, Tanenbaum EJ, Hekmati T, Wang C, Tang G, Chen H, and **Berenson JR**, “The Anti-Myeloma Effects of the Selective JAK1 Inhibitor (INCB052793) Alone and in Combination *in vitro* and *in vivo*,” *Annals of Hematol*. 98(3):691-703 (2019).

251. Chen H, Li M, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, and **Berenson JR**, “Serum BCMA Reduces Binding of Anti-BCMA Antibody to Multiple Myeloma Cells,” *Leukemia Res.* 81:62-66 (2019).
252. Shah J, Usmani S, Stadtmayer E, Rifkin R, **Berenson JR**, Berdeja J, Lyons R, Klippel Z, Chang Y, and Niesvizky R, “Oprozomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma,” *Clinical Lymphoma, Myeloma and Leukemia.* 19(9): 570-578 (2019).
253. Maglione PJ, Huaibin MK, Tokuyama M, Gyimesi G, Soof CM, Mingjie L, Sanchez E, Chen H, Radigan L, **Berenson JR**, and Cunningham-Rundles C, “Serum B Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies,” *J Allergy and Clin Immunol.* 2019 Aug 17. pii: S2213-2198(19)30718-4.
254. Ghermezi M, Spektor TM, and **Berenson JR**, “The Role of JAK Inhibitors in Multiple Myeloma: A Review,” *Clinical Advances in Hematology & Oncology.* 17(9):500-505 (2019).
255. Udd KA, Rassenti LZ, David ME, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Spektor TM, Kipps TJ, and **Berenson JR**, “Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia,” *Targeted Oncology.* 14(5):551-561 (2019).
256. Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, Cao J, Hekmati T, Zahab B, Nosrati J, Wen M, Wang CS, Tang G, Xu N, and **Berenson JR**, “JAK1/2 Pathway Inhibition Suppresses M2 Polarization and Overcomes Resistance of Myeloma to Lenalidomide by Reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 Expression,” *Brit J Haematol.* 188(2):283-294 (2020).
257. Moreau P, Stewart AKS, Dimopoulos M, Siegel D, Facon T, **Berenson JR**, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, and Mateos VM, “Once-weekly (70 mg/m²) versus Twice-weekly (56 mg/m²) Dosing of Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 Trials,” *Cancer Medicine.* 9:2989-2996 (2020).
258. Henning C, Wang J, Swift R, Eades B, Spektor TM, and **Berenson JR**, “Removal of A Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report,” *Case Reports in Oncology.* 13(3):1103-1110 (2020).
259. **Berenson JR**, To J, Spektor T, Turner C, Sanchez A, Ghermezi M, Eades BR, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss R, Lim S, and Vescio R, “A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” *Clinical Cancer Res.* 26(10):2346-2353 (2020).

260. Henning C, Meyers S, Eades B, Swift B, Bussell L, Spektor TM and **Berenson JR**, “The Efficacy of Topical Use Crisaborole 2% Ointment for Skin Lesions from Necrobiotic Xanthogranuloma Associated with Multiple Myeloma,” *Clinical Lymphoma, Myeloma and Leukemia*. 20(8): e492-e495 (2020).
261. Meyers S, Henning C, Swift R, Eades B, Spektor TM, and **Berenson JR**, “Treatment with Elotuzumab in Combination with Dexamethasone Achieves a Complete Remission in a Previously Treated Multiple Myeloma Patient: A Case Report,” *Clinical Lymphoma, Myeloma and Leukemia*. 20(11):e801-e804 (2020).
262. Regidor B, Swift R, Eades B, Emamy-Sadr M, Tarhini F, Spektor TM, and **Berenson JR**, “Frequent Occurrence of Hypophosphatemia among Multiple Myeloma Patients Treated with Elotuzumab: A Single Clinic Retrospective Study,” *Annals of Hematol*. 100(4):1079-1085 (2020).
263. Jew S, Chang T, Bujarski S, Spektor TM, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, and **Berenson JR**, “Normalization of Serum B-cell Maturation Antigen Levels Predicts Overall Survival in Multiple Myeloma Patients Starting Treatment,” *Brit J Haematol*. 192:272-280 (2021).
264. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Wen M, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang CS, Xu N, Spektor TMS, and **Berenson JR**, “Ruxolitinib Reverses Checkpoint Inhibition by Reducing PD-L1 Expression and Increases Anti-tumor Effects of T-cells in Multiple Myeloma,” *Brit J Haematol*. 192:568-576 (2021).
265. Jew S, Bujarski S, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Spektor T, and **Berenson JR**, “Estimating a Normal Reference Range for Serum B-cell Maturation Antigen Levels for Multiple Myeloma Patients,” *Brit J Haematol*. 192(6):1064-1067 (2021).
266. Regidor B, Goldwater M-S, Wang J, Swift R, Eades B, Emamy-Sadr M, Eshagian S, Spektor TM, and **Berenson JR**, “Low Dose Venetoclax in Combination with Bortezomib, Daratumumab and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients—A Single Center Retrospective Study,” *Annals of Hematol*. 100:2061-2070 (2021).
267. Bujarski S, Goldwater M, Regidor BS, Jew S, Swift RA, Eades BR, Emamy-Sadr M, Souther E, Li M, Wang C, Xu N, Chen H, Spektor TM, and **Berenson JR**, “Baseline Serum B-cell Maturation Levels Predict Time to Disease Progression for Patients with Smoldering Multiple Myeloma,” *Eur J Haematol*. 107:318-323 (2021).
268. Bujarski S, Udd K, Soof C, Chen H, Spektor T, Safaie T, Li M, Sanchez E, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, and **Berenson JR**, “Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status among Relapsed/Refractory Multiple Myeloma Patients undergoing New Treatments,” *Targeted Oncology*. 16:503-515 (2021).

269. Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, **Berenson JR**, and Dispenzieri A, “Serum BCMA Levels Predict Outcomes in MGUS and Smoldering Myeloma Patients,” *Blood Cancer J.* 11:120-126 (2021).
270. Stampfer SD, Goldwater M, Jew S, Bujarski S, Daniely D, Regidor B, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Feinstein A, Spektor TM, and **Berenson JR**, “Response to mRNA Vaccination for COVID-19 among Patients with Multiple Myeloma,” *Leukemia.* 35:3534-3541 (2021).
271. Bujarski S, Sutanto C, Spektor TM, To J, Swift RA, Green T, Eades BR, Emamy-Sadr M, Souther E, and **Berenson JR**, “Use of Serum B-cell Maturation Antigen (sBCMA) Levels to Predict Outcomes for Myeloma Patients Treated with Ruxolitinib, Lenalidomide and Methylprednisolone,” *Hematological Oncology.* 40(2):243-248 (2022).
272. Yashar D, Spektor TM, Martinez D, Sanchez AJ, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, and Vescio R, and **Berenson JR**, “A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High-Risk Relapsed/Refractory Multiple Myeloma,” *Leukemia and Lymphoma.* 63(4):975-983 (2022).
273. Stampfer SD, Goldwater M-S, Bujarski S, Regidor B, Zhang W, Feinstein AJ, Jew S, Chen H, Xing N, Li M, Fung E, Aquino E, Swift R, Eshaghian S, Vail E, and **Berenson JR**, “Severe Breakthrough COVID-19 with a Heavily Mutated Variant in a Multiple Myeloma Patient 10 Weeks after Vaccination,” *Clinical Infection in Practice.* 13:100130 (2022).
274. Zeidan, AM, Cook RJ, Bordoni R, **Berenson JR**, Edenfield WJ, Zhou G, Asatiani E, and Savona MR, “A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 and Itacitinib Alone or in Combination with Standard Therapies for Advanced Hematologic Malignancies,” *Clinical Lymphoma, Myeloma and Leukemia.* 7:523-534 (2022).
275. Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, Moezi MM, Bessudo A, Coleman T, Hrom J, Eshaghian S, Swift RA, Eades BR, Lim S, and **Berenson JR**, “A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib,” *Experimental Hematol.* 111:79-86 (2022).
276. Soof CM, Spektor TM, Parikh SA, Slager SL, Rabe KG, Call TG, Kednerian SS, Ding W, Muchtar E, Ghermezi M, Kay NE, and **Berenson JR**, “Serum B-Cell Maturation Antigen as a Prognostic Marker for Untreated Chronic Lymphocytic Leukemia,” *Experimental Hematol.* 111:32-40 (2022).
277. **Berenson JR**, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Matthew Ghermezi, Eades BR, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, MD, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients,” *Hematological Oncology.* 40(5):906-913 (2022).

278. Afari J, Spektor TM, Turner C, Cohen A, Mackintosh R, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart J, Swift RA, Eades BR, Kim C, Kim S, Vescio R, and **Berenson JR**, “Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen,” *Experimental Hematology*. 114:54-60 (2022).
279. Xu N, Yu E, Ng N, Li M, BS, Bujarski S, Yin Z, Hekmati T, Yu J, Daniely D, Wang CS, Chen H, and **Berenson JR**, “The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7H3 in Multiple Myeloma,” *Hematological Oncology*. 48:578-582 (2023).
280. Regidor BS, Siddiqi D, Beatty BM, Goldwater M-S, Jew S, Bujarski S, Swift R, Kim S, and **Berenson JR**. “Efficacy of Venetoclax Plus Anti-CD38 Monoclonal Antibody-Containing Therapies among t(11;14) positive Multiple Myeloma Patients Regardless of Timing of Prior Treatment with this Antibody,” *Eur J. Hematol*. 110(2):222-223 (2023).
281. **Berenson JR**, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Swift R, Eades BM, Bujarski S, Regidor B, Kim C, Kim S, and Vescio R, “Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma,” *British J. Haematol*. 200(6):722-730 (2023).
282. Goldwater MS, Stampfer SD, Regidor BS, Bujarski S, Jew S, Chen H, Xu N, Li M, Dilawer S, Beatty B, Swift R, C, Kim S, and **Berenson JR**, “Third Dose of an mRNA COVID-19 Vaccine for Patients with Multiple Myeloma,” *Clinical Infection in Practice*. 17,100214 (2023).
283. Stampfer SS, Bujarski S, Goldwater M-S, Jew S, Regidor B, Chen H, Xu N, Li M, Fung E, Swift R, Beatty B, Eshaghian S, and **Berenson JR**, “Loss of Anti-Spike Antibodies Following mRNA Vaccination for COVID-19 among Patients with Multiple Myeloma,” *Cancer Reports*. 6(5):e1803 (2023).
284. Regidor BS, Scott Jew S, Goldwater M-S, Beatty BM, Bujarski S, Elsayed A, Danis R, Swift R, and **Berenson JR**, “Efficacy of Isatuximab in Combination with Steroids for the Treatment of Relapsed/Refractory Multiple Myeloma Patients Exhibiting Only Biochemical Progression—a Single Center Retrospective Study,” *European J Hematol*. 111(4):628-635 (2023).
285. Kim S and **Berenson JR**, “Predicting Outcomes and Monitoring Disease in Patients with Multiple Myeloma,” *Clinical Advances in Hematol. and Oncol*. 21:484-493 (2023).
286. Jew S, Bujarski S, Regidor B, Emany-Sadr M, Swift R, Eades B, Eshaghian S, and **Berenson JR**, “Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients,” *Targeted Oncology*. 18:735-747 (2023).
287. Del Dosso A, Tadevosyan E, and **Berenson JR**, “Preclinical and Clinical Evaluation of the Janus Kinase Inhibitor Ruxolitinib in Multiple Myeloma,” *Oncotarget*. 15:65-75 (2024).
288. Jew S, Goldwater M-S, Bujarski S, Regidor B, Emany-Sadr M, Swift R, Eades B, Said J, and **Berenson JR**, “The Incidence of Translocation t(11;14) among Patients with Multiple Myeloma in a Single Clinic,” *Am J Clin Pathol*. 161:16-23 (2024).

289. **Berenson JR**, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BM, Bujarski S, Sebhat Y, Ray R, Kim S, Del Dosso A, and Vescio R, “A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone,” *Targeted Oncology*. 19:343-357 (2024).
290. Danis R, Regidor B, Bujarski S, Scott Jew S, Goldwater M-S, Swift R, Eades B, Marsiye Emamy-Sadr M, and **Berenson JR**, “Serum B-Cell Maturation Antigen Levels Reflect Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report,” *Case Reports in Oncology*. 17(1):747-752 (2024).
291. Yashar D, Bernard Regidor B, Marissa-Skye Goldwater M-S, Bujarski S, Del Dosso A, and **Berenson JR**, “Targeting B-Cell Maturation Antigen for Monitoring and Treatment of Relapsed/Refractory Multiple Myeloma Patients: A Comprehensive Review,” *Therapeutic Advances in Hematology*. [https:// 15:2040620741275797](https://doi.org/10.1177/152040620741275797) (2024).
292. ElSayed A, Mettias S, Danis R, Kim S, and **Berenson JR**, “Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis,” *Perspectives in Clinical Research*. 16:106-107 (2025).
293. Mettias S, Elsayed A, Moore J, and **Berenson JR**, “Multiple Myeloma: Improved Outcomes from a Rapidly Expanding Number of Therapeutic Options,” *Targeted Oncology* 20:247-267 (2025).
294. Frenkel M, Alteber Z, Ning Xu N, Li M, Chen H, Hayoun D, Granit R, Cojocaru G, **Berenson J**, and Ophir E, “The Inhibitory Receptor PVRIG Is Dominantly Expressed in the Bone Marrow of Patients with Multiple Myeloma, and its Blockade Enhances T-Cell Engager’s Immune Activation,” *Experimental Hematol*. 143:104696 (2025).
295. Danis R, Bujarski S, Yashar D, Del Rosso A, Moore J, Mettias S, and **Berenson JR**, “Outcomes of Triple-Class Refractory Multiple Myeloma Patients at a Single Clinic: A Retrospective Study,” *Leukemia Research*. 151:107677.
296. Moore JT, Mettias SM, Swift R, Eades B, Eshaghian S, Schwartz G, and **Berenson JR**, “Clinical Outcomes for Unselected, Newly Diagnosed Multiple Myeloma Patients,” *Haematologica* (in press).

RESEARCH PAPERS – Submitted

297. Freytes CO, Stewart K, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Jacobs C, DiPersio J, Anderson K, **Berenson JR**, and Sing A, “CD34 Selection of Autologous Peripheral Blood Progenitor Cells Does Not Delay Immune Reconstitution or Increases the Incidence of Infections in Patients Transplanted for Multiple Myeloma,” (submitted).

298. Menke D, Chadburn A, Green E, **Berenson JR**, Said J, and Thome S, “Pathogenic Implications of Differences in Detection of HHV-8 Genome and HHV-8 vIL-6 Production in Castleman’s Disease: Implications for Pathogenesis,” (submitted).
299. Hortobagyi GN, Theriault RL, **Berenson JR**, Lipton A, Kowalski MO, and Seaman JJ, “Skeletal-Related Events Associated with Metastatic Breast Cancer and Multiple Myeloma: A Comparative Analysis of Three Multicenter, Randomized Trials of Pamidronate Therapy,” (submitted).
300. Chen T, Ma P, Ravera C, Deckert F, **Berenson JR**, Goodin S, LoRusso P, Schran H, and Seaman J, “Plasma and Urine Pharmacokinetics of Zoledronic Acid in Cancer Patients with Bone Metastases by Noncompartmental and Compartmental Analyses,” (submitted).
301. **Berenson JR**, “Constitutively Active Nuclear Transcription Factor NF-κB has Recently Emerged as a Major Underlying Factor in the Development,” (submitted).
302. Yeh H and **Berenson J**, “New Directions in the Treatment of Multiple Myeloma,” Medscape (submitted).
303. Baritaki S, Suzuki E, Umesawa K, Spandidos D, **Berenson JR**, Daniels TR, Penichet ML, Palladino M, and Bonavida B, “Reversal of Tumor Cell Resistance to TRAIL-Mediated Apoptosis by the Novel Proteasome Inhibitor, NPI-0052, via Inhibition of the Yin Yang 1 and Up-Regulation of DR5,” (submitted).
304. Bashey A, Pérez WS, Zhang M-J, Anderson KC, Ballen K, **Berenson JR**, Fonesca R, Fréytes CO, Gale RP, Gibson J, Giralta SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, and Vesole DH, and Parameswaran H, “Syngenic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Comparison to Autologous Transplantation,” (submitted).
305. Cueto J, Waterman G, and **Berenson J**, “Achievement of Long-term Durable Remission with Single-Agent Zoledronic Acid for a Patient Active Multiple Myeloma,” (submitted).
306. Papanastassiou J, Anderson G, **Berenson J**, Chung G, Van Meirhaeghe J, Phillips F, Scott M, Small B, and Vrionis F, “Which Patients May Not Benefit from Vertebral Augmentation? Treatment Algorithm for Vertebral Compression Fractures,” (submitted).
307. Chen H, Zhang Y, Mao H, Zhao A, Du F, Gian J, Yang J, Wei J, Liu X, Sha Z Han Y, Situ W, Li C, Sheng L, Xu Y, Shou Z Vardanyan S, Bonavida B, and **Berenson J**, “Serum Autoantibodies Directed Against Moesin N1-297/C471-577 is Elevated in Immune Thrombocytopenia,” (submitted).
308. Halleluyan R, Keilty D, and **Berenson JR**, “Extramedullary Multiple Myeloma Involving the Pancreas: A Case Report,” (submitted).
309. Mettias S, Cheung J, Moore J, and **Berenson JR**, “Treatment of a Previously Untreated Multiple Myeloma Patient with Daratumumab and Glucocorticosteroids Achieves a Complete Remission and Resolves Neutropenia: A Case Report,” (submitted).

310. Goldwater M-S, Moore J, Sean Bujarski S, Danis R, Khan Z, Li M, Behare S, Swift R, Emamy-Sadr M, Eades B, and **Berenson JR**, “Serum B-Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients with Waldenström's Macroglobulinemia,” (submitted).

311. Moore J, Tadevosyan E, Sebhat Y, Goldwater M-S, Cheung J, Swift R, Eades B, Schwartz G, Eshaghian S, Vescio R, and **Berenson JR**, “A Pilot Study of Selinexor, Methylprednisolone, and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients,” (submitted).

INVITED EDITOR / EDITORIALS / NEWS

1. **Berenson JR**, Guest Editor, “Skeletal Metastases / Hypercalcemia,” *Journal of Clinical Oncology, Classic Papers and Current Comments*, 4:2, 387-393 (1999).

2. **Berenson JR**, Guest Editor, “Bisphosphonates: Novel Anti-Cancer Drugs,” *Expert Opinion on Investigational Drugs*, December (1999).

3. **Berenson JR**, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, and Knight R, “Long-term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events,” *Classic Papers and Current Comments*, 4:2:411-420, (1999).

4. **Berenson JR**, “PS-341: Prospecting a New Hope for Myeloma,” *Blood*, 101:4:1, February 15, 2003.

5. **Berenson JR**, Section Editor, “Supportive Cancer Therapy,” (2002).

6. Hillner BE, **Berenson JR**, Fanale M, and Hortobagyi GN, “Bisphosphonates in the Prevention and Treatment of Bone Metastases,” *Oncology*, 17:9 (2003).

7. Borad MJ, Yang HH, Swift R, and **Berenson JR**, “Interactive Clinical Case Study: Objective Response and Normalized Renal Function with Melphalan, Trisenox and Ascorbic Acid Combination (MAC) Therapy in a Patient with Azotemic, Late-stage Multiple Myeloma,” *KOL Newsletter*, 1:1:9-10 (2003).

8. **Berenson JR**, “Phase II Study of Arsenic Trioxide Twice-Weekly Dosing in Patients with Multiple Myeloma (CTI-1063),” *Trisenox*, (KOL Newsletter), 1:1, (2003).

9. **Berenson JR**, “Prospective, Open-Label, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma,” *Trisenox*, (KOL Newsletter), 1:1, (2003).

10. **Berenson JR**, “Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention,” – Peer Viewpoint, J Support Oncol, 2:3:205-220 (2004).
11. **Berenson JR** and Yeh HS, “Osteonecrosis of the Jaw in Patients with Cancer Receiving Intravenous Bisphosphonates,” Peer Viewpoint, Oncology, 20:1 (2006).
12. Lipton A and **Berenson JR**, editors for “Bone and Haematological Problems,” Current Opinion in Supportive and Palliative Care, 1:2 (August 2007).
13. **Berenson JR**, “New Developments in Multiple Myeloma Management,” Coping, 32 (May/June, 2007). www.copingmag.com.
14. **Berenson JR** and Yellin O, “New Drugs in Multiple Myeloma,” Curr Opin Support Palliat Care. 2:197-203 (2008).
15. Bijay N and **Berenson JR**, “Updates in the Treatment of Newly Diagnosed Multiple Myeloma: Combination Therapy with Bortezomib, Pegylated Doxorubicin, and Dexamethasone,” Oncology Biotech News (Supplement), pages 1-5 (April 2010).
16. **Berenson JR** and Lipton A, editors for “Bone and Haematological Problems,” Curr Opin Support Palliat Care (2009).
17. **Berenson JR** and Lipton A, editors for “Bone and Haematological Problems,” Curr Opin Support Palliat Care, 16 (9) (2010).
18. **Berenson JR** and Lipton A, editors for “Bone and Haematological Problems,” Curr Opin Support Palliat, (2013).
19. **Berenson JR**, “Improving Bone Health in Patients with Multiple Myeloma,” Value-Based Care in Multiple Myeloma 8:7-8 (Dec 2012).
20. **Berenson JR**, “Better and Brighter Outcomes for Cryoglobulinemia,” Oncology 27(11):1125-26, 1128 (Nov 2013).
21. **Berenson JR**, “Cost-Effective Use of Imaging Modalities for Diagnosis and Monitoring in Multiple Myeloma: Commentary,” Value-Based Care in Multiple Myeloma (Nov 2013).
22. **Berenson JR** and Lipton A, editors for “Bone and Haematological Problems,” Curr Opin Support Palliat, 8(4):405-428 (2014).
23. **Berenson JR**, “Bone Targeted Therapies for Cancer Patients and Bone Cell Biology; Where Do We Stand,” Current Opinion in Supportive and Palliative Care 8(4):405-406 (2014).
24. **Berenson JR**, “Progression-Free Survival in a Treatment Option for Relapsed/Refractory Multiple Myeloma,” Peer Insights 2016:3-4 (Feb 2016).

25. **Berenson JR** and Lipton A, editors for “Bone and Haematological Problems,” *Curr Opin Support Palliat*, 10(4):336-342 (2016).
26. Spektor TM and **Berenson JR**, “Circulating Proteasomes: Circulating Myeloma with a New Potential Biomarker,” *Leuk Lymphoma*, e-published.
27. Spektor TM and **Berenson JR**, Commentary: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777,” *ASCO Post* 8(5):74-76 (March 25, 2017).

CONFERENCE REPORTS

1. **Berenson JR**, “Relationship of Oncogenes to Human Cancer,” *Proceedings of the Fifteenth National Meeting of the Chemical Ligand Assay Society*, 15:23-26 (1989).
2. Barlogie B and Alexanian R (Workshop participants included Bataille R, **Berenson JR**, et al, “Second International Workshop on Myeloma: Advances in Biology and Therapy of Multiple Myeloma,” Meeting Report printed in *Cancer Research* 49:7172-7175 (1989).
3. **Berenson JR**, Hart S, Cao J, Waldburger K, Palomares D, Miller RA, and Lichtenstein A, “Expression of Shared Idiotypes and V_H Gene Families by Patients with Monoclonal Gammopathies” In: Third International Workshop 1:31-32 (1991).
4. **Berenson JR**, “The Molecular Genetics of Multiple Myeloma,” *The First Annual Clinical Conference of the International Myeloma Foundation*, Phoenix, Arizona, June 25-28 (1992).
5. **Berenson JR**, “The Management of Myeloma-Associated Bone Disorders,” *The First Annual Clinical Conference of the International Myeloma Foundation*, Phoenix, Arizona, June 25-28 (1992).
6. Alim A, Razavi M, **Berenson JR**, and Udkoff R, “Bone Marrow MR Patterns in Multiple Myeloma Using Spin Echo and Gradient Echo with Opposed Phase Fat Suppression,” 78th Scientific Assembly of the Radiological Society of North America, to be held in Chicago, IL, November 29-December 4 (1992).
7. **Berenson JR**, Cao J, Vescio R, Hong C, Kim A, and Lichtenstein A, “Identification of Malignant Cells in Multiple Myeloma Bone Marrow with Immunoglobulin V_H Gene Probes by Fluorescent in Situ Hybridization and Flow Cytometry,” *American Association for Cancer Research Conference of Molecular Approaches to Cancer Immunotherapy*, La Jolla, California, November 7-11 (1993).
8. **Berenson JR**, “Advances in Supportive Care in Multiple Myeloma,” 1996 Update on Diagnostic and Treatment Strategies for Multiple Myeloma, *American Society of Hematology Meeting*, Orlando, Florida, December 6 (1996).

9. **Berenson JR**, “The Role of Bisphosphonates in the Treatment of Bone Metastases”, Multiple Myeloma Update, San Diego, CA (1997).
10. **Berenson JR**, “Bisphosphonates in Multiple Myeloma”, Innovative Medical Communications, First Annual Winter Oncology Conference, Supportive Care in Cancer (1997).
11. **Berenson JR**, “New Elements in the Diagnosis and Treatment of Multiple Myeloma”, part of the ASH annual meeting in San Diego (1997).
12. **Berenson JR**, “Kaposi HSV in Multiple Myeloma”, IBMTR/ABMTR Keystone Conference Center (1998).
13. **Berenson JR**, Vescio R, Schiller G, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Benyunes M, Jacobs C, Dipersio J, and Anderson K, “Tumor Purging in Multiple Myeloma Using CD34 Selection: A Phase III Trial”, Innovations in Cell Therapy with Advancements for Patient Care, A Symposium (1998).
14. **Berenson JR**, “The Use of Bisphosphonates in Multiple Myeloma”, Congress 1998 De La Societe Francaise D’Hematologie (1998).
15. **Berenson JR**, “New Treatments in Multiple Myeloma”, Advances in Hematological Malignancies, Mont Tremblant, Quebec, Canada (1998).
16. **Berenson JR**, “Pathogenesis of Multiple Myeloma: The Emerging Role of a Viral Etiology,” New Elements in the Diagnosis and Treatment of Multiple Myeloma Symposium as part of the ASH Symposia Highlights (1998).
17. **Berenson JR**, “Bone Metastasis,” ASCO Fall Conference (1998).
18. **Berenson JR**, “Novel Approaches to Transplantation in Myeloma,” ASBMT IBMTR-ABMTR Keystone Resort, Colorado (1999).
19. **Berenson JR**, “New Advances in the Biology and Treatment of Myeloma,” American Society of Clinical Oncology Fall Education Conference, San Francisco, CA (1999).
20. **Berenson JR**, “The Use of Bisphosphonates in Patients with Multiple Myeloma,” The 1st Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Hobart, Tasmania (1999).
21. **Berenson JR**, “HHV-8 and its Role in the Aetiology of Multiple Myeloma” The 1st Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Hobart, Tasmania (1999).
22. **Berenson JR**, “Clinical Studies of CD34+ Selection in Multiple Myeloma Autografts: Fulfilling the Early Promise?” The 1st Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Hobart, Tasmania (1999).

23. **Berenson JR**, “New Advances in the Biology and Treatment of Myeloma Bone Disease,” 1999 Multiple Myeloma Update, Part of the Corporate Friday Program (1999).
24. **Berenson JR**, “Biology and Treatment of Myeloma Bone Disease,” Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma Symposium, Cedars-Sinai Medical Center, Los Angeles, CA (2001).
25. **Berenson JR**, “Perspectives de los bisfosfonatos de 3rd generacion,” XLII Reunion Nacional AEHH and XVI Congreso Nacional SETH Symposium, Bilbao, Spain (2000).
26. **Berenson JR** and Shakespeare W. “Development of a Novel Bone-Targeted Src Tyrosine Kinase Inhibitor AP23451 Having Potent In Vitro and In Vivo Anti-Resorptive Properties.” MMRF Update on Myeloma Conference, New York, NY, October (2002).
27. **Berenson JR**, “Myeloma & Plasma Cell Disorders,” Myeloma Conference, Los Angeles, CA April 2-3, (2004).
28. **Berenson JR**, “Multiple Myeloma and Related Plasma Cell Dyscrasias,” ASH, San Diego, CA, December (2004).
29. Coleman RE, Guise TE, Lipton A, Roodman GD, **Berenson JR**, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, and Weilbaeher KN, “Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference,” Clinical Cancer Research (2008).

BOOKS & BOOK CHAPTERS

1. **Berenson JR**, Zighelboim J and Gale RP, “Acute Lymphocytic Leukemia,” In: Cancer Treatment, second edition, Haskell, CM (ed.), W.B. Saunders Company, Philadelphia, Chapter 62 (1985).
2. Casciato D and **Berenson JR**, “Immunoproliferative Diseases,” In: Manual of Bedside Oncology, second edition, Casciato DA and Lowitz BB (eds.), Little, Brown and Company, Boston, Chapter 21 (1988).
3. **Berenson JR** and Gale RP, “Acute Lymphocytic Leukemia,” In: Cancer Treatment, third edition, Haskell, CM (ed.), W.B. Saunders Company, Philadelphia, Chapter 57 (1990).
4. Lichtenstein A and **Berenson JR**, “Myeloma, Macroglobulinemia, and Heavy Chain Disease,” In: Cancer Treatment, third edition, Haskell, CM (ed.), W.B. Saunders Company, Philadelphia, Chapter 61 (1990).
5. Casciato D and **Berenson JR**, “Immunoproliferative Diseases,” In: Manual of Bedside Oncology, second edition, Casciato, DA and Lowitz, BB (eds.), Little, Brown and Company, Boston, Chapter 21 (1995).

6. Vescio RA, Lichtenstein A and **Berenson JR**, “Myeloma, Macroglobulinemia, and Heavy Chain Disease,” In: Cancer Treatment, fourth edition, Haskell, CM (ed.), W.B. Saunders Company, Philadelphia, Chapter 98 (1995).
7. **Berenson JR**, Vescio RA, and Schiller G, “Multiple Myeloma”, In: Conn’s Current Therapy, W.B. Saunders Company, Philadelphia, PA (1997).
8. **Berenson JR**, “Plasma Cell Dyscrasias”, In: The Merck Manual of Diagnosis and Therapy, Edition 18, Merck Research Laboratories, Rahway, NJ (1998).
9. **Berenson J** and Casciato D, “Plasma Cell Disorders,” In: Manual of Clinical Oncology, fourth edition, Casciato DA and Lowitz BB (eds.), Little, Brown and Company, Boston, Chapter 22 (1999).
10. **Berenson JR**, “Myeloma,” In: Current Cancer Therapeutics, Third Edition, Chapter 21 (1999).
11. **Berenson JR** and Vescio, RA, “The Molecular Biology of Multiple Myeloma,” In: Molecular Haematology, Provan D and Gribben J, Blackwell Science Ltd, London, Journal Clin Oncol (2000).
12. **Berenson J**, “Biology and Treatment of Myeloma Bone Disease,” In: Cancer and the Skeleton, Rubens, R and Mundy, G, Martin Dunitz Ltd. Publishers, London, Chapter 6 (2000).
13. Vescio RA and **Berenson JR**, “Myeloma, Macroglobulinemia and Amyloidosis,” In: Cancer Treatment, fifth edition, Haskell CM (ed), W.B. Saunders Company, Philadelphia, PA
14. **Berenson JR**, “Myeloma,” In: Current Cancer Therapeutics, 4th ed., Kirkwood, JR, Lotze, MT, Current Medicine, Inc., Philadelphia, PA (2001).
15. **Berenson JR** and Casciato DA, Chapter 22: “Plasma Cell Disorders,” in Manual of Clinical Oncology, 4th edition, Casciato DA and Lowitz BB (eds.), Lippincott, Williams & Wilkins, Philadelphia, PA, 443-460 (2000).
16. Anderson KC (Chair), Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, and **Berenson J**, “Multiple Myeloma: New Insights and Therapeutic Approaches,” in Hematology 2000: American Society of Hematology Education Program Book, Schechter GP, Berliner N, Telen MJ and Bajus JL (eds), San Francisco, CA, 147-165, December 1-5 (2000).
17. **Berenson JR**, “Myeloma,” in 4th Edition Current Cancer Therapeutics, John M. Kirkwood, MD, Michael T. Lotze, MD and Joyce M. Yasko, PhD (eds.), Current Medicine, Inc., Philadelphia, PA, 323-333 (2001).
18. **Berenson JR**, “Plasma Cell Disorders,” Merck Manual, (2002).
19. **Berenson J**, “Myeloma Bone Disease,” in Myeloma, Jayesh Mehta, MD and Seema Singhal, MD, (eds), Martin Dunitz Publishers, United Kingdom, 97-117 (2002).

20. Schiller G and **Berenson J**. “Advances in the Biology and Treatment of Multiple Myeloma” in Chronic Leukemias and Lymphomas, The Humana Press, Totowa, NJ, 215-248 (2002).
21. **Berenson JR**. “Plasma Cell Disorders” in The Merck Manual of Medical Information, Second Home Edition, Merck & Co., Inc., West Point, PA, 1006-1010 (2003).
22. **Berenson JR**, “Management of Skeletal Complications,” in Bone Disease and Myeloma, Martin Bergsagel, MD (ed) (2003).
23. **Berenson JR**, “Biology and Management of Multiple Myeloma,” in Current Clinical Oncology, 385, May (2004).
24. **Berenson JR**, “Bisphosphonates for the Treatment of Multiple Myeloma,” in Robert Coleman, MD’s book, Richard Edelstein (ed), (in press).
25. **Berenson JR** and Casciato DA, Chapter 22: “Plasma Cell Dyscrasias and Waldenstrom’s Macroglobulinemia,” in Manual of Clinical Oncology, 5th Edition, Casciato DA (ed), Lippincott, Williams & Wilkins, Philadelphia, PA, 458-479 (2004).
26. **Berenson JR**, Biology and Management of Multiple Myeloma, **Berenson JR** (ed), Humana Press, Totowa, NJ, (2004).
27. **Berenson JR**, “Myeloma Bone Disease” in Best Practice & Research: Clinical Haematology, Rowe JM (ed), Kyle RA (guest ed), 18:4:653-672 (2005). Doi: 10.1016/j.beha.2005.03.001 <http://www.sciencedirect.com>
28. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Home Edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ (2008).
29. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ (2009)
30. **Berenson JR** and Casciato DA, Chapter 22: “Plasma Cell Dyscrasias and Waldenstrom’s Macroglobulinemia” In Manual of Clinical Oncology, 6th Edition, Casciato, DA (ed), Territo MC (associate editor), Wolters Kluwer | Lippincott Williams & Wilkins Health, Philadelphia, PA, 471-494 (2009).
31. Chansky HA, Casciato DA, and **Berenson JR**, Chapter 33: “Bone and Joint Complications,” in Manual of Clinical Oncology, 6th Edition, Casciato DA (ed) and Mary Territo (assoc editor), Lippincott, Williams & Wilkins, Philadelphia, PA, 644-657 (2009).
32. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual: Home Health Edition. Third Edition, Merck & Co., Inc., West Point, PA, 1051-1055 (2009).
33. **Berenson JR**, Chapter 6: “Bisphosphonates in the Treatment of Myeloma Bone Disease” in Myeloma Bone Disease, David Roodman (ed). Humana Press, New York City, NY, 117-133 (2010).

34. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Jazirehi AR, and **Berenson J**, Chapter 24: “Nitric Oxide Donors are a New Class of Anti-Cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis,” Ben Bonavida (ed) Humana Press/Springer, New York City, NY, 459-477 (2010).
35. **Berenson JR** and Casciato DA, Chapter 22: “Plasma Cell Dyscrasias and Waldenstrom’s Macroglobulinemia,” in Manual of Clinical Oncology, 7th Edition, Casciato DA (ed) and Mary Territo (associate editor), Lippincott, Williams & Wilkins, Philadelphia, PA, 553-582 (2012).
36. Casciato DA, **Berenson JR**, and Chansky HA, Chapter 33: “Bone and Joint Complications,” in Manual of Clinical Oncology, 7th Edition, Casciato DA (ed) and Mary Territo (assoc editor), Lippincott, Williams & Wilkins, Philadelphia, PA, 766-783 (2012).
37. Sanchez E, Chen H, and **Berenson JR**, “Biological Basis for Therapeutic Intervention in Multiple Myeloma: Novel *In Vivo* Models in Myeloma,” In Multiple Myeloma, Nikhil Munshi and Ken Anderson (ed), in press.
38. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ (2013).
39. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, 20th edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ, 1176-1183 (2018).
40. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, 21st edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ, 1176-1183 (2019).
41. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Consumer Edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ (2021).
42. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, 22nd edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ (2021).
43. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, 23rd edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ, 1176-1183 (2023).
44. **Berenson JR**, “Plasma Cell Disorders” in The Merck Manual Professional Edition, 24th edition, continuously updated at www.merckmanuals.com. Publisher, Merck & Co., Inc., Whitehouse Station, NJ, 1176-1183 (in press).

INTERNET PUBLICATIONS & PROGRAMS

1. **Berenson JR** and Vescio RA, "Pathogenesis of Multiple Myeloma," UpToDate, (2000)
<http://uptodate.com>
2. **Berenson JR**, Anderson, K, Blade, J, Kyle R, and Munshi, N, Multiple Myeloma Patient Symposium: "Novel Therapeutic Approaches in the Treatment of Multiple Myeloma," October 6 (2000)
<http://www.healthtalk.com/mmen/mmrfr/replay.html>
3. **Berenson JR**, "Potent New Drug Cuts Cancer Pain and Fractures," Today's Cancer News @ cancerfacts.com, April 4 (2001)
[http://www.cancerfacts.com/Home+News.asp?NewsId=1199&CB=\\$CancerTypeId=4](http://www.cancerfacts.com/Home+News.asp?NewsId=1199&CB=$CancerTypeId=4)
4. **Berenson JR**, "Treating Bone Cancer," reported by Ivanhoe Broadcast News, Inc., April 3 (2001)
<http://ivanhoe.com/docs/newsflash/treatingbonecancer.html>
5. Schorr M, (Reporter), "New Bone Cancer Drug Effective, Easy to Administer," (article on zoledronic acid quoting **James Berenson, MD**), April 4 (2001) <http://www.reutershealth.com>
6. **Berenson JR**, "New Drug May Beat Bone Cancer," (article on zoledronic acid), June 18 (2001)
http://dailynews.yahoo.com/h/kgtv/20010618/lo/834461_1.html
7. **Berenson JR**, "Beating Bone Cancer," (article on zoledronic acid), Reviews: Diseases, August 7 (2001). <http://www.rnews.com/health>
8. **Berenson JR**, "New Drug May Beat Bone Cancer," (article on zoledronic acid), Yahoo!News, August 7 (2001) http://dailynews.yahoo.com/h/kgtv/20010618/lo/834461_1.html
9. **Berenson JR**, "Former Villain May Have Hidden Virtues" article on use of thalidomide to treat multiple myeloma, The New Scientist, 15:1274, August 4 (2001).
10. **Berenson JR**, "New Bone Cancer Drug Effective, Easy to Administer" article on zoledronic acid to treat bone metastasis, on-line April 4 (2001). <http://www.reutershealth.com>
11. **Berenson JR**, "Treating Bone Cancer," April 3 (2001). <http://www.ivanhoe.com>
12. **Berenson JR**, "Reducing the Complications of Cancer that has Spread to the Bone," May (2001)
<http://www.ivanhoe.com>
13. **Berenson JR**, "Potent New Drug Cuts Cancer Pain and Fractures," April 4 (2001)
<http://www.cancerfacts.com>
14. **Berenson JR**, reviewer for American Society of Clinical Oncology (ASCO) website, November (2001). <http://www.oncology.com> & https://cms.oncology_admin/med_reviewer
15. **Berenson JR**, "Treatment Strategies for Myeloma Bone Disease," Multiple Myeloma Research

Foundation's series *Multiple Myeloma Case Challenge Series*, January through December (2003)
<http://www.multiplemyeloma.org> & <http://www.cancereducation.com>

16. **Berenson J**, "Multiple Myeloma Treatment Guidelines," reviewer for the National Oncology Alliance (NOA) website, May (2003). <http://www.noainc.com>
17. **Berenson JR**, Chair, "Bone Overview of Bone Metastases and Bisphosphonates," in New Currents in Treatment of Bone Metastases: A Case Based Approach, September (2003).
<http://www.projectsinknowledge.com>
18. **Berenson JR**, Chair - New Currents in Treatment of Bone Metastases: A Case Based Approach, February (2004). <http://www.projectsinknowledge.com>
19. **Berenson JR**, Current Topics in Bone Metastases: Therapeutic Update (2003)
<http://www.imeronline.com/>
20. **Berenson JR**, Chair and Higano CS, MD, Faculty – Tx Reporter, September 8, (2003)
www.projectsinknowledge.com/urol/
21. **Berenson JR**, Chair and Higano CS, MD, Faculty – Tx Reporter, November 8, (2003)
www.projectsinknowledge.com/urol/
22. **Berenson JR**, Chair and Higano CS, MD, Faculty – Tx Reporter, February 1, (2004)
www.projectsinknowledge.com/urol/
23. **Berenson JR**, Chair and Higano CS, MD, Faculty – Tx Reporter (2004).
www.projectsinknowledge.com/urol/
24. **Berenson JR**, Founding Member "Skeletal Wellness Institute for Cancer," website formed in (2004) www.swicancer.org
25. **Berenson JR**, "Bone Health for People Living with Multiple Myeloma," CancerCare, April (2005). <http://www.cancercare.org>
26. **Berenson JR** and Munshi, N. Great Debates - Therapeutic Options for Relapsed/Refractory Patients: Case-Based Analysis of Treatment Options in Multiple Myeloma, August (2005).
http://www.cancereducation.com/cancersyspagesnb/a/mmrf/mm0503/index_fwd.cfm
27. **Berenson JR**, "Putting Clinical Information into Practice," UpToDate (2005).
<http://uptodate.com>
28. Kyle RA and **Berenson JR**, "The Use of Bisphosphonates in Patients with Multiple Myeloma," UpToDate (2006). <http://www.uptodate.com>
29. Agus ZS and **Berenson JR**, "Treatment of hypercalcemia," UpToDate, (10/3/2007).
<http://uptodate.com>

30. **Berenson JR**, Multiple Myeloma: Optimizing Care Across the Disease Spectrum (2008). <http://www.medscape.com/viewprogram/14624>
31. **Berenson JR** – UpToDate – Ongoing Editor “The Use of Bisphosphonates in Patients with Multiple Myeloma,” UpToDate (9/30/2010) <http://uptodate.com>
32. **Berenson JR**- UpToDate- Ongoing Editor “Risks of Bisphosphonate Therapy in Malignancy,” UpToDate (11/10/10) <http://uptodate.com>
33. **Berenson J**, Raje N, Roodman D, and Drake M, “To the Bone Marrow...And Beyond! Optimizing Bone-Related and Anti-Tumor Properties of Bisphosphonates for Patients with Multiple Myeloma,” webcast (11/17/10 through 11/17/11) <http://updates@imedex.com>
34. **Berenson JR** and Stopeck AS, - UpToDate- ongoing editor “Risks of Therapy with Bone Modifying Agents in Patients with Malignancy” <http://uptodate.com>
35. **Berenson JR**, - UpToDate- ongoing editor “Hypercalcemia of Malignancy” <http://uptodate.com>
36. **Berenson JR** and Stopeck AS, - UpToDate- ongoing editor “Risks of Therapy with bone Antiresorptive Agents in Patients with Advanced Malignancy” <http://uptodate.com>
37. Shane, E and Berenson JR, “Treatment of Hypercalcemia,” UpToDate, (5/22/2019). <http://uptodate.com>
38. **Berenson JR**, - UpToDate- Ongoing Editor “Hypercalcemia of Malignancy,” <http://uptodate.com>
39. **Berenson JR** and Stopeck AS, - UpToDate- Ongoing Editor “Risks of Therapy with Bone Antiresorptive Agents in Patients with Advanced Malignancy,” <http://uptodate.com>
40. **Berenson JR** and Stopeck AS, UpToDate- Ongoing Editor “Medication-related Osteonecrosis of the Jaw in Patients with Cancer,” <http://uptodate.com>
41. **Berenson JR** and Stopeck AS, UpToDate- Author “Multiple Myeloma: The Use of Osteoclast Inhibitors,” <http://uptodate.com> (2025).

LETTERS TO THE EDITOR

1. **Berenson J**, et al. “Long-term Pamidronate in Multiple Myeloma,” Response to Letter-to-the Editor from John F. Seymour, J Clin Oncol (Correspondence) 16:2572-2573 (1998).
2. **Berenson J**, “Relevant Clinical End Points in Bisphosphonate Trials,” J Clin Oncol

(Correspondence) 16:3204-3205 (1998).

3. **Berenson JR**, Lichtenstein A, Porter L, et al, "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," J Clin Oncol 16:593-602 (1998), Editorial Commentary by Ishmael Jaiyesimi, DO, MS, with [hypertext links to the article in PubMed](#).
4. Schiller GJ, Vescio R and **Berenson J**, "Cytomegalovirus Infection Following Transplantation of Autologous CD34-Selected Progenitor Cells," Blood 96:1194 (2000).
5. **Berenson JR**, "Peer Viewpoint," Supportive Oncology, 2: 3, May/June (2004).
6. **Berenson JR**, "Re: Letters to the Editor from Lugassy and Balla Re: "Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid," The Oncologist (2005).
7. **Berenson JR** and Yeh HS, "Clinical Observations - Comment on: 'Cavo M, Zamagni E, Tosi P, et al. Superiority of Thalidomide and Dexamethasone over Vincristine-Doxorubicin-Dexamethasone (VAD) as Primary Therapy in Preparation for Autologous Transplantation for Multiple Myeloma. Blood. 106:1:35-39 (2005)' and 'Rajkumar SV, Comment on Cavo et al, page 35 - Multiple Myeloma: The Death of VAD as Initial Therapy, Blood. 2005; 106:1:2-3," Blood, (2005).
8. **Berenson JR** and Yeh HS, "The Van Poznak/Estilo Article Reviewed," Oncology, 1065-1066 (August 2006).
9. **Berenson JR** and Andreu-Vieyra C, "MPR vs. Tandem Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients," (submitted).

PROCEEDINGS, SYMPOSIA, REVIEWS, & OTHER NON-PEER-REVIEWED PUBLICATIONS

1. Fefer A, Einstein AB, and **Berenson JR**, "Adoptive Chemo-immunotherapy of Viral Tumors in Mice," In: Proceedings of the American Society of Microbiology Symposium of Tumor Virus Infections and Immunity, Philadelphia, PA (1975).
2. Fefer A, Einstein AB, Jr, Cheever MA, and **Berenson JR**, "Adoptive Chemo-immunotherapy and Immunotherapy of Viral Tumors in Mice," Ann. NY Acad of Science 276:573-582 (1976).
3. **Berenson JR**, "Leukocyte A Interferon: A New Treatment for Non-Hodgkin's Lymphoma," Cancer
4. **Berenson JR**, Lichtenstein AK, Cao J, Hart S, Palomares D, and Miller RA, "Racial Differences in the Expression of Shared Idiotypes by Paraproteins From patients with Monoclonal Gammopathies," Neoplasia, Epidemiology and Biology of Multiple Myeloma, Springer-Verlag, New York, 87-95 (1991).

5. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, Lichtenstein A, Lill M, Hall J, and **Berenson J**, “Autologous CD34+ Selected Peripheral Blood Progenitor Cell Transplants in Multiple Myeloma,” The Latest Advances and Strategies for Hematopoietic Stem Cell Therapies Nashville, TN (1994).
6. **Berenson JR**, Vescio RA, Hong CH, Cao J, Kim A, Lee CC, Schiller G, **Berenson JR**, and Lichtenstein AK, “Multiple Myeloma Clones are Derived from a Cell Late in B Lymphoid Development,” Current Topics in Microbiology & Immunology, Mechanisms of B-Cell Neoplasia Springer-Verlag, New York, NY (1994).
7. Barlogie B, Anderson K, **Berenson JR**, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, and Vesole D, “Transplants for Multiple Myeloma,” Proceedings of the Seventh International Symposium in Arlington, TX 399-400 (1994).
8. Vescio R, Schiller G, Lee M, Sahebi F, Spitzer G, Freytes C, Cao J, Hong C, Wu C, Lee C, Kim A, Lichtenstein A, Berenson R, and **Berenson JR**, “CD34-Positive Peripheral Blood Stem Cell Transplantation in Multiple Myeloma,” Autologous Marrow and Blood Transplantation 7:411-416 (1994).
9. Barlogie B, Anderson K, **Berenson J**, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon, S, Tricot, G, and Vesole, D, “Transplants for Multiple Myeloma”, J. Bone Marrow Transplantation 15 (Suppl. 1): S234-S239 (1995).
10. **Berenson JR**, Schiller G, Vescio RA, and Lichtenstein AK, “CD34 Peripheral Stem Cell Transplantation in Multiple Myeloma”, J. Bone Marrow Transplantation 15 (Suppl. 1): S240-S246 (1995).
11. Rosen L, Vescio R and **Berenson JR**, “Multiple Myeloma and Chronic Lymphocytic Leukemia” In: Current Opinion in Hematology 2:275-282 (1995).
12. Silverman S, Vescio R, Silver D, Renner S, Weiner S, and **Berenson JB**, “Silicone Gel Implants and Monoclonal Gammopathies: Three Cases of Multiple Myeloma and the Prevalence of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance,” In: Immunology of Silicones, M. Potter and N.R. Rose eds., Springer-Verlag, Berlin 367-374 (1995).
13. **Berenson J**, “Role of Bisphosphonates in Management of Myeloma-Associated Skeletal Disease”, Lymphoma Biology & Research 1:7 (1995).
14. **Berenson JR**, “The Use of Pamidronate in Multiple Myeloma”, Myeloma Today 2:3-5 (1996).
15. **Berenson JR**, “Pamidronate: A New Treatment for the Skeletal Complications of Multiple Myeloma,” V H S Q 1:23-24 (1996).
16. **Berenson JR**, “Pamidronate in the Treatment of Osteolytic Bone Lesions in Multiple Myeloma

Patients-The American Experience”, British Journal of Clinical Practice (Suppl. 87) 5-7 (1996).

17. Vescio R, Rosen L, Schmulbach E, and **Berenson J**, “Multiple Myeloma and Chronic Lymphocytic Leukemia,” Current Opinion in Hematology 3:288-296 (1996).

18. Bataille R, Manolagas SC, and **Berenson JR**, “Pathogenesis and Management of Bone Lesions in Multiple Myeloma”, In: Hematology/Oncology Clinics of North America, W.B. Saunders Company, Philadelphia, PA 11:349-361 (1997).

19. **Berenson JR**, “The Stem Cell of Myeloma and the Role of Purging,” In: Advances in Myeloma. (1997).

20. **Berenson JR**, Kyle R, and Anderson K, Editors, “Proceedings for the Sixth International Workshop on Multiple Myeloma”, Cancer, Research Therapy and Control (1997).

21. **Berenson JR**, “The Efficacy of Pamidronate Disodium in the Treatment of Osteolytic Lesions and Bone Pain in Multiple Myeloma”, Contemporary Pharmacotherapy, in press (1997).

22. **Berenson JR**, “Bisphosphonates Improve Quality of Life in Myeloma Patients with Bone Disease”, Oncology News International, (1997).

23. **Berenson JR**, “Supportive Therapy in Multiple Myeloma: New Ways to Look at an Old Problem”, Hematology, Educational Program, American Society of Hematology (1997).

24. Rettig M, Said J, and **Berenson JR**, Response from commentary of “Multiple Myeloma and Kaposi’s Sarcoma-Associated Herpesvirus-A Paracrine Model of Tumorigenesis?” Trends in Microbiology 5:424-426 (1997).

25. Berenson R, Vescio R, Schiller G, Lee M, Freytes C, Spitzer G, Cao J, Hua C, Han E, Belson D, and **Berenson JR**, “CD34 Positive Peripheral Blood Stem Cell Transplantation in Multiple Myeloma”, Proceedings of the Eighth International Symposium in Arlington, Texas, Autologous Marrow and Blood Transplantation (1997).

26. **Berenson JR**, “The Association of Kaposi’s Sarcoma Virus in Multiple Myeloma and Other Disorders,” Current Trends and Clinical Significance for Minimal Residual Cancer in Transplantation Medicine, Super Friday (1997).

27. **Berenson JR**, “The Role of Kaposi’s Sarcoma Associated Herpes Virus Infected Dendritic Cells in Multiple Myeloma,” Society for Biological Therapy, 12th Annual Scientific Meeting (1997).

28. **Berenson JR**, “Pamidronate: A New Treatment for the Skeletal Complications of Multiple Myeloma”, V.H.S.Q. (1997).

29. Rettig MB, Said JW, Sun R, Vescio RA, and **Berenson JR**, “Kaposi’s Sarcoma-Associated Herpesvirus Infection and Multiple Myeloma”, Technical Comments, Science, 278:1969-1973 (1997).

30. Berenson, JR, "Bisphosphonates in Multiple Myeloma", Cancer Supplement 80:1661-1667 (1997).
31. **Berenson JR**, "Tumor Cell Purging in Multiple Myeloma Using CD34 Selection: Results of Clinical Trials," Innovations in Cell Therapy with Advancements for Patient Care, San Diego Convention Center (1997).
32. Vescio RA and **Berenson J**, "Clinical Benefits and Risks of Tumor Purging:" In the Role of Tumor Purging in Autologous Transplantation, Ed. John Gribben, 37-45 Discovery International (1997).
33. **Berenson J**, "The Efficacy of Pamidronate Disodium in the Treatment of Osteolytic Lesions and Bone Pain in Multiple Myeloma", Reviews in Contemporary Pharmacotherapy, 9:195-203 (1998).
34. **Berenson J**, "Amelioration of Myeloma-Associated Bone Disease by Treatment with Bisphosphonates," Bone Metastases in Cancer, Winter (1998).
35. **Berenson J**, "Treatment of the Bony Complications of Myeloma," Haematologica 83 (Suppl. 1), October (1998).
36. **Berenson J**, "Treatment of the Bony Complications of Myeloma," European Society of Oncology, Athens, Greece, August (1998).
37. **Berenson J**, "Aredia: Optimising Supportive Therapy in Multiple Myeloma", 38th British Haematology Society, Glasgow, Scotland, April 27-30 (1998).
38. **Berenson J**, "Multiple Myeloma: A New Possible Etiologic Factor-HHV-8-A New Treatment for the Bony Complications-Bisphosphonates", ISH-EHA Combined Haematology Congress, Amsterdam, the Netherlands, July 4-8 (1998).
39. Bataille R, Manolagas SC, and **Berenson JR**, "Pathogenesis and Management of Bone Lesions in Multiple Myeloma," European School of Oncology, August 29-30 (1998).
40. **Berenson J** and Lipton, A, "Pharmacology and Clinical Efficacy of Bisphosphonates", Current Opinion in Oncology 10:566-571 (1998).
41. **Berenson J**, "Myeloma: New Etiologies and New Agents," Hematologic Malignancies, Houston, Texas (1998).
42. **Berenson J** and Lipton A, "Use of Bisphosphonates in Patients with Metastatic Bone Disease", Oncology 12:1573-1581 (1998).
43. **Berenson JR**, "Etiology of Myeloma: What's New, "Multiple Myeloma Update: New Insights and Future Directions (1998).
44. **Berenson JR**, "Update on the Biology of Multiple Myeloma," ASH Educational Book, 63-88

(1998).

45. **Berenson JR**, “Bone Metastases,” ASCO Educational Book, p. 3-10 (1998).
46. Anderson K, **Berenson J**, and Kyle R, Editors, “VI International Workshop on Multiple Myeloma 1997,” Cancer Research Therapy Control (1998).
47. **Berenson J**, “Oncogenic Events in Multiple Myeloma,” Cancer Research Therapy Control, 43-45 (1998).
48. Vescio RA and **Berenson JR**, “The Role of Human Herpesvirus-8, (HHV-8), in Multiple Myeloma Pathogenesis,” Mechanisms of B Cell Neoplasia, 15th Workshop (1998).
49. **Berenson JR**, Bergsagel PL, and Munshi N, “Initiation and Maintenance of Multiple Myeloma,” Seminars in Hematology (Suppl. 3) 36:9-13 (1999).
50. **Berenson J** and Lipton A, “Bisphosphonates in the Treatment of Malignant Bone Disease,” Annual Review of Medicine, 50:237-48 (1999).
51. **Berenson J** and Vescio R, “HHV-8 and Multiple Myeloma,” Pathologie Biologie 47:115-118 (1999).
52. Henick K, Vescio R, and **Berenson J**, “Recent Advances in the Treatment of Multiple Myeloma,” Current Opinion in Hematology, 5:254-258 (1998).
53. Vescio RA and **Berenson JR**, “The Role of Human Herpesvirus-8, (HHV-8), in Multiple Myeloma Pathogenesis,” Current Topics in Microbiology and Immunology, Mechanisms of B cell Neoplasia, 246:403-409 (1998).
54. **Berenson JR**, “Etiology of Myeloma: What’s New,” Sem Oncology 36:9-13 (1999).
55. **Berenson J**, Bergsagel PL, and Munshi N, “Initiation and Maintenance of Multiple Myeloma,” Leukemia 36:9-13 (1999).
56. Anderson KC, Durie BGM, Barlogie B, **Berenson JR**, and Kyle RA, “New Advances in the Biology and Treatment of Myeloma Bone Disease,” Corporate Friday Program *New Advances in Biology and Treatment*, ASH annual meeting, December (1999).
57. **Berenson J**, “New Advances in the Biology and Treatment of Myeloma,” American Society of Clinical Oncology Fall Education Conference and Educational Symposia, November (1999).
58. Vescio R and **Berenson J**, “Autologous Transplantation: Purging and the Impact of Minimal Residual Disease,” In: Hematology / Oncology Clinics of North America: Hematopoietic Stem Cell Therapy, Schiller, GJ, Guest Editor, WB Saunders Company, A Division of Harcourt Brace & Company, 13: 969-986, October (1999).

59. Sjak-Shie NN, Vescio RA, and **Berenson JR**, “The Role of Human Herpesvirus-8 in the Pathogenesis of Multiple Myeloma,” In *Monoclonal Gammopathies and Related Disorders*, RA Kyle and MA Gertz, Guest Editors, *Hematology/Oncology Clinics of North America*, 13:6:1159-1167 (1999).
60. Sjak-Shie NN, Vescio RA, and **Berenson JR**, “Recent Advances in the Treatment of Multiple Myeloma,” *Current Opinion in Hematology*, 7: 241-246 (2000).
61. **Berenson JR**, Sjak-Shie NN, and Vescio RA, “The Role of Human and Viral Cytokines in the Pathogenesis of Multiple Myeloma,” *Seminars in Cancer Biology*, 10:383-391, (2000).
62. **Berenson J**, “Angiogenesis and the role of NF- κ B in multiple myeloma,” Multiple Myeloma Research Foundation, *Angiogenesis as a Therapeutic Target in Multiple Myeloma* Conference (2000).
63. **Berenson J**, “New Advances in the Biology and Treatment of Myeloma Bone Disease,” *Seminars in Hematology*, October (Suppl 9) 37:4 (2000).
64. **Berenson J**, Featured Speaker, “New Advances in the Biology and Treatment of Myeloma Bone Disease,” Novel therapeutic Approaches in the Treatment of Multiple Myeloma Symposium, sponsored by Harvard Medical School Dept. of Continuing Education, Dana-Farber Cancer Institute and the Multiple Myeloma Research Foundation (MMRF), October 5 (2000).
65. **Berenson JR**, Featured Speaker, International Myeloma Foundation & Lymphoma & Leukemia Society Support Group Meeting, Newport Beach, CA, December 9 (2000).
66. **Berenson JR**, Featured Speaker, “Focus on Bisphosphonates,” in *Bisphosphonates: Advanced Perspectives and Clinical Utility*, Continuing Education Satellite Symposium in conjunction with the 35th Annual ASHP Midyear Clinical Meeting, Las Vegas, NV, December 5 (2000).
67. **Berenson J**, Review of “New Advances in the Biology and Treatment of Myeloma Bone Disease,” manuscript based on December 2000 ASHP presentation, *Am J of Health-system Pharmacy*, (2001).
68. **Berenson J**, Co-Chair, “Biology and Treatment of Myeloma Bone Disease,” *Novel Therapeutic Approaches in the Treatment of Multiple Myeloma* Symposium, Cedars-Sinai Medical Center, Los Angeles, CA, February 10 (2001).
69. **Berenson J**, “*From the Lab to the Clinic: Novel Approaches in Myeloma Therapy*,” teleconference series, February – March (2001).
70. **Berenson J**, “Newer Bisphosphonates in Oncology and Novel Approaches to Metastatic Bone Disease,” 5th Annual Winter Oncology Conference, *Advances in Hematological Malignancies & Supportive Care in Cancer*, Whistler, British Columbia, Canada, March 7-11 (2001).
71. **Berenson J**, Paget Symposium for the 3rd North American Symposium on Skeletal Complications of Malignancy, (2001).

72. Kyle R, Anderson KC, Barlogie B, **Berenson JR**, Dalton WS, and Durie BGM, *Multiple Myeloma: Clinical Perspectives for the New Millennium Multiple Myeloma Update 2000*, Continuing Medical Education Monograph (in press).
73. **Berenson J**, “Affecting tumors in Their Microenvironment,” *Targeting the Tumor Microenvironment: Symptom Management Symposium*, during the 26th Annual Congress of the Oncology Nursing Society, San Diego, CA, May 19 (2001).
74. **Berenson JR**, “Novel Therapeutic Approaches in the Treatment of Multiple Myeloma: Targeting the Bone Micro-environment,” CD-Rom production, Postgraduate Institute for Medicine, Englewood, CO, May (2001).
75. **Berenson JR**, “Effective New Bone Metastases Drug Easy to Administer,” *Oncology Spectrums: The Journal of Integrated Cancer Medicine*, 2:5:311, May (2001).
76. **Berenson JR**, “Bone Disease in Myeloma,” review in Current Treatment Options in Oncology, David S. Ettinger, Editor, Phillip R. Greipp, Section Editor, 2:3:271-283, June (2001).
77. **Berenson JR**, “Challenging Cases in Hematology,” Network for Medical Communication & Research, LLC, Network for Oncology Communication & Research, San Francisco, CA, August 3-4 (2001).
78. **Berenson JR**, “Clinical and Practice Management Issues in the Use of Bisphosphonates to Prevent and Delay Bone Metastasis,” Meniscus Educational Institute, audioconference series, December 11 (2001).
79. **Berenson JR** and Yee GC, “Breakthrough in IV Bisphosphonate Therapy: Management of Hypercalcemia of Malignancy (HCM),” Strategic Implications International, (in press).
80. **Berenson JR**, “New Advances in the Biology and Treatment of Myeloma Bone Disease,” American Society of Clinical Oncology (ASCO) Educational Book, 38th Annual Meeting, 487-495, May 18-21 (2002).
81. Richardson PG, Barlogie B, **Berenson J**, Traynor A, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Esseltine D, Kauffman M, Adams J, Schenkein D, and Anderson KC, Proceedings of the American Society of Clinical Oncology 38th Annual Meeting in Orlando, FL, 21:40:11a, May 18-21 (2001).
82. **Berenson J** – Co-Chair with Jain V, Foss F, Lill M, Lynch J Jr, Morrison V, Poplack D, Sawyers C, Schilder R, Timmerman J, and Weir W. “Current Trends in Leukemia, Lymphoma & Myeloma,” ASCO 2002 Update, October 12 (2002).
83. **Berenson JR**, Co-Chair with Anderson KC, Barlogie B, and Dalton WS, “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma,” Multiple Myeloma Research Foundation, New York, NY, October 4-5 (2002).

84. **Berenson JR**, “The Role of Bisphosphonates in Myeloma,” Lymphoma & Myeloma 2002, New York, NY, October 3-5 (2002).
85. **Berenson JR**, “Advances in the Biology and Treatment of Myeloma Bone Disease,” Seminars in Oncology, 29:4 (Suppl. F – August) (2002).
86. **Berenson JR**, “Update of Information Reported at ASCO on Multiple Myeloma,” Myeloma Today, June (2002).
87. **Berenson JR**, “Inhibitors of Intracellular Signaling Molecules,” International Meetings & Science, Lake Buena Vista, FL, May (2002).
88. **Berenson JR**, “Myeloma – Managing Bone Disease,” Corporate Friday Symposium on Challenging Cases in Myeloma & Plasma Cell Dyscrasias preceding the 44th ASH Annual Meeting, Philadelphia, PA, December (2002).
89. **Berenson JR**, “Treatment Strategies for Myeloma Bone Disease,” Case Challenges in Multiple Myeloma, March (2003).
90. **Berenson JR**, “Preclinical overview and rationale for single agent and combined treatment of multiple myeloma with TRISENOX* (arsenic trioxide),” IXth International Workshop on Multiple Myeloma Palacio de Congresos, Salamanca, Spain, May (2003).
91. **Berenson JR**, “New advances in the biology and treatment of multiple myeloma,” IXth International Workshop on Multiple Myeloma Palacio de Congresos, Salamanca, Spain, May (2003).
92. Anderson KC, Alexanian R, **Berenson JR**, Harousseau JL, Kyle RA, Rajkumar V, and Treon SP, “Myeloma & Plasma Cell Dyscrasias,” Preceding the 44th American Society of Hematology Annual Meeting, (2003).
93. **Berenson JR**, National Oncology Alliance Guideline Review, May 9 (2003).
94. **Berenson JR**, Course Director, “Multiple Myeloma and Lymphoma,” Novel Therapeutic Approaches, Multiple Myeloma Research Foundation, Medical Education Collaborative, Lymphoma Research Foundation, February (2004).
95. Barlogie B, **Berenson JR**, Jagannath S, Kyle RA, and Rajkumar SV, “Focus on Treatment of Smoldering Myeloma, Treatment of Relapsing Disease and Role of New Agents in Various Settings,” Focus on Myeloma & Plasma Cell Disorders Conference, Los Angeles, CA, April (2004).
96. **Berenson JR**, “Multiple Myeloma: A New Treatment Paradigm (Introduction),” Multiple Myeloma Research Foundation, Anaheim, CA, May (2004).
97. **Berenson JR**, Lipton A, Major P, and Rosen L, “Safety and Convenience of Bisphosphonate Infusions,” Davos Meeting, 61, March 11 (2004).

98. **Berenson JR**, “Current Topics in Bone Metastases,” Institute for Medical Education & Research (IMER), Boston, MA (2004).
99. Lipton A, **Berenson JR**, Coleman RE, Guise TA, and Smith MR, Conference on Bone Cancer – CME Program, “Advances in Treating Metastatic Bone Cancer,” moderating Session III: Myeloma, Boston, MA, Oct 28 (2005).
100. **Berenson JR**, “Treatment of Myeloma Bone Disease,” Conference on Bone Cancer – CME Program, “Advances in Treating Metastatic Bone Cancer,” Boston, MA, Oct 28 (2005).
101. **Berenson JR** and Partington EW, “Bone Health for People Living with Multiple Myeloma,” *CancerCare* Telephone Education Workshop, April (2005).
102. Leonard J, Vescio R, and **Berenson JR**, “Current Trends in Leukemia, Lymphoma and Myeloma,” A Post-ASH Update, Santa Monica, CA, March 11 (2006).
103. **Berenson JR**, “Focus on Myeloma & Plasma Cell Disorders,” InterContinental Miami – Miami, FL, March 24-25 (2006).
104. **Berenson JR**, “Lymphoma & Myeloma,” The Waldorf=Astoria, New York, NY, October 19-21 (2006).
105. **Berenson JR**, “Zometa Hematology and Multiple Myeloma Advisory Board,” Sydney, Australia, April 9 (2005).
106. **Berenson JR**, “Focus on Myeloma & Plasma Cell Disorders,” Los Angeles, CA April 2-3 (2004).
107. **Berenson JR**, “Advances in Treating Metastatic Bone Cancer,” InfoMEDical Communications Inc., Cambridge, MA October 28-29 (2005).
108. **Berenson JR**, “Oncology Best Practices,” Physicians’ Education Resource, San Diego, CA October 25 (2005).
109. **Berenson JR**, “Skeletal Complications across the Cancer Continuum,” Interlink Healthcare Communications, CME Monograph, December 15 (2005).
110. **Berenson JR**, Musculoskeletal Advisory Board, Communication Strategies, Inc., Short Hills, NJ (June 14-15, 2007).
111. **Berenson J**, “Bortezomib in Newly Diagnosed Multiple Myeloma,” *Cancer World*, 31:40-41, (July/August 2009).
112. Jarzem P, **Berenson JR**, Tillman JB, Hussein MA, Pflugmacher R, Zonder J, and Vrionis FD, “A randomized trial of balloon kyphoplasty and nonsurgical care for cancer patients with vertebral compression fractures,” (CAFE) (2008).

113. **Berenson JR**, “Translating Multiple Myeloma Data to Practice: Journal and Conference Summaries (JACS),” (2010)
114. **Berenson JR**, “Multiple Myeloma: Treatment Updates,” *Advances in Leuk, Lymph, and Myeloma* (in press).
115. **Berenson JR**, “B-cell Maturation Antigen: A New Biomarker for B-cell Malignancies,” International Congress on Hematologic Malignancies, Waldorf-Astoria, New York City, New York, October 2015.
116. **Berenson JR**, “To Maintain or Not Maintain: Immunomodulators vs PI: Yes: Proteasome Inhibitors,” International Congress on Hematologic Malignancies, Waldorf-Astoria, New York City, New York, October 2015.

VIRTUAL MEETINGS/TALKS

1. **Berenson JR**, ASCO 2001 CME Virtual Meeting, “Biology and Bisphosphonate Therapy in Myeloma and Novel Approaches to Metastatic Bone Disease” (2001).
2. **Berenson JR**, ASCO 2001 CME Virtual Meeting, “Advances in the Biology and Treatment of Metastatic Bone Disease” (2001).
3. **Berenson JR**, Swift R and Yee GC, “Update on Bisphosphonates in the Prevention and Delay of Bone Metastasis,” from Therapeutic Updates in Oncology, Meniscus Educational Institute, September 11, 2001.
4. **Berenson JR**, Leukemia & Lymphoma Society, “Myeloma: New Developments in Treatment and Research,” October 23, 2001.
5. **Berenson JR**, International Myeloma Foundation, “Perspectives in Multiple Myeloma: Directions Toward New Therapeutic Options,” Rationale and Future Directions Section of Teleconference Live and Geared towards Hematologists and Oncologists Internationally, November 6, 2001. (CME)
6. **Berenson JR**, Multiple Myeloma Research Foundation (MMRF), “Case Challenges in Multiple Myeloma,” Web-based case studies, March 18, 2003. (CME)
7. **Berenson JR**, Projects in Knowledge (PIK), August 20, 2003. (CME)
8. **Berenson JR**, Projects in Knowledge (PIK), October 8, 2003. (CME)
9. **Berenson J**, *Advances in the Management of Bone Health & Skeletal Complications in Cancer:*

Advances in the Management of Bone Health in Multiple Myeloma, Clinical Care Options: Oncology, Postgraduate Institute for Medicine, June 15, 2009 – June 14, 2010. (CME-CE Certified)
<http://clinicaloptions.com/Oncology/Treatment/Updates/Bone Health>

10. **Berenson J**, “Serum BCMA: A Promising New Biomarker for Multiple Myeloma and CLL Patients,” presented at Virtual Summit: BCMA Targeted Therapies, June 2021.

COMMENTARIES – Published

1. **Berenson JR**, Commentary on Olson, KB and Pienta, KJ, “Use of Bisphosphonates in the Treatment of Prostate Cancer,” *Oncology* 14:9:1366-1367 September (2000).
2. **Berenson JR**, (Commentary on Abstr. 27), Coleman, M and Leonard, JP, “Clarithromycin, Low-Dose Thalidomide, and Dexamethasone Produces consistent Responses in Myeloma and Waldenstrom’s Macroglobulinemia,” *Oncology (Suppl. 12)* 14:11:34-44 November (2000).
3. **Berenson JR**, (Commentary on Abstr. 28), Barlogie, B, “Thalidomide in the Management of Multiple Myeloma: The Arkansas Experience in > 300 Patients with Single-Agent and Combination Chemotherapy,” *Oncology (Suppl. 12)* 14:11:34-44 November (2000).
4. **Berenson JR**, (Commentary on Abstr. 99), “Activity of Thalidomide in Waldenstrom’s Macroglobulinemia,” *Oncology (Suppl. 12)* 14:11:34-44 November (2000).
5. **Berenson JR**, (Commentary on Abstr. 111), “Encouraging Improvement in Cytopenias of patients with Myelodysplastic Syndromes with Thalidomide,” *Oncology (Suppl. 12)* 14:11:34-44 November (2000).
6. **Berenson JR**, Guest Reviewer, Physician Perspective: Viewpoint of Specialists from the VIIIth International Myeloma Workshop, Banff, Alberta, Canada, May 4-8 (2001).
7. **Berenson JR**, “The Ramaswamy/Shapiro Article Reviewed,” *Oncology* Vol.17, No.9, p1272, September (2003).
8. **Berenson JR** (On article by Lipton A), “Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention - Peer Viewpoint,” *Journal of Supportive Oncology*, 2:3:213-214, May/June (2004).
9. **Berenson JR** and Hirschberg R, “In Response to Diel I, Bergner R - Letter to the Editor of *The Oncologist* Re: Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid,” *The Oncologist*, 10:84-87, (2005).

ABSTRACTS - Published

1. **Berenson JR**, Einstein AB, and Fefer A, “T-cell Mediated Syngeneic Adoptive Immunotherapy of a Friend Leukemia,” Proceedings of the Sixty-Sixth Annual Meeting of the American Association for Cancer Research 16:132 (Abstract 527) (1975). This talk was presented by J.R. Berenson, M.D.
2. Calame K, **Berenson JR**, and Clarke C, “DNA Sequence Analysis of an Immunoglobulin Gene Promoter Region,” Journal of Cellular Biochemistry, (Abstract 0818) (1982). This talk was presented at the CETUS-UCLA Gene Regulation meeting by K. Calame and J.R. Berenson.
3. **Berenson JR**, Wong R, Kim K, Brown N, and Lichtenstein A, “Clonal Antibody Gene Rearrangements of Peripheral Blood Lymphocytes in Multiple Myeloma Patients,” Blood 66:232A (1985). This talk was presented at the American Society of Hematology meeting in New Orleans, LA, December 1985.
4. **Berenson JR**, Wong R, Kim K, Brown N, and Lichtenstein A, “Evidence for Peripheral Blood B, but not T Lymphocyte Involvement in Multiple Myeloma,” Proceedings of the American Association for Cancer Research, 27:161 (1986). Presented at AACR meeting, Los Angeles, CA May 1986.
5. **Berenson JR**, Giorgi J, Okazaki I, and Tobinick E, “A Novel Clonal T Lymphocyte is Discovered in a Case of Cutaneous T-cell Lymphoma,” Blood, 68:243a (1986). Presented at the American Society of Hematology meeting in San Francisco, CA December 1986.
6. **Berenson JR**, Giorgi J, Okazaki I, and Tobinick E, “A Novel T Lymphocyte in the Peripheral Blood of a Patient with Typical Helper Phenotype Cutaneous T-cell Lymphoma,” J Cell Biochem, Abstract D403 (1987). Presented at the Schering-UCLA Symposia meeting.
7. **Berenson JR** and Koeffler HP, “Rearrangement and Expression of the Beta T Cell Receptor Gene in the Chronic Myelogenous Leukemia Cell Line BV173,” Clin. Res. 35:521A (1987). Presented at the American Federation for Clinical Research meeting in San Diego, CA 1987.
8. **Berenson JR** and Lichtenstein AK, “Rearrangement of the Beta T Cell Receptor Gene in Plasma Cells from a Patient with Multiple Myeloma,” Clin. Res., 35:521A (1987). Presented at the American Federation for Clinical Research meeting in San Diego, CA 1987.
9. **Berenson JR**, Yang J, and Mickel RA, “Gene Amplification of Bcl-1 in Head and Neck Squamous Cell Carcinomas,” Clin. Res., 36:168A (1988). Presented at the American Federation for Clinical Research meeting in Carmel, CA 1988.
10. **Berenson JR**, Yang J, Alessi D, and Mickel R, “Amplification of the Putative Oncogene Bcl-1 in head and neck Squamous Carcinomas,” In: Proceedings of the Seventy-Ninth Annual meeting of the American Association for Cancer Research 29:441 (1988). Presented at the American Association for Cancer Research meeting in New Orleans, LA, 1988.
11. Mickel R, Jie Y, and **Berenson JR**, “Bcl-1 and Int-2 Amplification in Head and Neck

Squamous Carcinomas - Correlation with Karyotypic Analysis,” Proceedings of the Second International Conference on Head and Neck Cancer, (1988). Presented at the Second International Conference on Head and Neck Cancer in Boston, MA 1988.

12. Lichtenstein A, **Berenson JR**, Adelman D, Norman D, Castle S, and Chang MP, “Production of Lymphokines by Bone Marrow Cells from Patients with Multiple Myeloma,” Blood, 72:247a (1988).
13. **Berenson JR**, Yang J, and Mickel R, “Bcl-1 and Int-2 Gene Amplification in Head and neck Squamous Cell Carcinomas - Correlation with Karyotypic Analysis,” Special Conference of the American Association for Cancer Research (1988). Abstract presented at the conference in Chatham, MA, October 1988.
14. **Berenson J**, Yang J, and Mickel R, “Co-amplification of Bcl-1 and Int-2 in Head and Neck Carcinomas,” J Cellular Biochem, 13B:80 (1989). Abstract presented at Triton Biosciences-UCLA Symposia in Keystone, CO, January 1989.
15. **Berenson J**, Adelman D, Norman D, Castle S, Chang MP, and Lichtenstein A, “Cytokine Production by Bone Marrow Cells and Serum Levels in Patients with Multiple Myeloma,” Second International Workshop on Myeloma: Advances in Biology and Therapy, 2:10-11 (1989). Abstract presented at the workshop in Houston, TX, April 1989.
16. **Berenson JR**, Adelman D, Norman D, Castle S, Chang M, and Lichtenstein A, “Cytokine Production by Bone Marrow Cells in Multiple Myeloma Patients,” Proceedings of the Eightieth Annual Meeting of the American Association for Cancer Research, 30:329 (1989). Abstract presented at the conference in San Francisco, CA May 1989.
17. **Berenson JR**, Yang J, Koga H, Slamon D, and Mickel RA, “Bcl-1 and Int-2 Co-amplification in Squamous Cell Carcinomas of the Head and Neck and Lung,” Proceedings of the Eightieth Annual Meeting of American Association for Cancer Research, 30:440 (1989). Abstract presented at the conference in San Francisco, CA May 1989.
18. **Berenson JR**, Lichtenstein A, Hart S, and Miller R, “Detection of Shared Idiotypes in the Serum and Bone Marrow of Multiple Myeloma Patients,” Blood, 74:53A, (1989). Abstract presented at the Hematologic Malignancies plenary session of the American Society of Hematology meeting in Atlanta, GA, December 1989.
19. Hudnall SD and **Berenson JR**, “Evidence of a Clonal Isotope Switch Within the Pseudofollicular Proliferation Centers of Small Lymphocytic Lymphoma: Implications Regarding the Origin of Proliferation Centers,” Lab. Invest., 62:46A (1990). Presented at the International Academy of Pathology, Boston, MA, March 1990.
20. Moy RL, Eriksen E, Amron DA, Waldburger K, and **Berenson JR**, “Co-incubation of Basal Cell Carcinoma and Fibroblasts Yields Enhanced Basal Cell Carcinoma (BCC) Proliferation by a Soluble Factor Released from Fibroblasts,” Clin. Res., 38:584A (1990). Presented at the National Meeting of the American Federation for Clinical Research, Washington, D.C., May 1990.

21. Paquette RL, **Berenson JR**, Lichtenstein A, McCormick F, and Koeffler HP, “NRAS Mutations in Multiple Myeloma,” Proceedings of the American Association for Cancer Research, 31:133 (1990). Presented at the annual meeting, Washington, D.C. May 1990.
22. **Berenson JR**, Adelman D, Yang J, and Mickel RA, “IL-1 and IL-6 are Produced by Head and Neck Squamous Cell Carcinoma Lines Containing Hstfl and Int-2 Amplification,” Proceedings of the American Association for Cancer Research 31:46 (1990). Presented at the annual meeting, Washington, D.C., May 1990.
23. Gera J, Waldburger K, **Berenson JR**, and Lichtenstein A, “Resistance of Ovarian Cancer Lines to Tumor Necrosis Factor (TNF) Correlates with Over-Expression of HER2/neu Oncogenes,” FASEB J.,4: A1945 (1990). Presented at the FASEB meeting, New Orleans, LA, June 1990.
24. **Berenson JR**, Cao J, Waldburger K, and Lichtenstein AK, “V_H Gene Family Usage in Multiple Myeloma,” Proceedings of the American Association for Cancer Research 32:271 (1991).
25. Cao J, Smulsen M, Waldburger K, Lichtenstein AK, and **Berenson JR**, “Deletion of Genetic Material from a Poly(ADP-ribose) Polymerase-like Gene on Chromosome 13 Occurs Frequently in Patients with Monoclonal Gammopathies,” Proceedings of the American Association for Cancer Research 32:310 (1991).
26. Lichtenstein A, Fady C, Gera J, Gardner A, Kelley D, **Berenson JR**, and Campbell V, “Resistance of HER2-neu-over-expressing Tumor Lines to Lymphocyte Cytotoxicity,” Proceedings of the American Association for Cancer Research 32:235 (1991).
27. Sawicki MP, Wan YJY, Johnson CL, **Berenson JR**, and Passaro E, Jr, “Loss of Heterozygosity on Chromosome 11 in Sporadic Gastrinomas,” Bio/Technology (1991).
28. **Berenson JR**, Hart S, Cao J, Waldburger K, Palomares D, Miller RA, and Lichtenstein A, “Expression of Shared Idiotypes and V_H Gene Families by Patients with Monoclonal Gammopathies,” Multiple Myeloma from Biology to Therapy: Abstracts Book of III International Workshop, 3:31-32. Presented at the Third International Workshop on Myeloma, Torino, Italy, (April 1991).
29. **Berenson JR**, Hart S, Cao J, Waldburger K, Palomares D, Miller RA, and Lichtenstein A, “Immunoglobulin Gene Usage and Idiotypic Expression in Patients with Monoclonal Gammopathies.” Presented at the First Annual B-Cell Neoplasia Workshop on Comparative Biology and Therapy, Little Rock, Arkansas, (May 1991).
30. Kunkel LA and **Berenson JR**, “A Higher Frequency of Nonhematological Malignancies in Patients with Monoclonal Gammopathy of Undetermined Significance than Multiple Myeloma,” Blood 78:467A (1991).
31. **Berenson JR**, Cao J, Newman R, and Lichtenstein AK, “V_H Gene Family Usage is Nonrandom in Multiple Myeloma,” Blood 78:122A (1991). Presented at the 33rd Annual Meeting of the American Society of Hematology, Denver, TX., December (1991).

32. Vescio RA, Cao J, Lichtenstein AK, and **Berenson JR**, “IgM-producing B-lymphocytes are part of the Malignant Clone in Multiple Myeloma,” *Proceedings of the American Association for Cancer Research* 33:229 (Abstr. 1371) (1992).
33. Schiller G, Lieb G, Lee M, Nimer S, Territo M, Gajewski J, Wolin M, Lill M, Vescio R and **Berenson JR**, “Busulfan-Cyclophosphamide Conditioning Followed by Transplantation of Autologous Peripheral Blood Progenitor Cells as Treatment for Advanced Multiple Myeloma,” *Blood* 80 (Suppl. 1):121a (1992).
34. Persselin JE, Jien ML, McGrath M and **Berenson JR**, “Anti-IgG Antibody Activity is Prevalent Among IgG3 and IgG4 Myelomas,” *American College of Rheumatology, 56th Annual Scientific Meeting*, October 11-15, 1992, Atlanta, GA (1992).
35. Alim AA, Razavi MK, **Berenson JR**, and Udkoff RC, “Different Bone Marrow MR Imaging Patterns in Multiple Myeloma with Spin-Echo and Gradient Echo Sequences with Opposed-Phase Fat Suppression,” *Journal of Magnetic Resonance Imaging*, 3 (Suppl.):110 (1993).
36. Schiller G, Vescio R, Lee M, Bearman S, Spitzer G, Freytes C, Lill M, Berenson R, and **Berenson JR**, “Transplantation of Autologous CD34-Positive Peripheral Blood Stem Cells as Treatment for Multiple Myeloma,” *Blood*, 82 (Suppl.):198A (1993).
37. Kunkel L, Vescio R, Cao J, Hong C, Schiller G, Lichtenstein A, and **Berenson JR**, “Unconventional Mechanisms Used to Generate the IG Heavy Chain Third Complementarity Determining Region (CDR3) in B Cell Malignancy,” *Blood*, 82 (Suppl.):248A (1993).
38. Cao J, Vescio R, Hong C, Kim A, Lichtenstein AK, and **Berenson JR**, “Identification of Malignant Cells in Multiple Myeloma Bone Marrow with Immunoglobulin VH Gene Probes by Fluorescent in Situ Hybridization and Flow Cytometry,” *Blood*, 82 (Suppl.):248A (1993).
39. Vescio R, Hong CH, Cao J, Lee C, DerDanielian M, Lichtenstein AK, and **Berenson JR**, “Multiple Myeloma Clones are Derived from Post-Class Switch Precursor Cells,” *Blood*, 82 (Suppl.):259A (1993).
40. Kunkel LA, Vescio R, Cao J, Schiller GJ, Lichtenstein AK, and **Berenson JR**, “The CDR3 Regions of Multiple Myeloma Patients Reveal Characteristics Seen in Fetal Lymphoid Development,” *Blood*, 82 (Suppl.):259A (1993).
41. Vescio RA, Cao J, Hong CH, Newman R, Lichtenstein AK, and **Berenson JR**, “Somatic Hypermutation of VH Genes in Multiple Myeloma is Unaccompanied by Intracлонаl Diversity,” *Blood*, 82 (Suppl.):259A (1993).
42. Kim A, Vescio R, Lee C, Lichtenstein AK, and **Berenson JR**, “Cytokine Production by Bone Marrow Stroma from Patients with Myeloma,” *Blood*, 82 (Suppl.):569A (1993).
43. **Berenson JR**, Hart S, Miller R, Lichtenstein A, and Kyle R, “Expression of Shared Idiotypes by

Paraproteins from Patients with Monoclonal Gammopathy of Undetermined Significance,” IV International Workshop in Multiple Myeloma. Program and Abstracts (Abstr. P-5):129 (1993).

44. Kim A, Vescio R, Lee C, Lichtenstein A, and **Berenson J**, “Enhancement of Bone Marrow Stroma IL-6 Production by IL-1b and TNF α is Most Marked in Myeloma Patients with Bone Disease,” IV International Workshop in Multiple Myeloma. Program and Abstracts (Abstr. P-25):139 (1993).
45. Vescio R, Cao J, Kunkel L, Hong C, Schiller G, Lichtenstein A, Newman R, and **Berenson JR**, “Immunoglobulin Produced by the Malignant Cells in Multiple Myeloma Frequently Results from an Antigenically Driven Process and the 5’ End of the J Segment is Often Truncated,” IV International Workshop in Multiple Myeloma. Program and Abstracts (Abstr. P-49):151 (1993).
46. Kunkel LA, Vescio R, Cao J, Hong C, Schiller GJ, Lichtenstein AK, and **Berenson JR**, “Coding Ends with Direct Repeat Sequence Homology Influence DH-JH Recombinations,” Blood, 82 (Suppl. 1):259a (1993).
47. Schiller GJ, Lee M, Nimer S, Territo M, Gajewski J, Vescio R, and **Berenson JR**, “Busulfan/Cyclophosphamide Conditioning Followed by Transplantation of Allogeneic Bone Marrow or Autologous Peripheral Hematopoietic Progenitor Cells for the Treatment of Advanced Stage Multiple Myeloma,” J Clinical Oncology, 13:408 (1993).
48. Alim AA, Razavi MK, **Berenson JR**, and Udkoff RC, “Different Bone Marrow MR Imaging Patterns in Multiple Myeloma with Spin-Echo and Gradient-Echo Sequences with Opposed-Phase Fat Suppression,” MRI (Suppl.) 3(P):368 (1993).
49. Schiller G, Vescio R, Lee M, Bearman S, Spitzer G, Freytes C, Lill M, Berenson R, and **Berenson JR**, “Transplantation of Autologous CD34-Positive Peripheral Blood Stem Cells as Treatment for Multiple Myeloma,” J Cellular Biochemistry, (Suppl.) 18B:81 (1994).
50. **Berenson JR**, Vescio R, Cao J, Hong C, Schiller G, Lichtenstein A, and Berenson RJ, “Multiple Myeloma Clones are Derived from a Cell Late in B Lymphoid Development,” J Cellular Biochemistry, (Suppl.) 18B:80 (1994).
51. Vescio R, Hong C, Cao J, Kim A, Schiller G, Lichtenstein A, Berenson R, and **Berenson JR**, “The Hematopoietic Stem Cell Antigen, CD34, is Not Expressed on the Malignant Cells in Multiple Myeloma,” J Clinical Oncology, 13:408 (1994).
52. Kunkel L, Ireland P, **Berenson J**, Territo M, Rosen P, and Schiller G, “Transplantation of Peripheral Blood Progenitor Cells After Myeloablative Conditioning for the Treatment of Resistant Non-Hodgkin’s Lymphoma and Hodgkin’s Disease,” Proceedings of the Thirtieth Annual Meeting of the American Society of Clinical Oncology, 13:377 (1994).
53. King BL, Lichtenstein A, **Berenson J**, Martinez-Maza O, Berek JS, and Kacinski BM, “Two Cross-Contamination Events Involving the SK-OV-3 Ovarian Adenocarcinoma Cell Line Detected by DNA Typing,” American Journal of Pathology, 144:486-491 (1994).

54. **Berenson JR**, Schiller G, Vescio R, Lee M, Sahebi F, Spitzer G, Freytes C, Bearman S, Cao J, Hong C, Kim A, Lichtenstein A, and Berenson RJ, “CD34 Peripheral Stem Cell Transplantation in Multiple Myeloma,” *Cancer Investigation*, 13:(Suppl. 1) (1994).
55. Tu Y, Fady C, Vescio R, **Berenson J** and Lichtenstein A, “Induction of apoptosis in Multiple Myeloma Cell Lines,” *Proceedings of 85th Annual Meeting of the American Association of Cancer Research*, 35:312 (1994).
56. **Berenson J**, Lichtenstein AK, Porter L, Bordoni R, George S, Lipton A, Keller A, Simeone J, Heffernan M, Seaman J, and Knight R, “Pamidronate Disodium Reduces the Occurrence of Skeletal-Related Events (SRE) in Advanced Multiple Myeloma (MM),” *Blood*, 84 (Suppl. 1):386a (1994).
57. Schiller G, Rosen L, Vescio R, Spitzer G, Freytes C, Lill M, Lee M, Berenson R, and **Berenson JR**, “Threshold Dose of Autologous CD34-Positive Peripheral Blood Progenitor Cells (PBPC) Required for Engraftment After Myeloablative Treatment for Multiple Myeloma,” *Blood*, 84 (Suppl. 1):207a (1994).
58. Vescio R, Cao J, Hong C, Hua C, Lee C, Schiller G, Freytes C, Spitzer G, Hall J, Lichtenstein A, **Berenson J**, and Berenson R, “CD34-Positive Ceptrate Selection Leads to a 4-5 Log Reduction in Tumor Burden in Myeloma PBC Autografts Based on PCR and Poisson Distribution Analysis,” *Blood*, 84 (Suppl. 1):399a (1994).
59. Kim A, Vescio RA, Cao J, Hong CH, Rettig M, Vovan T, Lichtenstein AK, and **Berenson JR**, “CD38 is Expressed on Most but Not All Malignant Cells in Multiple Myeloma,” *Blood*, 84 (Suppl. 1):656a (1994).
60. Cao J, Vescio RA, Kim A, Hong, CH, Lee C, Lichtenstein A, and **Berenson JR**, “The CD10 Antigen is Expressed on a Subpopulation of Malignant Cells in All Patients with Multiple Myeloma,” *Blood*, 84 (Suppl. 1):171a (1994).
61. **Berenson JB**, Schiller G, Vescio R, Lee M, Sahebi F, Spitzer G, Freytes C, Cao J, Hong C, Kim A, Lichtenstein A, and Berenson R, “CD34-Selected Peripheral Stem Cell Transplantation in Multiple Myeloma,” *Annals of Oncology*, 5 (Suppl. 8):126 (Abstr. 0632) (1994).
62. Tu Y, Vescio R, Berenson R, **Berenson JB**, and Lichtenstein A, “Adriamycin and Etoposide Upregulate BCL-2 Expression in Multiple Myeloma Plasma Cells,” *Blood*, 84 (Suppl. 1):172a (1994).
63. Tu Y, Vescio R, **Berenson JB**, and Lichtenstein A, “Increased expression of BCL-2 induced by exposure of targets to Adriamycin, etoposide and hydrogen peroxide,” *Proceedings of the American Association for Cancer Research*, 36:13 (1995).
64. Nagami G, Solomon A, **Berenson JB** and Lichtenstein A, “Toxicity of Bence Jones Proteins in Cultured Mouse Renal Epithelial Cell Lines,” *Journal of Investigative Medicine*, 43 (Suppl. 2):263A (1995).
65. Rettig M, Hong C, Vescio R, Kim A, Han E, Shin J, Lichtenstein A, and **Berenson JB**,

“Reduction of Tumor Cells in Multiple Myeloma (MM) Peripheral Blood Using a CD38 Immunoabsorption Column,” Proceeding in the American Society of Clinical Oncology, 14:1351 (1995).

66. **Berenson JB**, Vescio R, Schiller G, Rettig M, Freytes C, Spitzer G, Anderson K, Hall J, Berenson R, and Lichtenstein, A, “Multiple Myeloma: What is the Optimal Way to Purge Autografts Without Affecting Engraftment?” Vth International Workshop on Multiple Myeloma, La Baule, France (Abstr. 3.41) (1995).

67. Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Lichtenstein A, and **Berenson JR**, “Quantitative Comparison of Multiple Myeloma Tumor Contamination in Bone Marrow Harvest and Leukaphereses Autografts,” Vth International Workshop on Multiple Myeloma, La Baule, France (Abstr. 3.38) (1995).

68. Lichtenstein A, Dimopoulos A, Lipton A, Keller A, Ballester O, Simeone J, Reitsma J, Heffernan M, Seaman J, Knight R, Solomon A, Nagami G, and **Berenson J**, “Skeletal and Renal Complications of Myeloma,” Vth International Workshop on Multiple Myeloma, La Baule, France (Abstr. 3.75) (1995).

69. Tu Y, Xu F, Vescio R, **Berenson J**, and Lichtenstein A, “Resistance to Apoptosis in Myeloma Cells”, Vth International Workshop on Multiple Myeloma, La Baule, France, (Abstr. 3.78) (1995).

70. Vescio RA, Kieber-Emmons T, Lee JC, Wu CH, Cao J, Shin J, Lichtenstein AK, and **Berenson JR**, “Immunoglobulin Heavy Chain Gene Analysis Proves that Myeloma Oncogenesis Occurs Late in B-Cell Development”, Vth International Workshop on Multiple Myeloma, La Baule, France, (Abstr. 3.19) (1995).

71. **Berenson J**, Lichtenstein A, Porter L, Lipton A, Dimopoulos M, Simeone J, Heffernan M, Seaman J, and Knight R, “Pamidronate Disodium Therapy and the Reduction of Skeletal-Related Events (SRE) in Multiple Myeloma (MM),” 12th Asia Pacific Cancer Conference, (APCC):197 (1995).

72. **Berenson JR**, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma JD, Heffernan M, Seaman J, and Knight RD, “Aredia Reduces the Bony Complications of Multiple Myeloma,” Cancer Investigation 14 (Suppl. 1):53-54 (1995).

73. Tasaka T, **Berenson J**, Hiramata T, and Koeffler HP, “Analysis of the INK4 Family of Genes in Multiple Myeloma,” Blood, 86 (Suppl. 1):63a (1995).

74. Rettig MB, Vescio RA, Cao J, Wu CH, Lee JC, Han E, Lichtenstein AK and **Berenson JR**, “V_H Gene Usage in Multiple Myeloma (MM): Complete Absence of the V_H4.21 (V_H4-34) Gene,” Blood, 86 (Suppl. 1):60a (1995).

75. Tu Y, Xu F, Liu J, Vescio R, **Berenson JR**, Krajewski S J, Reed J and Lichtenstein A, “Expression of BCL-X in Multiple Myeloma Plasma Cells,” Blood 86 (Suppl. 1):62a (1995).

76. Xu F, Tu Y, Liu J, Vescio R, **Berenson JR** and Lichtenstein A, “Interleukin-6 Protection against

Multiple Myeloma Plasma Cells: Role of Cell Cycle Alterations, BCL-Family of Proteins and Protein Tyrosine Kinases”, Blood 86 (Suppl. 1):61a (1995).

77. Rosen L, Lichtenstein A, Heffernan M, Seaman J, Knight R, and **Berenson JR**, “Serial Beta 2 Microglobulin Levels Correlate with Morbidity and Mortality in Multiple Myeloma”, Blood 86 (Suppl. 1):188a (1995).

78. Lightner A, Rosen L, Vescio R, Schiller G, and **Berenson JR**, “Infectious Complications in Multiple Myeloma”, Blood 86 (Suppl. 1):188a (1995).

79. Schiller G, Vescio R, Mittal-Henkle A, Rose L, Beesemyer R, and **Berenson JR**, “A Phase I-II Study of Infusional Idarubicin, Cyclophosphamide, and Etoposide for the Treatment of Resistant Multiple Myeloma”, Blood 86 (Suppl. 1):842a (1995).

80. **Berenson JR**, Lichtenstein A, Porter L, Bordoru R, George S, Lipton A, Keller A, Heffernan M, and Seaman J, “Long-Term Pamidronate Disodium Therapy Leads to a Reduction in Skeletal Related Episodes (SREs) in Stage III Multiple Myeloma Patients and an Improvement in Survival in Those on Salvage Therapy” Blood 86 (Suppl. 1):442a (1995).

81. Han EJ, Vescio RA, Rettig MB, Cao J, Wu CH, Lee JC, Rosen L, Schiller G, Lichtenstein AK, and **Berenson JR**, “Mobilization of Peripheral Blood Progenitor Cells (PBPC) in Patients with Multiple Myeloma (MM) Does Not Increase Tumor Contamination”, Blood 86 (Suppl. 1):401a (1995).

82. Vescio RA, Han EJ, Lee JC, Wu CH, Cao J, Shin J, Schiller GJ, Rettig MB, Lichtenstein AK, and **Berenson JR**, “Quantitative Comparison of Multiple Myeloma Tumor Contamination in Bone Marrow Harvest and Leukaphereses Autografts”, Blood 86 (Suppl. 1):234a (1995).

83. Berenson R, Schiller G, Vescio R, Lee M, Spitzer G, Freytes C, Hall J, Lichtenstein A, and **Berenson JR**, “CD34-Selected Peripheral Stem Cell Transplantation in Multiple Myeloma,” Proceeding in the EBMT ‘95 to be held in Davos, Switzerland, March 19-23, 1995.

84. Schiller G, Vescio R, Freytes CO, Lee M, Spitzer G, Lill M, Berenson R, and **Berenson J**, “CD34 Positive Peripheral Blood Stem Cell (PBSC) Transplantation After Myeloablative Treatment for Multiple Myeloma (MM)”, 5th Annual Symposium on Cancer Research in San Antonio on July 28, 1995.

85. Heiss SG, Seeger LL, Yao L, Gentili A, Gold RH, and **Berenson JR**, “Helical CT for the ‘Myeloma Survey’”, FYI, 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America, November 26-December 1, 1995.

86. **Berenson JR**, Lichtenstein A, Porter L, Bordoni R, George S, Lipton A, Keller A, Heffernan M, Seaman J, and Knight R, “Long-Term Pamidronate Disodium Therapy Leads to a Reduction in Skeletal Related Episodes (SREs) in Stage III Multiple Myeloma Patients and an Improvement in Survival in Those on Salvage Therapy”, Bone 17:597-618 (#67) December (1995).

87. Lipton A, **Berenson JR**, Harvey H, Givant M, Kowalski J, Seaman J, and Knight R, “Phase I

Study of a New Bisphosphonate in Patients with Osteolytic Bone Metastases”, Eur J of Cancer 31A (Suppl. 5):S197 (1995).

88. Berenson R., Schiller G., Vescio R., Lee M., Spitzer G., Freytes C, Hall J, Lichtenstein A, and **Berenson JR**, “CD34-Selected Peripheral Stem Cell Transplantation in Multiple Myeloma,” Proceeding in the EBMT ‘95, Davos, Switzerland, March 19-23, 1995.
89. Schiller G, Vescio R, Freytes CO, Lee M., Spitzer G, Lill M., Berenson R, and **Berenson JR**, “CD34 Positive Peripheral Blood Stem Cell (PBSC) Transplantation After Myeloablative Treatment for Multiple Myeloma (MM)”, 5th Annual Symposium on Cancer Research in San Antonio on July 28, 1995.
90. **Berenson JR**, Vescio R, Rettig M, Cao J, Wu CH, Han E, Lee JC, Rosen L, Schiller G, and Berenson R, “Reducing Tumor Contamination in Autologous Products for Patients with Multiple Myeloma”, Presented at the Second International Symposium on Cytokines in Bone Marrow Transplantation, March 21-23, 1996.
91. **Berenson J**, Vescio R, Schiller G, Lee M, Freytes C, Spitzer G, Cao J, Wu C, Han E, Belson D, and Berenson R, “CD34 Positive Peripheral Blood Stem Cell Transplantation in Multiple Myeloma,” Eighth International Symposium on Autologous Marrow and Blood Transplantation; proceedings at the Arlington Cancer Center on August 18-21, 1996.
92. Seeger LL, Heiss SG, Yao L, Gentili A, Gold RH, Learch TJ, Johnson CA, Vescio RA, and **Berenson JR**, “Helical CT for the Myeloma Survey,” Proceedings in ASCO 15:1400 (1996).
93. Rosen LS, Lipton A, Savage A, Kowalski M, Miller JA, Knight R, Seaman J and **Berenson JR**, “Phase I Trial of Zoledronate (CGP-42446), a New Bisphosphonate, in Patients with Osteolytic Bone Lesions,” Proceeding in ASCO 15:1570 (1996).
94. **Berenson JR**, Lipton A, Rosen LS, Savage A, Kowalski M, Heffernan M and Knight R, “Phase I Clinical Study of a New Bisphosphonate, Zoledronate (CGP-42446), in Patients with Osteolytic Bone Metastases”, Blood 88:586a (1996).
95. Tasaka T, **Berenson JR**, Vescio R, Said JW, Park D, and Koeffler HP, “KSHV Sequences in Lymphoid Tissues,” Immunodeficiency and HIV Infection, Blood 88 (Suppl. 1):500a, (1996).
96. **Berenson JR**, “Pamidronate in the Treatment of Bone Metastases-The American Experience,” British Journal of Clinical Practice (Suppl. 87) page 3, (1996).
97. Vescio RA, Kunkel L, Wu CH, Cao J, Han EJ, Belson DJ, Rettig M, Schiller GJ, and **Berenson JR**, “Multiple Myeloma Heavy Chain CDR3 Analysis Reveal Mutational Hot Spots, Frequent D-D Fusions, and Prior Antigenic Selection”, Blood 88:294a, (1996).
98. Vescio RA, Schiller GJ, Stewart AK, Anderson KC, DiPersio JF, Noga SJ, Ballester OF, Rugo

H, Freytes CO, Wu CH, Han EJ, Cao J, Belson DJ, and **Berenson JR**, “Quantitative Assessment of Myeloma Peripheral Blood and Bone Marrow Tumor Burden in Patients Undergoing Autologous Transplantation,” *Blood* 88:641a (1996).

99. Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, and **Berenson JR**, “Pamidronate Reduces IL-6 Production by Bone Marrow Stroma from Multiple Myeloma Patients,” *Blood* 88:104a (1996).

100. Rettig MB, Pold M, Nguyen V, Cao J, Vescio RA, and **Berenson JR**, “Translocations into the Immunoglobulin Heavy Chain Gene (IgH) in Multiple Myeloma (MM),” *Blood* 88:294a (1996).

101. Schiller G, Vescio R, Lee M, Spitzer G, Freytes C, Lill M, Berenson R, and **Berenson JR**, “Long-Term Outcome of a Phase II Study of Autologous CD34+ Peripheral Blood Stem Cell Transplantation as Treatment for Multiple Myeloma,” *Blood* 88:483a (1996).

102. Seaman J, **Berenson JR**, Rosen L, Vescio R, Lau H, Woo M, Sioufi A, Kowalski M, and Knight R, “The Pharmacokinetics of Pamidronate Disodium (P) in Cancer Patients with Normal or Impaired Renal Function”, Proceedings at the American Society for Clinical Pharmacology and Therapeutics on March 5-8, 1997, 218: Abstr # 94 (1997).

103. **Berenson JR**, Hortobagyi G, Lipton A, Knight R, Heffernan M, Mellars K, and Seaman J, “Pamidronate (Aredia)-A New Standard for the Treatment of Bone Metastases and Multiple Myeloma Patients”, 14th Asia Pacific Cancer Conference, 4th Hong Kong International Cancer Congress, November 1997.

104. **Berenson JR**, “Myeloma and the Use of Pamidronate”, ASCO 16:M4 (1997). Presented in the Meet the Professor Sessions at the 1997 ASCO meeting.

105. Lipton A, **Berenson JR**, Savage A, Kowalski M, Seaman J, and Knight R, “The Effects of the Bisphosphonate, Zoledronate, When Administered as a Short Intravenous Infusion in Patients with Bone Metastases: A Phase I Study”, ASCO 16:240a (1997).

106. **Berenson JR**, Vescio R, Schiller G, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmayer E, Sahebi F, Tarantolo FS, Stiff P, Pinero L, Dalton W, Ho A, Benyunes M, Jacobs C, Dipersio J, and Anderson K, “Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation for Patients with Advanced Multiple Myeloma: Results of a Phase III Study Evaluating CD34-Selected Versus Unselected Autografts”, Proceedings from the 5th International Blood Cell Transplantation Symposium, Omaha, Nebraska, (1997).

107. Tasaka T, Asou H, Munker R, Said J, **Berenson JR**, Naga, M, Takahara J, and Koeffler P, “Hypermethylation of the p16^{INK4A} Gene in Multiple Myeloma”, *Blood* 90:244a (1997).

108. Rettig M, Vescio R, Ma H, Moss T, Schiller G, and **Berenson JR**, “Detection of Kaposi’s Sarcoma-Associated Herpesvirus in the Peripheral Blood of Multiple Myeloma Patients”, *Blood* 90:587a (1997).

109. Rettig M, Vescio R, Ma H, Moss T, Schiller G, Solomon A, Said J, and **Berenson JR**,

“Detection of Kaposi’s Sarcoma-Associated Herpesvirus in the Dendritic Cells of Waldenstrom’s Macroglobulinemia and Primary Amyloidosis Patients”, *Blood* 90:86a (1997).

110. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, Dipersio J, Anderson K, and **Berenson JR**, “Myeloma Cell Tumor Reduction in PBPC Autografts Following CD34 Selection: The Results of a Phase III Trial Using the Ceprate Device”, *Blood* 90:421a (1997).

111. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, Dipersio J, Anderson K, and **Berenson JR**, “Increase in Circulating Tumor Cell Burden During Mobilization Chemotherapy Predicts for Relapse After Autologous Transplantation in Multiple Myeloma Patients”, *Blood* 90:565a (1997).

112. Vescio R, Wu C, Rettig M, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Pinero L, Dalton W, Ho A, Schiller G, Benyunes M, Jacobs C, Dipersio J, Anderson K, and **Berenson JR**, “The Detection of KSHV is Increased by Mobilization Chemotherapy and Reduced in Autografts by CD34-Selection”, *Blood* 90:565a (1997).

113. **Berenson JR**, Rettig M, Heppner K, Vescio R, Ma H, Schiller G, Belson D, Savage A, Nishikubo C, Shintaku I, Koeffler P, Asou H, Pinkus G, Schrage M, Green E, and Said J, “Bone Marrow Biopsies from Bone Multiple Myeloma Patients Contain Kaposi’s Sarcoma-Associated Herpesvirus”, *Blood* 90:587a (1997).

114. Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Kogut N, Tarantolo S, Stiff P, Pineiro L, Dalton W, Ho A, Vescio R, Benyunes M, Jacobs C, DiPersio J, Anderson K, and **Berenson JR**, “A Phase III Study Evaluating CD34+-Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation for Patients with Advanced Multiple Myeloma: Engraftment Results”, *Blood* 90:218a (1997).

115. Renner S, Weisz J, Fleishman A, Taylor J, Vescio R, Rettig M, **Berenson JR**, Krajewski S, Reed JC, and Lichtenstein A, “BCL-2/BAX Expression in Plasma Cell Dyscrasias”, *Blood* 90:91a (1997).

116. Nepom GT, Masewicz S, Rettig M, Belson D, Vescio R, and **Berenson JR**, “Functional Deficits in Bone Marrow-Derived Dendritic Cells Infected with KSHV in Multiple Myeloma Patients”, *Blood* 90:353a (1997).

117. Rettig M, Vescio R, Ma H, Schiller G, Savage A, and **Berenson JR**, “Sequence Variability of HHV-8 From the Dendritic Cells of Multiple Myeloma Patients”, *Blood* 90:86a (1997).

118. Pold M, Rettig M, Munroe D, Vescio R, Hall J, and **Berenson J**, “Expression of Novel Genes in Human Chromosomal Locus 11q13”, *Blood* 90:317a (1997).

119. Said JW, Rettig M, Heppner K, Shintaku JP, Koeffler HP, Asou H, Pinkus J, Browne P, Shah S, **Berenson JR**, and Pinkus GS, “Localization of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) in Bone Marrow Biopsies from Patients with Myeloma”, *Modern Pathology* 11:139A (1998).

120. **Berenson J**, Rosen L, and Vescio R, et al. “Pharmacokinetics of Pamidronate Disodium in Patients with Cancer with Normal or Impaired Renal Function,” *Bone Depeche* 4:15-16 (1998).
121. **Berenson J**, “Oncogenesis in Multiple Myeloma”, *British J of Haematology* 102: HiF-0562 (1998).
122. Ali SM, Esteva FJ, Hortobagyi G, Henick K, **Berenson JR**, Harvey H, Seaman J, Knight R, and Lipton A, “Safety of Longterm Use of Bisphosphonates in Cancer Patients,” *ASCO* 17:43a (1998).
123. Freytes CO, Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Jacobs C, Dipersio J, Anderson K, **Berenson JR**, and Sing A, “CD34 Selection Did Not Delay Immune Recovery Nor Increase Frequency of Infections in Multiple Myeloma Patients Transplanted on a Phase III Trial,” *Blood* 92 (Suppl. 1):660a (1998).
124. **Berenson J**, Crowley J, Barlogie B, and Salmon S, “Alternate Day Oral Prednisone Maintenance Therapy Improves Progression-Free and Overall Survival in Multiple Myeloma Patients,” *Blood* 92 (Suppl. 1):318a (1998).
125. **Berenson J**, Zinner D, Bleeker G, Zacker C, and DiCesare J, “Cost of Treating Skeletal Related Events Associated with Osteolytic Metastases,” *Blood* 92 (Suppl. 1):274b (1998).
126. **Berenson J**, Webb I, Henick K, Vescio R, Swift R, Anderson K, and Seaman J, “A Phase II Dose-Ranging Trial of Single-Agent Pamidronate for Relapsed/Refractory Multiple Myeloma,” *Blood* 92 (Suppl. 1):107a (1998).
127. Henick K, Vescio R, Ma MJ, Derdanelian M, Moss TJ, and **Berenson J**, “HHV-8 is Rarely Detected in the Peripheral Blood Dendritic Cells of Close Contacts of Patients with Multiple Myeloma,” *Blood* 92 (Suppl. 1):96a (1998).
128. Henick K, Vescio R, Scott S, Lee M, Schiller G, and **Berenson J**, “The Use of Pamidronate Prior to Autologous Peripheral Blood Stem Cell Transplant Does Not Impact Mobilization or Engraftment in Multiple Myeloma Patients,” *Blood* 92 (Suppl. 1):273a (1998).
129. Sjak-Shie N, Ma H, DerDanielian M, Vescio R, Kaminsky M, Mikail A, Henick K, Schiller G, Moss T, and **Berenson J**, “Incidence of HHV-8 Infection in Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance,” *Blood* 92 (Suppl. 1):97a (1998).
130. Sjak-Shie N, Ma H, DerDanielian M, Vescio R, Moss T, and **Berenson J**, “Human Herpesvirus-8 is Not Detectable in Blood or Uninvolved Bone Marrow of Patients with Solitary Plasmacytomas,” *Blood* 92 (Suppl. 1):97a (1998).
131. Pold M, Chen G, Vescio R, and **Berenson J**, “Identification of a Novel Gene in The Chromosomal Locus 11q13,” *Blood* 92 (Suppl. 1):70a (1998).
132. Pold M, Zhou J, Chen G, Vescio R, and **Berenson J**, “Identification of a Novel Member of the

Mage Tumor Antigen Family,” Blood 92 (Suppl. 1):432a (1998).

133. Vescio R, Stewart A, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Dipersio J, Anderson K, and **Berenson J**, “Circulating Multiple Myeloma Cell Burden Predicts Disease Relapse Following Autologous Transplantation,” Blood 92 (Suppl. 1):97a (1998).

134. Beksac M, Ma M, DerDanielian M, Zhang L, Liu J, Kuzu I, Ereku S, Vescio R, and **Berenson JR**, “Frequent Demonstration of Human Herpesvirus 8 (HHV-8) in Bone Marrow Biopsy Samples from Turkish Patients with Multiple Myeloma (MM),” Blood 92 (Suppl. 1):96a (1998).

135. Ma H, Vescio R, DerDanielian M, Schiller G, and **Berenson JR**, “The HHV-8 IL-8R Homologue and Interferon Regulatory Factor Genes are Frequently Expressed in Myeloma Bone Marrow Biopsies Whereas the vIL-6 is Rarely Found,” Blood 92 (Suppl. 1):515a (1998).

136. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Sing A, Jacobs C, Dipersio J, Anderson K, and **Berenson JR**, “Phase III Study Evaluating CD34 Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in 190 Patients with Advanced Multiple Myeloma,” Blood 92 (Suppl. 1):662a (1998).

137. Krieger MS, Schiller G, **Berenson JR**, Stewart AK, Noga SJ, Ballester O, Tarantolo S, Stiff P, Kuhn D, Scherzo E, Sing A, Jacobs C, White JM, and Dipersio J, “Collection of Peripheral Blood Progenitor Cells (PBPC) Based on a Rising WBC and Platelet Count Significantly Increases the Number of CD34+ Cells,” Blood 92 (Suppl. 1):122a (1998).

138. **Berenson JR**, “Alternate Day Oral Prednisone Maintenance Therapy Improve Progression-Free and Overall Survival in Multiple Myeloma Patients, Southwest Oncology Group Spring 1999 Group Meeting, Presented at Plenary Session, Phoenix, Arizona (1999).

139. **Berenson JR**, “Success in Multiple Myeloma,” Novartis Pharmaceuticals, Inc. Satellite Symposium, Davos, March 28, (1999).

140. Thurlimann B, **Berenson JR**, Lira-Puerto VM, Ammon A, Major P, Javier de la Serna F, Seaman J, and Vilimovskij A, “Renal Safety and Tolerability of 90 mg of Aredia (Pamidronate) Administered as an Intravenous 1 Hour Infusion: Preliminary Results,” ASCO 18:576a (1999).

141. Emmanouilides C, Vescio R, Chawla S, **Berenson JR**, Territo M, and Schiller G, “Successful Treatment of Relapsed Multiple Myeloma Using High Dose Chemotherapy with Non-Myeloablative Allogeneic Stem Cell Transplant,” ASCO 18:39a (1999).

142. Sjak-Shie N, Sultur G, Said J, Vescio R, and **Berenson JR**, “Angiogenesis and Vascular Endothelial Growth Factor Expression Correlate with the Degree of Bone Marrow Involvement in Multiple Myeloma,” Multiple Myeloma Workshop VII, Stockholm, (1999).

143. Vescio R, Ma H, Sjak-Shie N, Zhang L, Chen G, Pold M, Schiller G, Gao S, Moss T, Said J and

Berenson J, “Presence of HHV-8 in the Bone Marrow and Peripheral Blood Dendritic Cells of Patients with Multiple Myeloma,” VII International Conference on Malignant Lymphoma June 2-5 (1999).

144. **Berenson JR**, Webb IJ, Anderson K, Schlossman R, Vescio R, Doss D, Goon B, Swift R, Von Teichert J, Kowalski M and Seaman J, “Single-Agent Aredia for Relapsed / Refractory Multiple Myeloma,” American Society of Hematology, Blood 94 (Suppl. 1): 307b (1999).

145. Stewart AK, Schiller G, Vescio R, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schlossman R, Brown RA, Tully H, Sing A, Jacobs C, White M, Dipersio JF, Anderson KC, **Berenson J**, “CD34 Selection Does Not Prolong Disease Free or Overall Survival in Myeloma Patients Undergoing Autologous Stem Cell Transplant: Results of a Phase III Study,” American Society of Hematology, Blood 94 (Suppl. 1): 485a (1999).

146. **Berenson J**, Crowley J, Barlogie B, and Salmon S, “Alternate Day Oral Prednisone Maintenance Therapy Improves Progression-Free and Overall Survival in Multiple Myeloma Patients,” Southwest Oncology Group Newsletter 13:2 (1999).

147. Lipton A, **Berenson JR**, Levy E, and Knight R, “Phase II Study of the Bisphosphonate Zoledronate in Patients with Osteolytic Lesions,” Cancer-Induced Bone Diseases, Second International Conference, Davos, Switzerland, Abs#48 (1999).

148. **Berenson JR**, Webb I, Anderson K, Henick K, Vescio R, Doss D, Swift R, Goon B, Kowalski M, and Seaman J, “A Phase II Dose-Ranging Trial of Single-Agent Pamidronate for Relapsed / Refractory Multiple Myeloma,” Second North American Symposium on Skeletal Complications of Malignancy, October 15-16 (1999), Montreal, Canada.

149. Stewart AK, Vescio R, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Sing A, Jacobs C, DiPersio J, Anderson K, and **Berenson JR**, “An Update of a Phase III Study Evaluating CD34 Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in 190 Patients with Advanced Multiple Myeloma,” International Multiple Myeloma Workshop, September 1-5, Stockholm, Sweden, Abs # 035, p118 (1999).

150. Schiller G, Vescio R, and **Berenson JR**, “Thalidomide for the Treatment of Multiple Myeloma Relapsing After Autologous Peripheral Blood Progenitor Cell Transplant,” American Society of Hematology, Blood 94(S1): 317a (1999).

151. Douek DC, Betts MR, Brenchley JM, Zheng L, **Berenson JR**, Collins RH, Vescio RA, and Koup RA, “Contribution of the Thymus to Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplant in Adults,” Blood 94(S1): 604a (1999).

152. Sjak-Shie NN, Sultur GG, Said JW, Vescio RA, and **Berenson JR**, “Vascular Endothelial Growth Factor and Angiogenesis in Multiple Myeloma,” International Multiple Myeloma Workshop, September 1-5, Stockholm, Sweden, Abs # P154, p166 (1999).

153. Sjak-Shie NN, Suler GG, Said JW, Vescio RA, and **Berenson JR**, “Vascular Endothelial Growth Factor and Angiogenesis in Multiple Myeloma,” American Society of Hematology, Blood 94 (S1): 305a (1999).
154. Sjak-Shie NN, Tsingotildou AS, Zhang K, Vescio RA, Said JW, Lieberman J, and **Berenson JR**, “Development of a SCID-hu Animal Model That More Closely Resembles Human Multiple Myeloma,” American Society of Hematology, Blood 94(S1): 547a (1999).
155. Stewart AK, Schiller G, Vescio R, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schlossman R, Brown RA Tully H, Sing A, Jacobs C, White M, Dispersio JF, Anderson KC, and **Berenson J**, “CD34 Selection Does Not Prolong Disease Free or Overall Survival in Myeloma Patients Undergoing Autologous Stem Cell Transplant: Results of a Phase III Study,” American Society of Hematology, Blood 94 (S1): 714a (1999).
156. Ma HJ, Sjak-Shie NN, Vescio RA, Zhang L, Glowalla A, Pold M, Beksac M, and **Berenson JR**, “Identification of a Myeloma Specific HHV-8 ORF65 Gene,” American Society of Hematology, Blood 94: 2170 (1999).
157. **Berenson JR**, “HHV-8 and its Role in the Aetiology of Multiple Myeloma,” “The Use of Bisphosphonates in Patients with Multiple Myeloma” and “Clinical Studies of CD34+ Selection in Multiple Myeloma Autografts: Fulfilling the Early Promise?” Presented at 1st Annual Scientific Meeting of the Haematology Society of Australia & New Zealand, October (1999).
158. Jazirehi AR, Ng CP, Schiller G, **Berenson JR**, and Bonavida B, “Cytotoxic and Sensitizing Pathways Mediated by Adriamycin on Multiple Myeloma Cell Lines,” In: Proceedings of the American Association of Cancer Research 91st Annual Meeting, Proceedings of the American Association for Cancer Research 41:822 (2000).
159. **Berenson JR**, Ravera C, Ma P, Gauron S, Deckert F, Sasaki Y, Sacki T, Takashima S, LoRusso P, Goodin S, Seaman J, Schran H, Lau H, and Zhou H, “Population Pharmacokinetics (PK) of Zometa,” Proceedings of ASCO, 19:209a (2000).
160. **Berenson JR**, “Myeloma – The Therapeutic Challenge,” Med Klin Suppl II; 19-2, October (2000).
161. **Berenson JR** and Vescio RA, “Thalidomide is an Effective Agent for Patients with primary Amyloidosis,” Chemotherapy Foundation Symposium XVIII – Innovative Cancer Therapy for Tomorrow – Presented by the Page and William Black Post Graduate School of the Mount Sinai School of Medicine and the Chemotherapy Foundation, New York, November (2000).
162. Vescio R, Liu J, Chen G, Wang J, Parker K, and **Berenson JR**, “Interleukin-1A and Interleukin-1B Polymorphisms Do Not Predict for Multiple Myeloma Bone Disease Severity or Outcome,” American Society of Hematology, (Abstr. # 3247), Blood 96:11:751a, (2000).
163. Beksac M, Ma HJ, Mikail A, Altamirano CV, Kurt M, Dalva K, Vescio RA, and **Berenson JR**,

- “Increased Telomerase Activity (TA) in CD38+ Bone Marrow Mononuclear Cells (BMMCs) from Multiple Myeloma (MM) Patients,” American Society of Hematology, (Abstr. 1575) Blood 96:11:365a, (2000).
164. Altamirano CV, Ma HJ, Parker KM, Glowalla A, Mikail AE, Sjak-Shie N, Vescio R, and **Berenson JR**, “RANKL is Expressed in Malignant Multiple Myeloma (MM) Cell Lines,” American Society of Hematology, (Abstr. 1578) Blood 96:11:365a, (2000).
165. Ma HJ, Parker KM, Altamirano CV, Mikail AE, Glowalla A, Vescio R, and **Berenson JR**, “Frequent Alteration of the IκB Gene in Multiple Myeloma (MM) Patients,” American Society of Hematology, (Abstr. 2918) Blood 96:11:678a, (2000).
166. Vescio RA and **Berenson JR**, “Thalidomide is an Effective Agent for Patients with Primary Amyloidosis,” American Society of Hematology, (Abstr. 5022) Blood 96:11:296b, (2000).
167. **Berenson JR**, Ma M, and Altamirano C, “New Inhibitors of NF-κB Signaling and Angiogenesis in Myeloma,” Vth Experts’ Roundtable in Multiple Myeloma, *Cell Signaling in Myeloma: Regulation of Growth and Apoptosis*, Multiple Myeloma Research Foundation (MMRF), May 3 (2001).
168. **Berenson JR**, “Increasing Rationale for Targeting VEGF and Anti-Angiogenesis Approaches to Myeloma Therapy,” VIIIth International Myeloma Workshop, (S13), Banff, Alberta, Canada, May 4-8 (2001).
169. Ma M, Altamirano CV, Manyak S, Parker K, Sjak-Shie N, Vescio R, and **Berenson JR**, “IκB/NFκB and Chemo-Resistance in Multiple Myeloma,” VIIIth International Myeloma Workshop, Banff, Alberta, Canada, (P23), May 4-8 (2001).
170. Sjak-Shie NN, Manyak SJ, Ma H, Altamirano CV, Vescio RA, and **Berenson JR**, “Clarithromycin Adds to the Efficacy of Steroid Therapy with/without Thalidomide in Multiple Myeloma: Clinical and Laboratory Evidence,” VIIIth International Myeloma Workshop, Banff, Alberta, Canada, (P158) May 4-8 (2001).
171. Altamirano CV, Ma HJ, Parker KM, von Tiechert J, Sjak-Shie N, Vescio R, and **Berenson JR**, “Malignant Multiple Myeloma (MM) Cells Express RANKL, a Moderator of Osteoclast Activation,” VIIIth International Myeloma Workshop, Banff, Alberta, Canada, (P205), May 4-8 (2001).
172. **Berenson JR**, “Biology and Bisphosphonate Therapy in Myeloma and Novel Approaches to Metastatic Bone Disease,” American Society of Clinical Oncology 2001 Educational Book, 142-151 (2001).
173. **Berenson JR**, “A Prospective, Open-Label, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Ascorbic Acid (MAC) in Patients with Relapsed or Refractory Multiple Myeloma,” 46th ASH Annual Meeting, Dec. 7-11, (2001).
174. Altamirano CV, Vescio RA, and **Berenson JR**, “The Role of RANKL, RANK and OPG in the

Pathogenesis of Multiple Myeloma,” Multiple Myeloma Research Foundation Bone Meeting, Chicago, IL, June (2001).

175. **Berenson JR**, Major P, Miller W, Schran H, Ravera C, Skerjanec A, and Waldmeier F, “Effect of Renal Function on the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Zoledronic Acid in Cancer Patients with Bone Metastases,” 43rd American Society of Hematology Annual Meeting, 98:11:167a, December (2001).

176. Greipp, P, Facon T, Williams CD, Lipton A, Mariette X, Feraud JP, **Berenson JR**, Harousseau JL, Alexanian R, Nakanishi A, Holloway D, Dunstan CR, and Bekker PJ, “A Single Subcutaneous Dose of an Osteoprotegerin (OPG) Construct (AMGN-0007) Causes a Profound and Sustained Decrease of Bone Resorption Comparable to Standard Intravenous Bisphosphonate in Patients with Multiple Myeloma,” 43rd American Society of Hematology Annual Meeting, 98:11:775a, December (2001).

177. Ma MH, Parker K, Manyak S, Altamirano CV, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Yang H, Sjak-Shie N, Vescio R, and **Berenson JR**, “Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Cells to Chemotherapeutic Agents and Overcomes Chemo-Resistance Through Inhibition of the NF- κ B Pathway,” 43rd American Society of Hematology Annual Meeting, 98:11:473a, December (2001).

178. Ma MH, Borad MJ, Friedman J, Glowalla A, Manyak S, Altamirano CV, Tang YM, Roussos E, Neeser J, Roy M, Yang H, Sjak-Shie N, Vescio R, and **Berenson JR**, “Arsenic Trioxide-Mediated Growth Inhibition and Apoptosis in Multiple Myeloma Cells Correlated with Inhibition of Nuclear Factor (NF)- κ B Activity,” 43rd American Society of Hematology Annual Meeting, 98:11:100a, December (2001).

179. Vescio RA, Sjak-Shie NN, Manyak SJ, Yang H, and **Berenson JR**, “Clarithromycin (Biaxin) Adds to the Efficacy and Toxicity of Steroid Therapy in Multiple Myeloma,” 43rd American Society of Hematology Annual Meeting, 98:11:312b-313b, December (2001).

180. Altamirano CV, Neeser JA, Manyak S, Tang YG, Sjak-Shie N, Okopnik J, Ma MH, Parker KM, Vescio R, and **Berenson JR**, “Malignant Multiple Myeloma Cells Expressing RANKL Induce the Formation of TRAP Positive Multinucleated Cells,” 43rd American Society of Hematology Annual Meeting, 98:11:637A, December (2001).

181. Altamirano CV, Pang S, Li LY, and **Berenson JR**, “Vascular Endothelial Growth Inhibitor (VEGI) Inhibits the Growth of Multiple Myeloma Plasma Cells and Induces Their Apoptosis,” 43rd American Society of Hematology Annual Meeting, 98:11:638a, December (2001).

182. Richardson PG, **Berenson JR**, Irwin D, Jagannath S, Traynor A, Rajkumar V, Alsina M, Kuter D, Srkalovic G, Siegel D, Barlogie B, Alexanian R, Orlowski R, Esseltine D, Kauffman M, Adams J, Schenkein DP, and Anderson KC, “Phase II Study of PS-341, a Novel Proteasome Inhibitor, Alone or in Combination with Dexamethasone in Patients with Multiple Myeloma Who Have Relapsed Following Front-Line Therapy and Are Refractory to Their Most Recent Therapy,” 43rd American Society of Hematology Annual Meeting, 98:11:774a, December (2001).

183. **Berenson JR**, “A Prospective, Open-Label, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Ascorbic Acid (MAC) in Patients with Relapsed or Refractory Multiple Myeloma,” 46th ASH Annual Meeting, Dec. 7-11, (2001)
184. Tang YG, Roussos E, Ma M, Altamirano CV, Yang H, Vescio RA, and **Berenson JR**, “Differential Expression of MAGE-A3 and MAGE-A6 Genes in Myeloma Cells Compared to Normal Lymphocytes,” 43rd American Society of Hematology Annual Meeting, 98:11:569a, December (2001).
185. Manyak SJ, Prakash S, Waterman BA, Ma MH, Altamirano CV, Tang YM, Sjak-Shie NN, Yang H, Vescio RA, and **Berenson JR**, “A Clinically Relevant *In Vivo* Model for Human Multiple Myeloma in SCID Mice,” 43rd American Society of Hematology Annual Meeting, 98:11:774a, December (2001).
186. Friedman JM, Ma MH, Manyak SJ, Borad MJ, Altamirano CV, Tang YM, Neeser JA, Okopnik J, Roussos E, Yang H, Vescio R, and **Berenson JR**, “Arsenic Trioxide Causes Apoptosis, Growth Inhibition and Increased Sensitivity to Chemotherapeutic Agents in Multiple Myeloma Cells Through Inhibition of Nuclear Factor (NF)- κ B Activity,” 93rd American Association for Cancer Research Annual Meeting, 43:925, March (2002).
187. Frohlich MW, Vescio R, **Berenson JR**, Rasmussen A, Kalamasz D, Roehrs H, Markham E, Green C, Berenson RJ, and Bonyhadi M, “Ex Vivo Activation and Expansion of T-Cells from the Peripheral Blood of Multiple Myeloma Patients Using the Xcellerate™ Process,” for the American Society for Blood and Marrow Transplantation, Tandem 2003 BMT Meeting, 9:2:155:112, (2003).
188. **Berenson JR**, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, Srkalovic G, Richardson P, Esseltine D, and Anderson K, “Experience with Long-Term Therapy Using the Proteasome Inhibitor, Bortezomib, in Advanced Multiple Myeloma (MM),” for Thirty-Eighth Annual Meeting Proceedings in ASCO (2002).
189. **Berenson JR**, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, Srkalovic G, Richardson P, Esseltine D, and Anderson KC. “Experience with Long-Term Therapy Using the Proteasome Inhibitor, Bortezomib, in Advanced Multiple Myeloma,” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2337:581 (2003).
190. Richardson PGG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar V, Esseltine D, Schenkein D, and Anderson KC. “Prognostic Factors Associated with Response in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Bortezomib,” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2338:581 (2003).
191. Lee S, Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Schenkein D, Esseltine D, and Anderson KC. “Quality-of-Life (QOL) and Clinical Benefit Assessment in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Bortezomib,” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2339:582 (2003).

192. Yang HH, Vescio RA, Adams J, Schenkein D, and **Berenson JR**. “A Phase I/II Study of Combination Treatment with Bortezomib and Melphalan (Vc+M) in Patients with Relapsed or Refractory Multiple Myeloma (MM),” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2340:582 (2003).
193. Jagannath S, Richardson P, Barlogie B, **Berenson JR**, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine D, and Anderson KC. “Phase II Trials of Bortezomib in Combination with Dexamethasone in Multiple Myeloma (MM): Assessment of Additional Benefits to Combination in Patients with Sub-Optimal Responses to Bortezomib Alone,” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2341:582 (2003).
194. Borad M, Vescio R, Yang HH, Swift R, and **Berenson JR**. “Melphalan, Arsenic Trioxide (ATO) and Ascorbic Acid Combination Therapy (MAC) for Treatment of Refractory Multiple Myeloma (MM),” for the Thirty-Ninth Annual Meeting Proceedings in the American Society of Clinical Oncology (ASCO), 2327:603 (2003).
195. **Berenson JR**, “Preclinical Overview and Rationale for Single Agent and Combined Treatment of Multiple Myeloma with Trisenox* (Arsenic Trioxide),” IXth International Workshop on Multiple Myeloma, Palacio de Congresos, Salamanca, Spain (2003).
196. **Berenson JR**. “New Advances in the Biology and Treatment of Multiple Myeloma,” IXth International Workshop on Multiple Myeloma, Palacio de Congresos, Salamanca, Spain (2003).
197. **Berenson JR**, participant, “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma Research Roundtable,” MMRF, European Journal of Haematology, 70:4:263-272 (2003).
198. Vij R, Borrello IM, Martin T, Vescio R, Siegel D, Bashey A, DiPersio JF, **Berenson JR**, Ferrand C, Janmohamed F, Yuan V, Bouchard L, Berenson RJ, Bonyhadi M, and Frohlich MW, “A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma,” 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:139:43a (2003).
199. Richardson PG, Briemberg H, Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlovski R, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, and Anderson KC, “Peripheral Neuropathy Following Bortezomib (VELCADE, Formerly PS-341) Therapy in Patients with Advanced Multiple Myeloma (MM): Characterization and Reversibility,” 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:512:149a (2003).
200. Yang HH, Swift R, Sadler K, Vescio R, Adams J, Schenkein D, and **Berenson JR**, “A Phase I/II Trial of VELCADE and Melphalan Combination Therapy (Vc+M) for Patients with Relapsed or Refractory Multiple Myeloma (MM),” 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:826:235a (2003).
201. Borad M, Swift RA, Sadler K, Yang H, and **Berenson JR**, “Melphalan, Arsenic Trioxide and

Ascorbic Acid 9MAC) is Effective in the Treatment of Refractory and Relapsed Multiple Myeloma (MM)," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:827:235a-236a (2003).

202. Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Alexanian R, Srkalovic G, Orlowski R, Richardson PG, Nix D, Guercioli R, Esseltine D, and Anderson KC, "Limited Experience from 2 Phase 2 Trials Suggests Bortezomib can be Given Safely in Multiple Myeloma (MM) Patients (pts) with Severe Renal Impairment with Comparable Responses and Toxicities," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:828:236a (2003).

203. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Bryant B, Mulligan G, Xiao H, Esseltine D, Schenkein DP, and Anderson KC, "Prognostic Factors for Response Parameters and Overall Survival in Patients with Multiple Myeloma (MM) Following Treatment with Bortezomib," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:1629:446a (2003).

204. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, Torre C, Barlogie B, **Berenson JR**, Singhal S, Schenkein DP, Esseltine D-LW, Anderson J, Heffner LT, and Anderson KC, "Evaluation of the Degree of Thrombocytopenia and Associated Risk Factors Following Bortezomib Therapy for Relapsed Multiple Myeloma," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:1632:447a (2003).

205. Chen H, Yang HH, Guangxu S, Yan X, Campbell R, and **Berenson JR**, "The C-Domain of TRAF6 is a Potential New Target for Inhibition of Multiple Myeloma," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:3465:931a (2003).

206. Yang HH, Yan X, Chen H, and **Berenson JR**, "Differential Synergistic Anti-Myeloma Effects of the COX-2 Inhibitor NS398 and Bortezomib on Doxorubicin-Sensitive and -Resistant Myeloma Cells," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:3488:936a-937a (2003).

207. Chen H, Yang HH, Guangxu S, Yan X, Campbell R, and **Berenson JR**, "The Role of Angiogenin on Multiple Myeloma (MM) Cell Migration and Invasion Using a Novel *In Vivo* Model," 45th Annual Meeting of the American Society of Hematology (ASH), Blood, 102:11:5243:379b (2003).

208. Frohlich MW, Vescio R, **Berenson JR**, Rasmussen A, Kalamasz D, Roehrs H, Markham E, Green C, Berenson RJ, and Bonyhadi M, "Ex Vivo Activation and Expansion of T Cells from the Peripheral Blood of Multiple Myeloma Patients Using the Xcellerate Process," American Society for Blood and Marrow Transplantation (ASBMT), 9:2, February (2003).

209. Vij R, Borrello IM, Martin T, Vescio R, Siegel D, Bashey A, DiPersio JF, **Berenson JR**, Ferrand C, Janmohamed F, Yuan V, Bouchard L, Berenson RJ, Bonyhadi M, and Frohlich MW, "A Phase I/II Study of Xcellerated T Cells after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma," Blood, 102 No. 11, November 16, p43a, 139, (2003).

210. Richardson PG, Briemberg H, Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Traynor A,

Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski R, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, and Anderson KC, “Peripheral Neuropathy Following Bortezomib (VELCADE, Formerly PS-341) Therapy in Patients with Advanced Multiple Myeloma (MM): Characterization and Reversibility,” *Blood*, 102:11:149a:512, (2003).

211. Yang HH, Swift R, Sadler K, Vescio R, Adams J, Schenkein D, and **Berenson JR**, “A Phase I/II Trial of Velcade and Melphalan Combination Therapy (Vc+M) for Patients with Relapsed or Refractory Multiple Myeloma,” *Blood*, 102:11:235a:826, (2003).

212. Jagannath S, Barlogie B, **Berenson J**, Singhal S, Alexanian R, Srkalovic G, Orlowski R, Richardson PG, Nix D, Guercioli R, Esseltine D, and Anderson KC, “Limited Experience from 2 Phase 2 Trials Suggests Bortezomib Can Be Given Safely in Multiple Myeloma (MM) Patients (Pts) with Severe Renal Impairment with Comparable Responses and Toxicities,” *Blood*, 102:11:236a:828, (2003).

213. Borad M, Swift RA, Sadler K, Yang H, and **Berenson JR**, “Melphalan, Arsenic Trioxide and Ascorbic Acid (MAC) is Effective in the Treatment of Refractory and Relapsed Multiple Myeloma (MM),” *Blood*, 102:11:235a:827, (2003).

214. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Bryant B, Mulligan G, Xiao H, Esseltine D, Schenkein DP, and Anderson KC, “Prognostic Factors for Response Parameters and Overall Survival in Patients with Multiple Myeloma (MM) Following Treatment with Bortezomib,” *Blood*, 102:11:446a:1629, (2003).

215. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, Torre C, Barlogie B, **Berenson JR**, Singhal S, Schenkein DP, Esseltine DW, Anderson J, Heffner LT, and Anderson KC, “Evaluation of the Degree of Thrombocytopenia and Associated Risk Factors Following Bortezomib Therapy for Relapsed Multiple Myeloma,” *Blood*, 102:11:447a:1632, (2003).

216. Chen H, Yang HH, Guangxu S, Yan X, Campbell R, and **Berenson JR**, “The C-Domain of TRAF6 is a Potential New Target for Inhibition of Multiple Myeloma,” *Blood*, 102:11:931a:3465, (2003).

217. Yang HH, Yan X, Chen H, and **Berenson JR**, “Differential Synergistic Anti-Myeloma Effects of the COX-2 Inhibitor NS398 and Bortezomib on Doxorubicin-Sensitive and –Resistant Myeloma Cells,” *Blood*, 102:11:936a:3488, (2003).

218. Chen H, Yang HH, Guangxu S, Yan X, Campbell R, and **Berenson JR**, “The Role of Angiogenin on Multiple Myeloma (MM) Cell Migration and Invasion Using a Novel In Vivo Model,” *Blood*, 102:11:379b:5243, (2003).

219. Borrello IM, Vij R, Vescio RA, Martin TG, Siegel D, **Berenson JR**, Janmohamed F, Bonyhadi M, Berenson RJ, and Frohlich MW, “A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma,” *American Society of Clinical Oncology*, 23:173:2540, (2004).

220. **Berenson JR**, “Arsenic Trioxide (Trisenox) in Multiple Myeloma: Significant Efficacy and a Manageable Toxicity Profile,” *Cancer Investigation*, 22: 1-104, (2004).
221. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Hideshima T, Esseltine DL, and Anderson KC, “Survival, Duration of Response, and Time of Progression with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma: An Update with Additional Follow-up,” *European Hematology Association*, 5:103:304 (2004).
222. Berenson R, Vij R, Borrello IM, Vescio RA, Martin TG, Siegel D, di Persio JF, Janmohamed F, Anderson K, Bonyhadi M, **Berenson JR**, and Frohlich MW, “A Phase I/II Study of Xcellerated T cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma,” *European Hematology Association*, 5:124: 355 (2004).
223. **Berenson JR**, “A Phase I/II Multicenter, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic and Vitamin C (Ascorbic Acid) (MAC) in Patients with Relapsed or Refractory Multiple Myeloma,” *European Hematology Association*, 5:128:365 (2004).
224. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine DL, Schenkein D, and Anderson K, “Factors Predictive of Clinical Outcome with Bortezomib (Velcade) in Patients with Relapsed, Refractory Multiple Myeloma,” *European Hematology Association*, 5:2:128:365a (2004).
225. **Berenson JR**, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, Srkalovic G, Richardson PG, Esseltine DL, and Anderson KC, “The Safety of Prolonged Therapy with the Proteasome Inhibitor Bortezomib (Velcade) in Relapsed and/or Refractory Multiple Myeloma (MM),” *European Hematology Association*, 5: Suppl 2:129:367, (2004).
226. Richardson P, Briemberg H, Jagannath S, Barlogie B, **Berenson JR**, Singhal S, Siegel DT, Irwin DH, Schuster MW, Srkalovic G, Orlowski R, Esseltine D, Wen P, Amato A, and Anderson KC, “Characterization and Reversibility of Peripheral Neuropathy in Patients with Advanced Multiple Myeloma Treated with Bortezomib (Velcade): The Summit and Crest Study Group,” *European Hematology Association*, 5:Suppl 2:129:368, (2004).
227. Jagannath S, Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine D, and Anderson KC, “Bortezomib in Combination with Dexamethasone for the Treatment of Patients with Relapsed and /or Refractory Multiple Myeloma,” *European Hematology Association*, 5: Suppl 2:130: 369, (2004).
228. **Berenson JR**, Yang HH, Swift R, Sadler K, Vescio R, Adams J, and Schenkein D, “Bortezomib and Melphalan Combination Therapy in Relapsed or Refractory Multiple Myeloma (MM): A Phase I/II Study,” *European Hematology Association*, 5: Suppl 2:130:370, (2004).
229. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, Torre C, Barlogie B,

Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, and Anderson KC, "Evaluation of the Severity and Risk of Thrombocytopenia with Bortezomib Therapy in Relapsed and Refractory Multiple Myeloma," *European Hematology Association*, 5: Suppl 2:130:371, (2004).

230. **Berenson JR**, Yang H, Swift R, Sadler K, Vescio R, Adams J, and Schenkein D, "Bortezomib in Combination with Melphalan in the Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study," *Blood* 104:11:64a:209, November (2004).

231. Siegel D, Vij R, Vescio RA, Borrello IM, Martin TG, **Berenson JR**, Ferrand C, Janmohamed F, Berenson RJ, and Frohlich MW, "A Phase I/II Study of Xcellerated T Cells after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma," *Blood* 104:11:265a: 925, November (2004).

232. Chen H, Zhu D, Campbell RA, James CP, Wang CS, Santos J, Bonavida B, and **Berenson JR**, "Pleiotrophin alone Induces Transdifferentiation of Human Monocytes and Bone Marrow Stem Cells into Endothelial Cells," *Blood* 104:11:412a:1472, November (2004).

233. **Berenson JR**, "A Phase I/II Multicenter, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) in Patients with Relapsed or Refractory Multiple Myeloma," *Blood* 104:11:659a: 2398, November (2004).

234. **Berenson JR**, Borrello IM, Vij R, Bashey A, Martin T, Boccia RV, Mohrbacher A, Simic A, Spitzer G, Meyer J, Berenson RJ, and Frohlich MW, "A Randomized Phase II Study of Xcellerated T Cells with or without Prior Fludarabine Therapy in Patients with Relapsed or Refractory Multiple Myeloma," *Blood* 104:11:662a:2410, November (2004).

235. Hussein MA, Niesvizky R, Munshi N, **Berenson JR**, Anderson KC, Ryan K, Baumgartner K, Miller DM, and McDonald M, "A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAB) in Patients with Refractory or Recurrent Multiple Myeloma," *Blood* 104:11, p663a, 2413, 16 November (2004).

236. Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, and **Berenson JR**, "Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to these Treatments In Vivo," *Blood* 104:11:677a:2467, November (2004).

237. Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, and **Berenson JR**, "Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of Both Arsenic Trioxide and Melphalan In Vitro and In Vivo," *Blood* 104:11:678a:2470, November (2004).

238. Chen H, Zhu D, Campbell RA, James CP, Li SG, Santos J, Wang CS, Bonavida B, and **Berenson JR**, "Pleiotrophin is Highly Expressed by Myeloma Cells Elevated in the Serum of Myeloma Patients, and is a New Autocrine Growth Factor for this B Cell Malignancy," *Blood* 104:11:915a:3349, November (2004).

239. Chen H, Campbell RA, Zhu D, Li SG, James CP, Santos J, Wang CS, Bonavida B, and **Berenson JR**, “Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis Through Regulation of the NF- κ B and JNK Pathways by Silencing TRAF6 C-Domain mRNA,” *Blood*, 104:11:916a:3355, November (2004).
240. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, Torre C, Barlogie B, **Berenson JR**, Singhal S, Schenkein DP, Esseltine DW, Anderson J, Xiao H, Heffner LT, and Anderson KC, “Evaluation of the Severity and Risk and Risk of Thrombocytopenia with Bortezomib Therapy in Relapsed and Refractory Multiple Myeloma,” *European Hematology Association* (submitted) (2004).
241. **Berenson JR**, Major P, Ravera C, Bilic S, and Schran H, “The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma,” *Blood*, 104:11:316b:4939, November (2004).
242. Hussein MA, **Berenson JR**, Niesvizky R, Munshi NC, Anderson KC, Ryan K, Baumgartner K, Miller DM, and McDonald M, “A phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma,” (ASA 2004).
243. Vij R, Vescio RA, Borrello IM, Martin TG, Siegel D, **Berenson JR**, Janmohamed F, Berenson RJ, and Frohlich MW, “A Phase I/II Study of Xcellerated T cells after Autologous peripheral blood stem cell transplantation in patients with multiple myeloma,” *ASBMT*, 11: 2:1:76: 226, February (2005).
244. Chen H, Zhu D, Campbell RA, James PC, Wang CS, Gordon MS, Bonavida B, and **Berenson JR**, “Pleiotrophin is a key switch of human monocytes and bone marrow stem cells into endothelial-like cells for angiogenesis in tumor growth,” *ASBMT* 11:2:1:85:252, February (2005).
245. Campbell RA, Gordon MS, Betancourt O, Juarez J, Donate F, Mazar A, and **Berenson JR**, “ATN-224, an Orally Available Small Molecule Inhibitor of SOD1, Inhibits Multiple Signaling Pathways Associated with Myeloma Progression and Has Antitumor Activity in a Murine Model of Refractory Myeloma Growth,” *AACR* (2005).
246. **Berenson JR**, Matous J, Ferretti D, Swift RA, Mapes R, Morrison B, Yeh H, and Bevivino S, “A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma,” *Blood* 106:11:2565, November (2005).
247. Gordon MS, Berenson AM, Drucker CB, Katz M, Lee HJ, Campbell RA, Chen H, Yeh HS, Bonavida B, Said J, and **Berenson JR**, “Peripheral Blood Cells from Multiple Myeloma Patients Show Increased Osteoclast and Decreased Osteoblast Gene Expression,” *Blood* 106:11:5098, November (2005).
248. **Berenson JR**, Major P, Swift RA, Vescio R, Rivera C, Bilic S, Gauron S, Denouel J, and Schran H, “The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma,” *Blood* 106:11:5192, November (2005).

249. Campbell RA, Chen H, Lee HJ, Yeh HS, Gordon MS, Bonavida B, Pang S, Said J, and **Berenson JR**, “Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth *In Vitro* and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM,” Blood 106:11:114, November (2005).
250. Neshat MS, Chen H, Gordon MS, **Berenson JR**, and Bonavida B, “Differential Presence of Truncated Forms of Transcription Factor Yin Yang 1 (YY1) in Bone Marrow of Multiple Myeloma Patients,” Blood 106:11:5083, November (2005).
251. **Berenson JR**, Long SA, and Bonyhadi ML, “Combined Cyto reduction and Infusion of Anti-CD3/Anti-CD28 Bead-Activated T Cells Prevent Diabetes in NOD Mice,” Blood 106:11:3036, November (2005).
252. **Berenson JR**, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Pomeroy JT, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Lindgren T, Moss R, Patel R, Ferretti D, Yeh H, and Bevivino S, “A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma,” Blood 106:11:720a:2564, November (2005).
253. Richardson P, Jagannath S, Hussein M, **Berenson JR**, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckj M, Faleck H, Zeldis J, Knight R, and Anderson KC, “A Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma,” Blood 106:11:449a:1565, November (2005).
254. Hussein MA, **Berenson JR**, Niesvizky R, Munshi NC, Harrop KL, McDonald M, and Drachman JG, “A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma,” Blood 106:11:723a:2572, November (2005).
255. Huerta-Yeppez S, Baritaki S, Hernandez-Cueto A, Anguino-Hernandez YM, Neshat M, Chen H, Campbell RA, Gordon MS, **Berenson JR**, and Bonavida B, “Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang (YY1) in Human Bone Marrow-Derived Multiple Myeloma,” Blood 106:11:948a:3394, November (2005).
256. Yeh H, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Gordon MS, Bonavida B, and **Berenson JR**, “Serum Pleiotrophin is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status,” Blood 106:11:954a:3417, November (2005).
257. Gordon MS, Lee HJ, Campbell RA, Chen H, Bonavida B, and **Berenson JR**, “Identification of Novel Receptors on Myeloma Cells and Monocytes that Contribute to Myeloma Tumor Proliferation and Angiogenesis,” Blood 106:11:704a:2507, November (2005).
258. Chen H, Campbell RA, Gordon MS, Manyak SJ, Wang C, Li M, Lee HJ, Wei J, Yeh HS, Bonavida B, and **Berenson JR**, “Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor,” Blood 106:11:701a:2494, November (2005).

259. Nervi B, Rettig MP, Ritchey JK, Bauer G, Walker J, Hess D, Herrbrich PE, Bonyhadi M, **Berenson JR**, Nolta JA, and DiPersio JF, “Naïve and *Ex Vivo* Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID 2M Null Mice: A New Xenogeneic Model for GvHD,” *Blood* 106:11:868a:3106, November (2005).
260. Chen H, Campbell RA, Wang C, Li M, Lee HJ, Yeh HS, Gui D, Gordon MS, Said J, Bonavida B, and **Berenson JR**, “Transdifferentiation of Monocytes into Endothelial Cells by Pleiotrophin,” *Blood* 106:11:117a:391, November (2005).
261. **Berenson JR**, Ritchey JK, Bonyhadi ML, and DiPersio JF, “Anti-CD3/Anti-CD28 Bead-Activated T Cells Facilitate Engraftment of Murine Histoincompatible Allogeneic Transplants after Low-Dose Radiation,” *Blood* 106:11:5221, November (2005).
262. **Berenson JR**, “New Targets and Strategies for Treating Multiple Myeloma,” Multiple Myeloma Research Foundation (an MMRF Roundtable), November (2005).
263. **Berenson JR**, Shirina N, and Chen YM, “Zoledronic Acid is Associated with a Survival Benefit in Patients with Multiple Myeloma Stratified by Baseline Bone Alkaline Phosphatase Levels,” MASCC Poster, (2006).
264. **Berenson JR**, Shirina N, Chen YM, and Dimopoulos M, “Survival in Patients with Multiple Myeloma Receiving Zoledronic Acid: Stratification by Baseline Bone Alkaline Phosphatase Levels,” *Journal of Clinical Oncology* 24:18S:423s:7505, (2006).
265. **Berenson JR**, Matous JV, Ferretti D, Swift RA, Mapes RA, Morrison B, and Yeh HS, “A Phase I/II Study of Arsenic Trioxide, Bortezomib, and Ascorbic Acid in Relapsed or Refractory Multiple Myeloma,” *Journal of Clinical Oncology* 24:18S:449s:7611, (2006).
266. Yeh HS, Swift RA, Ferretti D, Mapes RA, Goeckeler WF, and **Berenson JR**, “Phase I Study of Bortezomib and ¹⁵³Sm-lexidronam Combination for Refractory and Relapsed Multiple Myeloma,” *Journal of Clinical Oncology* 24:18S:450s:7614, (2006).
267. Richardson PG, Barlogie B, **Berenson JR**, Singhal S, Jagannath S, Rajkumar SV, Srkalovic G, Alsina M, and Anderson KC, “Extended Follow-up of a Phase II Trial in Relapsed, Refractory Multiple Myeloma,” *Cancer* 106:6:1316-1319, February (2006).
268. Yeh H, Swift RA, Ferretti D, Mapes R, Goeckeler W, and **Berenson J**, “Phase I Study of Bortezomib and ¹⁵³SM-Lexidronam Combination for Refractory and Relapsed Multiple Myeloma,” EHA 11th Congress, 91:1:272 (# 0738), June (2006).
269. **Berenson JR**, Matous J, Ferretti D, Swift RA, Mapes RA, Morrison B, and Yeh HS, “A Phase I/II Study of Arsenic Trioxide, Bortezomib, and Ascorbic Acid in Relapsed or Refractory Multiple Myeloma,” EHA 11th Congress, 91:1:92 (# 0245), June (2006).
270. **Berenson JR**, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Pomeroy JT, Steis R,

Flam M, Lutzky J, Jilani S, Volk J, Lindgren T, Moss R, Patel R, and Yeh H, “Efficacy and Safety of Melphalan/Arsenic Trioxide/Ascorbic Acid Combination Therapy (MAC) in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective, Multicenter, Phase II, Single-Arm Study,” EHA 11th Congress, 91:1:86 (#0230), June (2006).

271. **Berenson JR**, Shirina N, and Chen Y, “Zoledronic Acid is Associated with a Survival Benefit in Patients with Multiple Myeloma Stratified by Baseline Bone Alkaline Phosphatase Levels,” MASCC (2006).

272. Chen H, Li M, Campbell RA, Shalitin D, Wang CF, Sanchez E, Steinberg J, Wang J, Chang Y, Bonavida B, Deuel TF, and **Berenson JR**, “Zoledronic Acid Inhibits the Earliest Stages of Vasculogenesis: Blockage of the Transdifferentiation of Monocytes into Endothelial Cells Induced by Pleiotrophin and mCSF,” AACR Annual Meeting (2007) Poster # 4651.

273. Chen H, Li M, Campbell RA, Gordon MS, Shalitin D, Wang C, Berenson AM, Li J, Wong H, Wang J, Bonavida B, and **Berenson JR**, “Arsenic Trioxide Affects Early Stage Angiogenesis through Inhibition of CD14 Monocyte Transdifferentiation into Endothelial Cells Induced by Pleiotrophin and mCSF. Session Type: Poster Session, Board #395A ASH (2006).

274. Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Plowman GD, Fuh G, and **Berenson JR**, “Antibody Treatment Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma. Session Type: Oral Session ASH (2006).

275. **Berenson JR**, Swift RA, Mapes R, and Abaya CD, “Phase I Study of Bortezomib and Sm-Lexidronam Combination for Refractory and Relapsed Multiple Myeloma.” Session Type: Poster Session, Board #773-111 ASH (2006).

276. Campbell RA, Gordon MS, Sanchez E, Chen H, Turker L, Trac O, Li M, Pang S, Bonavida B, Said J, Drachman JG, and **Berenson JR**, “The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAG-1A, a CD40* Mouse Model of Human Multiple Myeloma.” Session Type: Poster Session, Board #735-111. ASH (2006).

277. Campbell RA, Sanchez E, Chen H, Turker L, Li M, Trac O, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Wallner B, Gale RP, and **Berenson JR** “ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model.” Session Type: Poster Session, Board #691-111 ASH (2006).

278. Campbell RA, Sanchez E, Chen H, Turker H, Li M, Trac O, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Jeffers M, Qian X, Lichtenstein HS, and **Berenson JR**, “Effects of a Novel Histone Deacetylase Inhibitor, PXD101, When Used as Monotherapy or in Combination with Bortezomib on Tumor Growth in Mouse Models of Human Multiple Myeloma.” Session type: Poster Session, Board #712-111 ASH (2006).

279. Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S,

Bonavida B, Said J, Berenson RJ, and **Berenson JR**, “PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth in Vitro and Chemosensitize Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma.” Session Type: Poster Session, Board #688-111 ASH (2006).

280. **Berenson JR**, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, and Reich SD, “A Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bus-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.” Session Type: Poster Session, Board #771-11 ASH (2006).

281. Chen H, Li M, Campbell RA, Gordon MS, Shalitin D, Wang CS, Berenson AM, Li J, Drucker CB, Bonavida B, and **Berenson JR**, “Blocking TRAF6 Function Domain by TRAF6 Dominant Negative (TRAF6dn) for Inhibition of Multiple Myeloma Cell Proliferative and Increase of Apoptosis through Regulation of NF-B and JNK Pathways.” Session Type: Poster Session, Board #663-111 ASH (2006).

282. Chen H, Li M, Gordon MS, Shalitin D, Wang CS, Berenson AM, Li J, Wong H, Bonavida B, and **Berenson JR**, “Pleiotrophin Is Highly Produced by Myeloma and Breast Cancer and Transdifferentiates Human Monocytes into Endothelial Cells That Are Incorporated into Tumoral Blood Vessels.” Session Type: Poster Session, Board #397-1 ASH (2006).

283. Shalitin D, Campbell R, Share DM, Sanchez E, Steinberg J, Chen H, Li M, Wang C, Bonavida B, Said J, and **Berenson J**, “Aberrant PTEN in MM monocytes: Role in MM angiogenesis,” International Myeloma Workshop: Poster Session: PO-230 Kos Island Greece (6/2007).

284. **Berenson JR**, Dimopoulos M, and Chen YM, “Zoledronic acid and survival in patients with high BALP,” International Myeloma Workshop: Poster Session: PO-326 Kos Island Greece (6/2007).

285. Campbell RA, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, and **Berenson JR**, “The mTOR inhibitor RAD001 (everolimus) inhibits myeloma tumor growth in vivo,” International Myeloma Workshop: Poster Session: PO-535 Kos Island Greece (6/2007).

286. Chen H, Campbell RA, Li M, Wang CS, Shalitin D, Sanchez E, Steinberg J, Gui D, Said J, Chang Y, Deuel TF, Bonavida B, and **Berenson JR**, “Inhibiting pleiotrophin reduces MM and endothelial growth,” International Myeloma Workshop Poster Session: PO-540 Kos Island Greece (6/2007).

287. Campbell R, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, Richon V, and **Berenson JR**, “In vivo effects of vorinostat in combination with bortezomib,” International Myeloma Workshop Poster Session: PO-543 Kos Island Greece (6/2007).

288. **Berenson JR**, Patel R, and Swift R, “Phase I trial of bortezomib (VEL) + samarium (SAM) in MM,” International Myeloma Workshop Poster Session: PO-623 Kos Island Greece (6/2007).

289. **Berenson JR**, Woytowicz D, Flam M, Cartmell A, Patel R, and Swift R, “Bortezomib +

ascorbic acid + melphalan upfront therapy,” International Myeloma Workshop Poster Session: PO-719 Kos Island Greece (6/2007).

290. **Berenson JR**, Dimopoulos M, and Chen YM, “Zoledronic Acid and Survival in Patients with High Balp,” PO-326, Haematologica, International Myeloma Workshop, 92(s2) (2007).

291. Campbell R, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, and **Berenson JR**, “The MTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma. Tumor Growth *In Vivo*,” PO-535, Haematologica, International Myeloma Workshop, 92(s2) (2007).

292. Chen H, Campbell RA, Li M, Wang CS, Shalitin D, Sanchez E, Steinberg J, Gui D, Said J, Chang Y, Deuel TF, Bonavida B, and **Berenson JR**, “Inhibiting Pleiotrophin Reduces MM and Endothelial Growth,” PO-540, Haematologica, International Myeloma Workshop, 92(s2) (2007).

293. Campbell R, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, Richon V, and **Berenson J**, “*In Vivo* Effects of Vorinostat in Combination with Bortezomib,” PO-543, Haematologica, International Myeloma Workshop, 92(s2) (2007).

294. **Berenson JR**, Jagannath S, Boccia R, Sobecks R, Belch A, Schwartz B, Gale RP, and Hussein M, “Phase-1/-2 Trials of Does and Schedule of Zio-101 (S-Dimethylarsino-Glutathione) in Multiple Myeloma,” PO-609, Haematologica, International Myeloma Workshop, 92(s2) (2007).

295. **Berenson JR**, Patel R and Swift R, “Phase I Trial of Bortezomib (VEL) + Samarium (SAM) in MM,” PO-623, Haematologica, International Myeloma Workshop, 92 (s2) (2007).

296. **Berenson JR**, Woytowicz D, Flam M, Cartmell A, Patel R, and Swift R, “Bortezomib + Ascorbic Acid + Melphalan Upfront Therapy,” PO-719, Haematologica, International Myeloma Workshop, 92 (s2) (2007).

297. Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon MS, Pang S, Bonavida B, Said J, Plowman GD, Fuh G, and **Berenson JR**, “Anti-VEGF Antibody Treatment Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma,” Abstract #846 ASH Annual Meeting Part 1 108:11 (11/16/06).

298. **Berenson JR**, Boccia RV, Hussein MA, Belch A, Boise L, Schwartz B, Gale RP, and Kornblau SM, “Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM),” Abstract #1966 ASH Annual Meeting Part 1 108:11 (11/16/06).

299. **Berenson JR**, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, and Reich SD, “Phase I Study of the [Cu. Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advance Hematologic Malignancies,” Abstract #2593 ASH Annual Meeting Part 1 108:11 (11/16/06).

300. Hussein MA, **Berenson JR**, Niesvizky, Munshi NC, Matous J, Harrop K, and Drachman JG,

“Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma,” Abstract #3576 ASH Annual Meeting Part 1 108:11 (11/16/06).

301. **Berenson JR**, Dimopoulos MA, and Chen YM, “Zoledronic Acid May Improve Survival Compared to Pamidronate in Patients with MM and High BALP Levels: Univariate and Multivariate Models of Hazard Ratios,” Abstract #3589 ASH Annual Meeting Part 1 108:11 (11/16/06).

302. **Berenson JR**, “Improving Myeloma Care: Preserving Functional Independence with Bisphosphonates and Advancing Treatment Through Deacetylase Inhibition/Emerging Evidence for Zoledronic Acid Benefits,” Haematologica, International Myeloma Workshop Kos Island Greece (6/25/07).

303. **Berenson JR**, “The Role of Bisphosphonates in the management of Myeloma,” Haematologica, International Myeloma Workshop Kos Island Greece (6/26/07).

304. **Berenson JR**, “Optimizing Therapy with Zoledronic Acid,” Haematologica, International Myeloma Workshop Kos Island Greece (6/2007).

305. **Berenson JR**, “The Role of Bisphosphonates in the Management of Myeloma,” Abstract S3.3, Haematologica, International Myeloma Workshop, 92(s2) (2007).

306. Shalitin D, Campbell R, Share DM, Sanchez E, Steinberg J, Chen H, Li M, Wang C, Bonavida B, Said J, and **Berenson JR**, “Aberrant PTEN in MM Monocytes: Role in MM Angiogenesis,” Poster Session: PO-230, International Myeloma Workshop Kos Island Greece (6/2007).

307. **Berenson JR**, Jagannath S, Reece D, Boccia R, Soebel R, Belch A, Schwartz R, Gate P, and Hussein M, “ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma,” J Clin Oncol, *JCO*.2007; 18Sv25 (468s).

308. **Berenson JR**, “The Role of Bisphosphonates in the Management of Myeloma,” Haematologica: The Hematology Journal 92(s2): S3.3 (2007).

309. Shalitin D, Campbell R, Share DM, Sanchez E, Steinberg J, Chen H, Li M, Wang C, Bonavida B, Said J, and **Berenson JR** “Aberrant Pten in MM Monocytes: Role in MM Angiogenesis,” Haematologica: The Hematology Journal 92(s2): PO-230 (2007).

310. **Berenson JR**, Dimopoulos M, and Chen YM, “Zoledronic Acid and Survival in Patients with High BALP,” Haematologica: The Hematology Journal 92(s2): PO-326 (2007).

311. Campbell R, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, and **Berenson JR**, “The mTOR Inhibitor RAD001 (everolimus) Inhibits Myeloma Tumor,” Haematologica: The Hematology Journal 92(s2): PO-535 (2007).

312. Chen H, Campbell RA, Li M, Wang CS, Shalitin D, Sanchez E, Steinberg J, Gui D, Said J, Chang Y, Deuel TF, Bonavida B, and **Berenson JR**, “Inhibiting Pleiotrophin Reduces MM and Endothelial Growth,” Haematologica: The Hematology Journal 92(s2): PO-540 (2007).

313. Campbell, R, Sanchez E, Steinberg J, Chen H, Shalitin D, Li M, Wang C, Pang S, Bonavida B, Said J, Richon V, and **Berenson JR**, “In Vivo Effects of Vorinostat in Combination with Bortezomib,” *Haematologica: The Hematology Journal* 92(s2): PO-543 (2007).
314. **Berenson JR**, Jagannath S, Boccia R, Sobecks R, Belch A, Schwartz B, Gale RP, and Hussein M, “Phase-1/-2 Trials of Dose and Schedule of ZIO-101 (S-dimethylarsino-glutathione) in Multiple Myeloma,” *Haematologica: The Hematology Journal* 92(s2): PO-609 (2007).
315. **Berenson JR**, Patel R, and Swift R, “Phase I Trial of Bortezomib (VEL) + Samarium (SAM) in MM,” *Haematologica: The Hematology Journal* 92(s2): PO-623 (2007).
316. **Berenson JR**, Woytowicz D, Flam M, Cartmell A, Patel R, and Swift R, “Bortezomib + Ascorbic Acid + Melphalan Upfront Therapy,” *Haematologica: The Hematology Journal* 92(s2): PO-719 (2007).
317. Yellin O, Crowley J, Swift R, Duvivier H, Nassir Y, and **Berenson JR**. “Factors that Determine Overall Survival Among Patients with Multiple Myeloma Treated with Zoledronic Acid.” *Clin Exp Metastasis, Proceedings of Skeletal Complications of Malignancy V*, Philadelphia, PA, 25 Suppl:2008: Abstract # S32:29 (October 25-27, 2007).
318. **Berenson JR**, Patel R, Yellin O, and Swift RA, “Phase I Trial of Bortezomib and Samarium Sm 153 Lexidronam in Refractory and Relapsed Multiple Myeloma,” *Chemotherapy Foundation Symposium XXV, Cancer Investigation*, 25(S1):33 (November 2007).
319. Terpos E, Cook R, Coleman R, Lipton A, and **Berenson JR**, “Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 1482 (11/ 2007).
320. **Berenson JR**, Cook R, Lipton A, Coleman R, and Terpos E, “Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 1499 (11/16/2007).
321. Chen H, Li M, Campbell R, Wang CS, Li J, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Chang Y, Bonavida B, Deuel TF, and **Berenson JR**, “Wnt/ β -Catenin Signaling is Essential for the Transdifferentiation of Monocytes into Endothelial Cells by mCSF and Pleiotrophin,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 1512 (11/ 2007).
322. Chen H, Li M, Li J, Campbell RA, Wang CS, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Bonavida B, and **Berenson JR**, “Blockage of TRAF6 Signaling Inhibits Osteoclast Formation and Tumor Cell through Blocking the NF- κ B and JNK Pathways in Multiple Myeloma,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 2511 (11/ 2007).

323. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Chen H, Shalitin D, Pang S, Said J, and **Berenson JR**, “The Novel Potent Pan-Deacetylase (DAC) Inhibitor, Panobinostat (LBH589), Markedly Enhances the Anti-Myeloma Effects of Chemotherapy *In Vitro* and *In Vivo*,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 2520 (11/ 2007).
324. Jagannath S, Barlogie B, **Berenson JR**, Siegel D, Irwin D, Richardson P, Niesvizky R, Alexanian R, Limentani S, Alsina M, Esseltine D-L, and Anderson KC, “Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 2717 (11/ 2007).
325. **Berenson JR**, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 3602 (11/ 2007).
326. **Berenson JR**, Yellin O, Boccia RV, Flam MS, Wong S-F, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 3606 (11/ 2007).
327. Chen H, Wang CS, Li J, Campbell RA, Li M, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Chang Y, Bonavida B, Deuel TF, and **Berenson JR**, “Zoledronic Acid Suppresses Vasculogenesis: A New Effect of Bisphosphonates,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 3913 (11/ 2007).
328. Shalitin D, Share M, Campbell RA, Steinberg J, Sanchez E, Wang J, Leuchter R, Li M, Wang CS, Chen H, and **Berenson JR**, “The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 4800 (11/ 2007).
329. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Leuchter R, Chen H, Shalitin D, Pang S, Said J, and **Berenson JR**, “The mTOR Inhibitor RAD001 (everolimus) Inhibits Myeloma Tumor Growth *In Vivo* and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 4801 (11/ 2007).
330. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Leuchter R, Chen H, Shalitin D, Pang S, Said J, Plowman GD, and **Berenson JR**, “An Anti-VEGF Antibody, in Combination with Bortezomib, Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 4802 (11/ 2007).

331. **Berenson JR**, Yellin O, Crowley J, Duvivier H, Nassir Y, and Swift RA, “Factors that Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 4842 (11/ 2007).
332. Baritaki S, Huerta-Yeppez S, Yeung K, Penichet M, Chen H, Shalitin D, **Berenson J**, and Bonavida B, “Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP Is Common in MM Tumor Cells,” 2007 American Society of Hematology (ASH) Meeting Abstracts, *Blood*, Part I, Vol. 110, Issue 11, Abstract# 4852 (11/ 2007).
333. Chen H, Li M, Campbell R, Wang CS, Li J, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Chang Y, Bonavida B, Deuel TF, and **Berenson JR**, “Wnt/ β -Catenin Signaling is Essential for the Transdifferentiation of Monocytes into Endothelial Cells by mCSF and Pleiotrophin.” American Society of Hematology 49th Annual Meeting, Abstract # 955081, 2007.
334. **Berenson JR**, Yellin O, Crowley J, Duvivier H, Nassir Y, and Swift RA, “Factors that Determine Overall Survival Among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.” American Society of Hematology 49th Annual Meeting, Abstract # 955145, 2007.
335. **Berenson JR**, Yellin O, Boccia RV, Flam MS, Wong S-F, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.” American Society of Hematology 49th Annual Meeting, Abstract # 956660, 2007.
336. Chen H, Li M, Li J, Campbell RA, Wang CS, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Bonavida B, and **Berenson JR**, “Blockage of TRAF6 Signaling Inhibits Osteoclast Formation and Tumor Cells by Blocking the NF κ B and JNK Pathways in Multiple Myeloma.” American Society of Hematology 49th Annual Meeting, Abstract # 955114, 2007.
337. Chen H, Wang CS, Li J, Campbell RA, Li M, Sanchez E, Steinberg J, Share M, Shalitin D, Wang J, Xie S-J, Chang Y, Bonavida B, Deuel TF, and **Berenson JR**, “Zoledronic Acid Suppresses Vasculogenesis: A New Effect of Bisphosphonates.” American Society of Hematology 49th Annual Meeting, Abstract # 955129, 2007.
338. **Berenson JR**, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-tolerated Frontline Regimen.” American Society of Hematology 49th Annual Meeting, Abstract # 956738, 2007.
339. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Chen H, Shalitin D, Pang S,

Said J, and **Berenson JR**, “The Novel Potent Pan-Deacetylase (DAC) Inhibitor, Panobinostat (LBH589) Markedly Enhances the Anti-Myeloma Effects of Chemotherapy *In Vitro* and *In Vivo*.” American Society of Hematology 49th Annual Meeting, Abstract # 956119, 2007.

340. Shalitin D, Share M, Campbell RA, Steinberg J, Sanchez E, Wang J, Leuchter R, Li M, Wang CS, Chen H, and **Berenson JR**. “The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects,” American Society of Hematology 49th Annual Meeting, Abstract # 956599, 2007.

341. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Leuchter R, Chen H, Shalitin D, Pang S, Said J, and **Berenson JR**, “The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth *In Vivo* and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide,” American Society of Hematology 49th Annual Meeting, Abstract # 956659, 2007.

342. Campbell RA, Sanchez E, Steinberg J, Share M, Wang J, Li M, Leuchter R, Chen H, Shalitin D, Pang S, Said J, Plowman GD, and **Berenson JR**, “An Anti-VEGF Antibody, in Combination with Bortezomib, Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma,” American Society of Hematology 49th Annual Meeting, Abstract # 956675, 2007.

343. Jagannath S, Barlogie B, **Berenson JR**, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine D-L, and Anderson KC, “Updated Survival Analyses After Prolonged Follow-up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.” American Society of Hematology 49th Annual Meeting, 2007.

344. Baritaki S, Huerta-Yepez S, Yeung KC, Penichet M, Chen H, Shalitin D, **Berenson JR**, and Bonavida B. “Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM) Compared to Other Tumor Types: Overexpression of RKIP and a Phosphorylated RKIP is Common in MM Tumor Cells.” American Society of Hematology 49th Annual Meeting, 2007.

345. Major P, **Berenson JR**, Vescio R, Ravera C, Skerjanec A, Bilic S, Gauron S, and Schran H, “Effects of zoledronic acid dose and infusion rate on pharmacokinetics, pharmacodynamics, and renal function in patients with bone metastases from prostate cancer,” EAU abstract (submitted).

346. Major P, **Berenson JR**, Vescio R, Ravera C, Skerjanec A, Bilic S, Gauron S, and Schran H, “Effects of zoledronic acid dose and infusion rate on pharmacokinetics, pharmacodynamics, and renal function in patients with bone metastases from prostate cancer,” AUA abstract 11/14/07 version (submitted).

347. Major P, **Berenson JR**, Vescio R, Ravera C, Skerjanec A, Bilic S, Gauron S, and Schran H, “Zoledronic acid (ZOL) dose infusion rate: pharmacokinetics (PK), pharmacodynamics (PD), and renal function in patients with bone metastases from prostate cancer (PC),” EAU (submitted).

348. Vrionis FD, Tillman JB, Hussein MA, Pflugmacher R, Jarzem P, Zonder J, and **Berenson JR**, Balloon Kyphoplasty Improves Both Roland-Morris Disability Scores and Bone Pain Among Cancer Patients with Vertebral Compression Fractures: Interim Analysis of Results from a Phase IV Randomized Trial, (CAFE) (2008).

349. **Berenson JR**, “New Treatments and Combination Strategies for Myeloma Bone Disease,” Advances in Treating Metastatic Bone Cancer: Second Cambridge Conference, April 4-5, 2008.
350. **Berenson JR**, Belch A, Reece D, Limentani S, Miller D, and Boccia R, “Evaluation of Two Parnaparin (S-dimethylarsino-glutathione) Schedules in Multiple Myeloma,” American Society of Clinical Oncologists (2008).
351. **Berenson JR**, Yellin O, Boccia RV, Flam MS, Wong S, Batuman O, Moezi MM, Woytowitz DV, Duvivier HL, Nassir Y, and Swift R, “Marked Improvement in Bone Mineral Density (BMD) for Patients (pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) using Zoledronic Acid (ZOL), J Clin Oncol. 26: 2008 (May 20 suppl; Abstr 8550).
352. Baritaki S, Huerta-Yepez S, Cabera-Munoz MDL, Rivera-Pazos C, **Berenson JR**, and Bonavida B. “Unique Pattern of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM): RKIP Overexpression and RKIP Phosphorylation is Common in MM Tumor Cells.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 2729:943 (December 2008).
353. Huerta-Yepez S, Rivera-Pazos C, Libra M, Baritaki S, Chen H, **Berenson JR**, and Bonavida B. “Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) Among Patients with Multiple Myeloma (MM).” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 2730:943 (December 2008).
354. Campbell RA, Sanchez E, Steinberg J, Shalitin D, Chen H, and **Berenson JR**, “Vorinostat Enhances the Anti-myeloma Effects of Melphalan and Bortezomib *In Vitro* and *In Vivo*,” 2008 American Society of Hematology Annual Meeting Abstract, 112(11): 843 (December 2008).
355. **Berenson JR**, Ervin T, Boccia RV, Batuman O, Swift R, Abaya CD, Mazar AP, Gordon GS, Reich SD, and Callahan JA, “Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib,” Blood (ASH Annual Meeting Abstracts) 112: 5185 (December 2008).
356. Chen H, Li M, Sanchez E, Wang CS, Berenson AM, Li J, Steinberg JA, Wang J, Shen J, Li Z-W, Bonavida B, and **Berenson JR**, “Characterization of Cancer Stem Cells in Multiple Myeloma.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 495:188 (December 2008).
357. Sanchez E, Campbell RA, Steinberg JA, Li M, Chen H, Bonavida B, and **Berenson JR**, “The Novel Proteasome Inhibitor CEP-18770 Inhibits Myeloma Tumor Growth *In Vivo* and Enhances the Anti-MM Effects of Melphalan.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 843:312 (December 2008).
358. **Berenson JR**, Tillman JB, Hussein MA, Pflugmacher R, Jarzem P, Exmouth S, and Vrionis FD. “Balloon Kyphoplasty Improves Both Roland-Morris Disability Scores and Bone Pain Among Cancer Patients with Vertebral Compression Fractures: Interim Analysis of Results from a Phase IV Random

Trial.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 3695:1266 (December 2008).

359. Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson AM, Steinberg JA, Chen H, Shen J, Li Z-W, Bonavida B, and **Berenson JR**. “A Novel Method for Screening Anti-Angiogenic Compounds: The Chorioallantoic Membrane (CAM)/Feather Bud (FB) Assay.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 1896:663 (December 2008).

360. Sanchez E, Steinberg J, Li, M, Chen H, Bonavida B, Deitcher SR, Hagey AE, and **Berenson JR**. “In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 2760:952-953 (December 2008).

361. Martinez-Paniagua M, Vega MI, Huerta-Yepez S, Baritaki S, **Berenson JR**, Hariharan H, and Bonavida B. “Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF- κ B Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 3623:1239-1240 (December 2008).

362. Paniagua MM, Vega MI, Huerta-Yepez S, Gonzalez B, Suarez V, Baritaki S, **Berenson JR**, and Bonavida B, “Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF- κ B Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1),” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11):Abstract # 4976 (December 2008).

363. Baritaki S, Chapman A, Wu K, Yeung K, Spandidos D, **Berenson JR**, Palladino MA, and Bonavida B, “The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-a Kinase Inhibitor Protein RKIP in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11) Abstract #2611:904-905 (December 2008).

364. Li Z-W, Shalitin D, Shen J, Share M, Li M, Wang CS, Sanchez E, Steinberg JA, Chen H, Bonavida B, and **Berenson JR**. “A Novel Targeted Therapeutic Approach to Multiple Myeloma Using Tumor Specific Anti-Sense RNA Sequences.” 2008 American Society of Hematology Annual Meeting Abstracts, 112(11): Abstract # 2727:942 (December 2008).

365. Baritaki S, Huerta-Yepez S, Cabera-Muñoz MdL, Rivera-Pazos C, Waterman B, Yeung K, Chen H, **Berenson JR**, and Bonavida B, “Unique Patterns of Raf-1 Kinase Inhibitory Protein (RKIP) Expression in Multiple Myeloma (MM): RKIP Overexpression and RKIP Phosphorylation is Common in MM Tumor Cells,” Blood (ASH Annual Meeting Abstracts), 112(11): Abstract # 2729 (December 2008).

366. Huerta-Yepez S, Rivera-Pazos C, Libra M, Baritaki S, Chen H, **Berenson JR**, and Bonavida B, “Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang I (YYI) Among Patients with Multiple Myeloma (MM),” Blood (ASH Annual Meeting Abstracts) 112: Abstract # 2730 (December 2008).

367. Suzuki E, Oya M, **Berenson JR**, Bonavida B, and Umezawa K, “In vitro and in vivo Anti-neoplastic Activity of Specific NF- κ B Inhibitor DHMEQ on Human Multiple Myeloma,” Blood (ASH Annual Meeting Abstracts), 112: Abstract # 4473 (December 2008).
368. Campbell RA, Sanchez E, Steinberg J, Share M, Li M, Chen H, Pang S, Said J, and **Berenson JR**, “The Potent Histone Deacetylase (HDAC) Inhibitor, Vorinostat, In Combination with Melphalan, Markedly Enhances the Anti-Myeloma Effects of Chemotherapy *In Vitro* and *In Vivo*,” Proceedings of the American Association of Cancer Research (AACR) Abstract # 733 (April 2008).
369. Baritaki S, Yeung K, Chatterjee D, Waterman B, Chen H, **Berenson JR**, Palladino M, Bonavida, Proceedings of the American Association of Cancer Research (AACR) Abstract # 2572 (April 2008).
370. **Berenson JR**, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Duvivier H, Nassir Y, Sefaradi A, Shamouelian A, and Swift RA, “Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL).” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 9: Abstract # 088 (February 2009).
371. Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson AM, Steinberg J, Chen H, Shen J, Li Z, Bonavida B, and **Berenson JR**, “A Novel Angiogenesis Model for Screening Anti-angiogenic Compounds,” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 103: Abstract # 202 (February 2009).
372. **Berenson JR**, Tillman JB, Hussein MA, Pflugmacher R, Jarzem P, Elmoufti S, and Vrionis FD. “A Phase III Trial of Kyphoplasty Versus Nonsurgical Care for Cancer Patients with Vertebral Fractures.” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 28: Abstract # 204 (February 2009).
373. Terpos E, **Berenson JR**, Lipton A, Coleman R, and Cook R. “High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma.” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 50: Abstract # 345 (February 2009).
374. **Berenson JR**, Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson AM, Steinberg J, Chen H, Shen J, Li Z, and Bonavida B. “A Novel Angiogenesis Model for Screening Antiangiogenic Compounds.” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 103: Abstract # 202 (February 2009).
375. **Berenson JR**, Campbell RA, Steinberg J, Li M, Chen H, Sanchez E, and Bonavida B. “Efficacy of CEP-18770 on Myeloma Growth.” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 104: Abstract # 205 (February 2009).
376. Mitsiades C, Richardson PG, Grant S, Pei X-Y, **Berenson JR**, Richon V, Garcia-Vargas J,

Rizvi S, and Anderson KC. “Vorinostat in Combination with Other Anti-MM Agents.” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 110: Abstract # 257 (February 2009).

377. Taylor-Harding B, **Berenson JR**, Miller C, Karlan BY, Orsulic S, and Walsh C, “Cyclin E Overexpressing Ovarian Cancers Demonstrate an Enhanced Response to the Proteasome Inhibitor Bortezomib,” Proceedings of the American Association of Cancer Research (AACR), Abstract # 4611 (April 2009).

378. **Berenson JR**, Yellin O, Mapes R, Eades B, Abaya CD, Strayer A, Nix D, and Swift RA, “A Phase II Study of a 1-hour Infusion of Romidepsin Combined with Bortezomib for Multiple Myeloma (MM) Patients with Relapsed or Refractory Disease.” J Clin Oncol 27 (supp): Abstract # e19508 (2009).

379. Yellin O, Crowley J, Swift RA, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, and **Berenson JR**, “Factors that determine overall survival among patients with multiple myeloma (MM) treated with zoledronic acid (ZOL).” J Clin Oncol 27 (supp): Abstract # e19519 (2009).

380. Waterman GN, Yellin O, Swift RA, Hilger J, and **Berenson JR**, “A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone for relapsed and refractory (R/R) multiple myeloma.” J Clin Oncol 27 (supp): Abstract # e19523 (2009).

381. **Berenson JR**, “Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma (MM): Current Phase I/II Combinations Using IMiD Compounds and Proteasome Inhibitors as Backbone,” Lymphoma & Myeloma 2009 (October 22-24, 2009).

382. Steinberg JA, Shen J, Sanchez E, Chen H, Li Z-W, Hilger J, and **Berenson JR**, “Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract #3832:1474-1475 (December 2009).

383. Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li Z-W, Chen H, and **Berenson JR**, “Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 1840:730-731 (December 2009).

384. Chen H, Hao R, Sanchez E, Shen J, Li M, Wang J, Wong E, Adler A, Hu M, Leung C, Wang C, Li Z-W, Bonavida B, and **Berenson JR**, “Pterostilbene: A Novel Histone Deacetylase 1 Inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract #3844:1478-1479 (December 2009).

385. Li M, Sanchez E, Li J, Wang C, Shen J, Hu M, Leung C, Wang J, Wong E, Adler A, Li Z-W, Chen H, Bonavida B, and **Berenson JR**, “TRAF6-Dominant Negative Peptides Show Potent Inhibitory Effects on Multiple Myeloma, Osteoclast Formation and Bone Resorption,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract #611:253 (December 2009)

386. Wirtschafter E, Wong E, Li M, Sanchez E, Wang C, Li J, Kessler R, Hu M, Leung C, Li Z-W, Chen H, Bonavida B, and **Berenson JR**, “Pleiotrophin is Highly Produced by Solid Tumors and Transdifferentiates Human Monocytes into Endothelial Cells,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 3050:1187-1188 (December 2009).
387. **Berenson JR**, Pflugmacher R, Jarzem P, Zonder JA, Tillman JB, Ashraf T, and Vrionis F, “Final Results of the First Randomized Trial Comparing Balloon Kyphoplasty (BKP) to Non-Surgical Management Among Cancer Patients with Vertebral Compression Fractures: Marked Improvement in Back Function, Quality of Life and Pain in the BKP Arm,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract #2873: 1121-1122 (December 2009).
388. Li Z-W, Shalitin D, Finefield J, Leung C, M Hu, Shen J, LI M, Wang C, Steinberg JA, Sanchez E, Chen H, William RM, Bonavida B, and **Berenson JR**, “Multiple Myeloma – Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 1851:735 (December 2009).
389. **Berenson JR**, Yellin O, Boccia RV, Nassir Y, Rothstein S, and Swift R, “A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM),” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 1855:736 (December 2009).
390. Huerta-Yepez S, Vega MI, Rivera-Pazo C, Martinez-Maza O, **Berenson JR**, and Bonavida B, “Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin’s Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 1932:766 (December 2009)
391. Baritaki S, Yeung K, Wu K, Chen H, **Berenson JR**, Palladino MA, and Bonavida B, “Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 3938:1514 (December 2009)
392. Li Z-W, Hu M, Leung C, Steinberg JA, Shen J, Li M, Wang C, Sanchez E, Bowers A, Greshock T, Miller K, Newkirk T, West N, Bradner JE, Williams R, Bonavida B, Chen H, and **Berenson JR**, “Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22):Abstract # 4925 (December 2009).
393. Li Z-W, Leung C, Hu M, Xiang J, Jian C, Steinberg JA, Shen J, Li M, Wang C, Sanchez E, Bonavida B, Chen H, Bai X, and **Berenson JR**, “CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 4927 (December 2009).
394. **Berenson JR**, Donahue DJ, Yellin O, Upadhyaya G, Nassir Y, and Swift RA, “A Randomized

Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 4234 (December 2009).

395. **Berenson JR**, Yellin O, Patel R, Chen C-S, Boccia RV, Colbourn D, Yang H, Gupta V, Geils GF, Nassir Y, Hilger J, and Swift R, “A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM),” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract # 4936 (December 2009).

396. Huerta-Yepe S, Militello L, Baritaki S, Rivera Pazos CM, Cabrera-Munoz MDL, Vega MI, Libra M, Malaponte G, Canevari S, Castellano G, Chen H, and **Berenson JR**, “Clinical Significance of YY1 overexpression in Human Hematopoietic Malignancies,” 2009 American Society of Hematology Annual Meeting Abstracts, Blood 114(22): Abstract #1932 (December 2009).

397. **Berenson JR**, “HDAC Inhibitors: Uncovering a New Way to Enhance the Efficacy of Anti-Myeloma Drugs,” presented at the Chemotherapy Foundation Symposium XXVII Abstracts of Innovative Cancer Therapy for Tomorrow in Current Treatment Options in Oncology 2009.

398. Taylor-Harding B, **Berenson J**, Miller C, Karlan B, Orsulic S, and Walsh C, “The Natural Dietary Phytochemical Indole-3-carbinole (I3C) Sensitizes Ovarian Cancer Cells to the Proteasome Inhibitor Bortezomib through Inhibition of Cyclin E Activity,” Proc American Association for Cancer Research (submitted for the 2010 meeting).

399. **Berenson JR**, Yellin O, Chen C, Patel R, Bessudo A, Boccia RV, Yang H, Gupta V, Hilger J, and Swift RA, “A Phase II Study of a Modified Pegylated Liposomal Doxorubicin (PLD), Bortezomib, and Dexamethasone for Patients with Previously Untreated Multiple Myeloma (MM),” J Clin Oncol, presented at ASCO meeting, Abstract# 8134 (June 2010).

400. Pflugmacher R, **Berenson JR**, Jarzem P, Zonder J, Tillman JB, Ashraf T, and Vronis FD, “Final Results of the First Randomized Trial Comparing Balloon Kyphoplasty (BKP) to Non-Surgical Management among Cancer Patients with Vertebral Compression Fractures,” EuroSpine 2010 Annual Meeting, in press.

401. Sanchez E, Li M, Wang C, Li Z-W, Chen H, Hilger J, Hibner B, and **Berenson JR**, “Using SCID-hu Models to Evaluate the Sequencing of Bortezomib Therapy for Multiple Myeloma (MM),” 2010 American Society of Hematology Annual Meeting Abstract # 28772, Blood 116:5012 (November 2010).

402. Sanchez E, Mingjie Li M, Wang C, de Castro-Abeger A, Li Z-W, Chen H, and **Berenson JR**, “Anti-Myeloma and Anti-Angiogenic Effects of the Novel Anthracycline Derivative INNO-206,” 2010 American Society of Hematology Annual Meeting, Abstract # 28779, Blood 116:4065 (November 2010).

403. Sanchez E, Li M, Wang C, Li Z-W, Chen H, and **Berenson JR**, “Efficacy and Tolerability of

CEP-18770 in Combination with Dexamethasone and Lenalidomide Using a SCID-hu Model of Multiple Myeloma (MM),” 2010 American Society of Hematology Annual Meeting, Abstract # 28784, Blood 116:4066 (November 2010).

404. Chen H, Mingjie Li M, Wang C, Wang J, Sanchez E, Li Z-W, Benjamin Bonavida B, Levy O, Dassa L, Cojocaru G, Levine Z, and **Berenson JR**, “Multiple Myeloma (MM) Highly Express CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib,” 2010 American Society of Hematology Annual Meeting, Abstract # 28787, Blood 116:4067 (November 2010).

405. Li M, Sanchez E, Wang CS, Schultz M, Wang J, Wong E, Li Z, Chen H, Bonavida B, Chou E, and **Berenson JR**, “Blockage of TRAF6 by Dominant Negative Peptides Inhibits Multiple Myeloma (MM) Cell Proliferation and Osteoclast Formation through NF- κ B, JNK and AKT Signal Transduction Pathway,” 2010 American Society of Hematology Annual Meeting, Abstract # 28789, Blood 116:4068 (November 2010).

406. Li Z-W, Ramirez D, Sanchez E, Wang C, Li M, Li J, Chen H, and **Berenson JR**, “Synergistic Anti-Myeloma Effects of the Lyn Kinase Inhibitor INNO-406 in Combination with Melphalan, Doxorubicin and Bortezomib,” 2010 American Society of Hematology Annual Meeting, Abstract # 28792, Blood 116:5015 (November 2010).

407. Chen H, Yu YH, Sanchez E, Li M, Liu H, Wang CS, Cueto J, Li Z-W, Bonavida B, and **Berenson JR**, “Pterostilbene is an Inhibitor of Histone Deacetylase (HDAC) 1 and Shows Marked Anti-Multiple Myeloma (MM) Effects Alone and Enhances the Anti-MM Activities of Both Bortezomib and Melphalan,” 2010 American Society of Hematology Annual Meeting, Abstract # 28797, (November 2010) (e-published).

408. Li J, Mingjie Li M, Wang CS, Wang J, Sanchez E, Li Z, Bonavida B, Chen H, and **Berenson JR**, “Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to Fc γ RIIb Reduces Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) Signaling Provides the Rationale for a Novel Therapeutic Approach to MM2010,” American Society of Hematology Annual Meeting, Abstract # 28798, Blood 116:455 (November 2010).

409. **Berenson JR**, Yellin O, Cartmell A, Woliver T, Flam M, Nassir Y, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), “Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” American Society of Hematology Annual Meeting, Blood 116:4936 (November 2010).

410. Mario I. Vega, Melisa Martinez-Paniagua, Sara Huerta-Yepez, Hari Hariharan, Chen H, **Berenson J**, and Bonavida B, “The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bclxl) by Galiximab (anti-CD80 mAb) in the Reversal of Resistance of B-NHL Cells to Chemotherapy,” American Society of Hematology Annual Meeting, Blood 116:4068 (November 2010).

411. Vega MI, Huerta-Yepez S, Martínez-Paniagua M, Baritaki S, Chen H, **Berenson JR**, and

Bonavida B, “Reversal of Drug/TRAIL-resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab,” American Society of Hematology Annual Meeting, Blood 116:4931 (November 2010).

412. Baritaki S, Suzuki E, Vega M, Chen H, **Berenson J**, and Bonavida BA, “Rituximab Inhibits the PI3K/Akt Survival Pathway in B-NHL Cells via Induction of the PTEN Tumor Suppressor: Pivotal Roles of the Inhibition of the PTEN Repressors Snail and YY1,” American Society of Hematology Annual Meeting, Blood 116:3152 (November 2010).

413. **Berenson JR**, Yellin O, Blumenstein B, and Philbeck T, “Rotary-Powered Bone Marrow Access Results in Shorter Procedure Time, Larger Core Specimens and Less Residual Pain for Patients,” Society of Interventional Radiology (submitted).

414. Chen H, Sanchez E, Wang CS, Li M, LI J, Delijani KD, Li Z, Bonavida B, Levitt D, and **Berenson JR**, “The Tyrosine Kinase Inhibitor bafentinib (INNO-406) Inhibits Osteoclast Formation and Bone Resorption,” Proceedings of the American Association for Cancer Research Annual Meeting, 2011.

415. **Berenson JR**, Yellin O, Bessudo A, Boccia R, Noga S, Garvenor D, Patel-Donnelly D, Siegel R, Kewalramani T, Gorak E, Swift R, and Bensen-Kennedy D, “An Open-Label, Phase 1/2 trial of Bendamustine Plus Bortezomib in Relapsed/Refractory Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).

416. **Berenson JR**, Yellin O, Kazamel T, Boccia R, Matous J, Dressler K, Nassir Y, Rothstein S, and Swift, R, “A Phase I/II Study of Oral Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).

417. **Berenson JR**, Yellin O, Kazamel T, Cartmell A, Woliver T, Flam M, Nassir Y, Vescio R, and Swift R, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).

418. Chen H, HuaYu Y, Sanchez E, Li M, Liu H, Wang C, Husain S, Bonavida B, and **Berenson JR**, “Pterostilbene is a Novel Histone Deacetylase 1 inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma,” International Myeloma Workshop (submitted for the 2011 meeting).

419. Chen H, Sanchez E, Wang C, Li M, Li J, Delijani K, Bonavida B, Levitt D, and **Berenson JR**, “The Tyrosine Kinase Inhibitor Bafetinib (INNO-406) Inhibits Osteoclast Formation and Bone Resorption,” International Myeloma Workshop (submitted for the 2011 meeting).

420. Li J, Li M, Wang C, Wang J, Sanchez E, Bonavida B, Chen H, and **Berenson J**, “Low FcγRIIb Binding Ability in Multiple Myeloma (MM) Cells Reduces Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) Signaling,” International Myeloma Workshop (submitted for the 2011 meeting).

421. Yellin O, **Berenson JR**, Kazamel T, Chen C-S, Cartmell A, Woliver T, Flam M, Bravin E,

Nassir Y, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol, presented at ASCO meeting, 29:524s, abstract #8082 (June, 2011).

422. **Berenson JR**, Yellin O, Bessudo A, Boccia, Noga S, Gravenor D, Patel-Donnelly D, Siegel R, Kewalramani T, Gorak E, Swift R, and Bensen-Kennedy D, “Efficacy and Safety of Bendamustine Plus Bortezomib in Relapsed/Refractory Multiple Myeloma: A Phase I/II Trial,” J Clin Oncol, presented at ASCO meeting, 29:521s, abstract #8070, (June 2011).

423. Kazamel T, **Berenson JR**, Yellin O, Boccia RV, Matous J, Dressler KA, Nassir Y, Rothstein S, and Swift R, “A Phase I/II Study of Oral Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol, 29: abstract e18574 (June 2011).

424. **Berenson JR**, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, Patel-Donnelly D, Siegel R, Kewalramani T, Gorak E, Swift R, and Bensen-Kennedy D, “An Open-Label, Phase 1/2 trial of Bendamustine Plus Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma,” European Hematology Association (submitted for the 2011 meeting).

425. Niesvizky R, Lonial S, Kumar S, Bensinger W, Baz R, Jakubowiak A, Zimmerman T, **Berenson JR**, Wang M, Reeder C, Liu G, Hui A-M, Berg D, Gupta N, and Richardson P, “Evaluation of Twice-Weekly and Weekly Dosing of the Investigational Agent MLN9708, an Oral Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1 Dose-Escalation Studies,” European Hematology Association (submitted for the 2011 meeting).

426. Li J, Leu A, Li M, Hobel E, Delijani K, Qiu J, Ramirez D, Lam A, Wang C, Sanchez E, Bonavida B, Chen H, and **Berenson JR**, “Frequent Dysregulation of Fc Gamma Receptor IIb (FcγRIIb) and Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) Signaling Occurs in Multiple Myeloma (MM) Patients,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1258 Abstract 2917 (December 2011).

427. Sanchez E, Nichols C, Lam A, Li M, Li J, Wang C, Beveridge C, Lista J, Chen H, and **Berenson JR**, “Efficacy and Tolerability of CEP-18770 in Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model of Multiple Myeloma (MM),” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1271 Abstract 2946 (December 2011).

428. Chen H, Li M, Li J, Dreyer M, Ahles C, Lee T, Qiu J, Wang C, Sanchez E, Bonavida B, Levy O, Dassin L, Cojocaru G, Levine Z, and **Berenson JR**, “Blockage of CGEN-928 Expression Down-Regulates AKT Signaling Pathway and Inhibits Multiple Myeloma (MM) Cell Proliferation,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118: Abstract (December 2011).

429. Li M, Dreyer M, Ahles C, Ramirez D, Nichols C, Lee T, Song M, Wang C, Sanchez E, Chen H, Bonavida B, and **Berenson JR**, “TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma,” American

Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1258-1259 Abstract 2919 (December 2011).

430. Vega M, Aviles-Salas A, Chaliapin R, Huerta-Yepez S, Hernandez-Pando R, Martinez-Managua M, Martinez-Miguel B, Hernandez-Atenogenes M, Verga G, Chen H, **Berenson JR**, Mayani H, and Bonavida B, “Association of the Activation of the p38 MAPK Pathway in Patients with DLBCL Who Are Unresponsive to CHOP,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1137 Abstract 2647 (December 2011).

431. Huerta-Yepez S, Baritaki S, Liu H, Mandez-Maldonado K MC, Penichet M, Verga M, Chen H, **Berenson JR**, Chatterjee D, and Bonavida B, “The Overexpression of Inactive Phosphorylated Raf-1 Kinase Inhibitory Protein (RKIP) in Multiple Myeloma (MM) Regulates the Resistance of Bortezomib-induced Cytotoxicity: Reversal of Resistance by the PKC Inhibitor Bisindolylmaleimide,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1248 Abstract 2892 (December 2011).

432. Liu H, Huerta-Yepez S, Rivera-Pazon C, Cabrera-Munoz M, Baritaki S, Vardanyan S, Penichet M, Chen H, **Berenson JR**, and Bonavida B, “Targeting the Over-Expressed Transcription Factor Ying-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:1708 Abstract 3991 (December 2011).

433. Kumar S, Bensinger W, Reeder C, Zimmerman T, **Berenson JR**, Berg D, Liu G, Gupta N, Bacco A, Hui A, and Niesvizky R, “Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results from a Phase 1 Dose-Escalation Study,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:371 Abstract 816 (December 2011).

434. **Berenson JR**, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, Patel-Donnelly D, Siegel R, Kewalramani T, Gorak E, Swift R, and Mayo D, “Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 118:808-809 Abstract 1857 (December 2011).

435. Van Meirhaege J, Papanastassiou J, Phillips FM, **Berenson JR**, Andersson G, Aghev K, and Vrionis FD, “Comparing Effects of Kyphoplasty, Vertebroplasty, and Nonsurgical Management in a Meta-analysis of Randomized and Nonrandomized Studies,” International Society for the Advancement of Spine Surgery meeting in Barcelona, Spain, presented in March 2012.

436. **Berenson JR**, Yellin O, Boccia R, Matous J, Dressler K, Jamshed, Kingsley, Harb, Noga, Nassir, and Swift R, “A Phase 1/2 Trial of Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol, submitted for ASCO meeting 2012.

437. Kumar Shaji, Bensinger W, Reeder C, Zimmerman T, **Berenson JR**, Guohui L, Berg D, Gupta

N, Di Bacco A, Hui A, and Niesvizky R, “Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN908 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM): A Phase 1 Study,” J Clin Oncol, submitted for ASCO meeting 2012.

438. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Robinson A, Madden E, Okjovat J-P, Waterman GN, Swift RA, Bonavida B, and **Berenson JR**, “Evaluation of Serum B-Cell Maturation Antigen in Multiple Myeloma,” J Clin Oncol, submitted for ASCO meeting 2012 (abstract e18549).

439. **Berenson JR**, Yellin O, Dichmann R, Patel-Donnelly D, Boccia R, Hilger J, Nassir Y, Swift R, and Vescio R, “A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Progressing While Receiving a Bortezomib-Containing Combination Regimen,” J Clin Oncol, submitted for ASCO meeting 2012 (abstract 8098).

440. Olafsson G, Mesterton J, **Berenson JR**, Vrionis F, and Alvares L, “Balloon Kyphoplasty Increases Quality of Life in Cancer Patients with Vertebral Compression Fractures,” ISPOR, presented at the 15th Annual European Congress, Abstract 38983 (November 2012).

441. Sanchez E, Li M, Wang C, Chen H, and **Berenson JR**, “Anti-Myeloma Effects of Carfilzomib with Cyclophosphamide (CY) or Bendamustine (Ben),” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 2952 (November 2012).

442. Sanchez E, Li M, Wang C, Chen H, Johnson DM, Lannutti BJ, and **Berenson JR**, “Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 4017 (November 2012).

443. Sanchez E, Li M, Kitto A, Li J, Wang CS, Rauch D, Delijani K, DeCorso K, Prajogi A, Chen H, and **Berenson JR**, “Serum levels of B-cell maturation antigen are elevated in multiple myeloma patients and correlate with disease status and overall survival,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 4026 (November 2012).

444. Chen H, Li J, Delijani K, Rauch D, DeCorso K, Prajogi A, Wang C, Sanchez E, Bonavida B, and **Berenson JR**, “Decreased LIMD1 Gene Expression Is Associated with HIF-1 Over-Expression and Angiogenesis in Multiple Myeloma,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 1829 (November 2012).

445. **Berenson JR**, Hilger J, Klein L, Eshaghian S, Nassir Y, Swift R, and Vescio R, “A Phase ½ Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin in Patients with Relapsed/Refractory Multiple Myeloma,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 2979 (November 2012).

446. **Berenson JR**, Hilger J, Dischmann R, Patel-Donnelly D, Boccia R, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift R, and Vescio R, “A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-

Containing Combination Regimen,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 4063 (November 2012).

447. **Berenson JR**, Hilger J, Dichman R, Patel-Donnelly D, Boccia R, Bessudo A, Stampelman L, Gravenor D, Eshaghian S, Chamras H, Nassir Y, Swift R, and Vescio R, “Multiple Myeloma (MM) Patients (Pts) Progressing While Receiving a Bortezomib (BTZ)-Containing Combination Regimen Frequently Respond When Carfilzomib (CFZ) Replaces BTZ: A Phase I/II Study,” J Clin Oncol 31, 2013 (suppl; Abstr 8599)

448. Hilger J, **Berenson JR**, Klein L, Bessudo A, Rosen P, Eshaghian S, Chamras H, Nassir Y, Swift R, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol 31, 2013 (suppl; Abstr 8598)

449. Kumar S, Bessinger W, Zimmerman T, Reeder C, **Berenson JR**, Berg D, Hui A, Gupta N, Bacco A, Yu J, Shou Y, and Niesvizky R, “Weekly MLN9708, An Investigational Oral Proteasome Inhibitor (PI), in Relapsed/Refractory Multiple Myeloma (MM): Results from a Phase I Study After Full Enrollment,” J Clin Oncol 31, 2013 (suppl; Abstr 8514)

450. Robinson AA, Kitto AZ, Cheema SK, Madden EK, Norberg AS, Fors DH, Diehl JW, Waterman GN, Hilger JD, Swift R, and **Berenson JR**, “Risk of Skin Cancer in Multiple Myeloma Patients: A Retrospective Cohort Study,” J Clin Oncol 31, 2013 (suppl; Abstr e20044)

451. **Berenson JR**, Klein L, Rifkin R, Patel P, Dixon S, Ou Y, and Cartnell A, “A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib in Combination with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):1934 (November 2013).

452. Pogue S, Taura T, Bi M, Mikesell G, Yun Y, Sho A, Sanchez E, Chen H, **Berenson JR**, and Wilson D, “Arming an Anti-CD38, Myeloma-Targeting Antibody with An Attenuated IFN α Provides >10,000-Fold Enhanced Tumor-Specific Activity Compared to Native IFN α ,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):1956 (November 2013).

453. Chen H, Li M, Vardanyan S, Gottlieb J, Wang C, Delijani K, Ben-Zvi J, Song M, Halleluyan R, Sanchez E, Bonavida B, and **Berenson JR**, “Increased M2 Macrophages and Higher Levels of the Tribble Family Member Trib1 in Monocytes are Associated with Progressive Disease in Multiple Myeloma (MM) Patients,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):3127 (November 2013).

454. **Berenson JR**, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Y, Swift RA, and Vescio R, “Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1/2 Trial,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):3218 (November 2013).

455. Li M, Vardanyan S, Gottlieb J, Wang C, Delijani K, Halleluyan R, Ben-Zvi J, Song M, Sanchez

E, Bonavida B, Chen H, and **Berenson JR**, “Higher TRAF6 and Fbox 3 Expression is with Progressive Multiple Myeloma and Blockage of TRAF6 Inhibits Tumor Growth and Bone Resorption,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):5362 (November 2013).

456. Sanchez E, Li M, Vardanyan S, Gottlieb J, Delijani K, Ben-Zvi J, Song M, Halleluyan R, Wang C, Chen H, and **Berenson JR**, “Carfilzomib Platform Study Using the LAGK-1A Multiple Myeloma Xenograft Model,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):4452 (November 2013).

457. Sanchez E, Li M, Vardanyan S, Gottlieb J, Delijani K, Ben-Zvi J, Song M, Halleluyan R, Wang C, Chen H, and **Berenson JR**, “Immunosuppression in Multiple Myeloma: The Evolving Role of Circulating BCMA,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122 Abstract 64617 (November 2013).

458. **Berenson JR**, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Y, Swift RA, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” J Clin Oncol 32, 2014 (suppl; Abstr e19586^).

459. **Berenson JR**, Klein L, Rifkin RM, Patel P, Dixon S, Ou Y, and Cartmell A, “Results of the Dose-Escalation Portion of a Phase I/II Study (CHAMPION-1) Investigation Weekly Carfilzomib in Combination with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma,” J Clin Oncol 32:5s, 2014 (suppl; Abstr 8594^).

460. Berenson A, Vardanyan S, Ghermezi M, Harutyunyan NM, Gottlieb J, Halleluyan R, Andreu-Vieyra C, Swift RA, and **Berenson JR**, “Lack of Significance of ISS Staging and Depth of Response in Predicting Overall Survival of Multiple Myeloma Patients,” Blood 124(21):5771 (December 2014).

461. Ghermezi M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Andreu-Vieyra C, Sanchez E, Swift RA, and **Berenson JR**, “Serum B-Cell Maturation Antigen Is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival,” Blood 124(21):3405 (December 2014).

462. Ravenborg N, Udd K, Berenson A, Costa F, and **Berenson JR**, “Vitamin D Levels Are Frequently Below Normal in Multiple Myeloma Patients and Are Infrequently Assessed by Their Treating Physicians,” Blood 124(21):5769 (December 2014).

463. Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Tang G, Sanchez E, Li M, Wang C, Ben-Zvi J, Garzio G, Chen H, Finlay J, and **Berenson JR**, “Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients,” Blood 124(21):2125 (December 2014).

464. Sanchez E, Li M, Gillespie A, Harutyunyan, Garzio G, Ben-Zvi J, Gottlieb J, Tang G, Wang C, Chen H, and **Berenson JR**, “Carfilzomib Overcomes Resistance to Bortezomib in the Human Lagk-1A Multiple Myeloma Xenograft Model,” Blood 124(21):5720 (December 2014).

465. Sanchez E, Gillespie A, Harutyunyan NM, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang C, Ben-Zvi J, Garzio G, Finlay J, Bonavida B, Chen H, and **Berenson JR**, “Circulating BCMA Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients,” *Blood* 124(21):4713 (December 2014).
466. **Berenson JR**, Bitran JD, Tabbara I, Lutzky J, Stampleman LV, Ailawadhi S, Steis R, and Moezi MM, “A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients Upon Retreatment with Bortezomib,” *Blood* 124(21):3469 (December 2014).
467. **Berenson JR**, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam MS, Eshaghian S, Nassir Y, Swift RA, and Vescio R, “A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma,” *Blood* 124(21):3469 (December 2014).
468. Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, Vardanyan S, Harutyunyan NM, Garzio G, Tang G, Bonavida B, and **Berenson JR**, “Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids,” *Blood* 124(21):2114 (December 2014).
469. Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, Vardanyan S, Harutyunyan NM, Garzio G, Tang G, Bonavida B, and **Berenson JR**, “Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib,” *Blood* 124(21):4106 (December 2014).
470. **Berenson JR**, Klein L, Rifkin RM, Patel P, Dixon S, Ou Y, and Cartmell A, “A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib in Combination with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma,” *Blood* 124(21):3654 (December 2014).
471. **Berenson JR**, Stampleman L, Bessudo A, Rose PJ, Klein L, Woliver T, Flam M, Eshaghian S, Nassir Y, Swift RA, Wang J, Benjamin E, Spektor TM, and Vescio R, “a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” *Blood*. 124(21):4774 (December 2014).
472. Pogue SL, Taura T, Bi M, Mikesell G, Yun Y, Sho E. Sanchez E, Chen H, **Berenson JR**, and Wilson D, “Anti-38-Attenkine™: A Myeloma-Targeting Immunocytokine with Engineered IFN α that Provides up to 100,000-fold Enhanced Tumor-Specific Activity Compared to Native IFN α ,” AACR Special Meeting on Hematologic Malignancies, 2014.
473. Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang CS, Ben-Zvi J, Garzio G, Bonavida B, Chen H, and **Berenson JR**, “Soluble BCMA Binds BAFF Resulting in Immune Deficiency in Multiple Myeloma Patients,” *Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis)* 7(s1) p62 (April 2015).

474. Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang C, Ben-Zvi J, Garzio G, Chen H, and **Berenson JR**, “Circulating BCMA Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients,” Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis) (April 2015).
475. Vardanyan S, Sanchez E, Li M, Wang C, Gillespie A, Spitzer M, Shvartsur A, Harutyunyan N, Garzio G, Tang G, Said J, Chen H, and **Berenson JR**, “Tumor Cells from Waldenstrom’s Macroglobulinemia Patients Express B-Cell Maturation Antigen and Its Serum Levels Correlate with Disease Status and Conventional M-Protein and IgM Levels,” Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis) (April 2015).
476. Ghermezi M, Vardanyan S, Harutyunyan N, Gottlieb J, Berenson A, Spitzer M, Andreu-Vieyra C, Sanchez E, Chen H, and **Berenson JR**, “Serum B-Cell Maturation Antigen Is a New Marker to Track Multiple Myeloma Patients,” Hematology Reports (7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis) (April 2015).
477. Harutyunyan N, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Tang G, Sanchez E, Li M, Wang C, Ben-Zvi J, Garzio G, Chen H, Finlay J, and **Berenson JR**, “Levels of Uninvolved and Involved Immunoglobulin Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients,” Hematology Reports 2015; 7 (s1) pg 25.
478. **Berenson JR**, Harutyunyan N, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Li M, Wang C, Tang G, Sanchez E, Ben-Zvi J, Garzio G, and Chen H, “Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients,” (20th Congress of the European Hematology Association Meeting) (Abstract release date May 21, 2015) EHA Learning Center. Berenson J. Jun 12, 2015; 102918 (May 2015).
479. **Berenson JR**, Ghermezi M, Vardanyan S, Harutyunyan N, Spitzer M, Gottlieb J, Berenson A, Andreu-Vieyra C, Li M, Wang C, Sanchez E, Swift RA, and Chen H, “Serum B-Cell Maturation Antigen is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival,” (20th Congress of the European Hematology Association Meeting) (Abstract release date May 21, 2015) EHA Learning Center. Berenson J. Jun 12, 2015; 100543 (May 2015).
480. **Berenson JR**, Vardanyan S, Sanchez E, Li M, Wang C, Gillespie A, Spitzer M, Shvartsur A, Harutyunyan N, Garzio G, Tang G, Said J, and Chen H, “Waldenstrom’s Macroglobulinemia Express B-Cell Maturation Antigen and Serum Levels Correlate with Disease Status and Conventional M-Protein and IgM Levels,” (20th Congress of the European Hematology Association Meeting) (Abstract release date May 21, 2015) EHA Learning Center. Berenson J. Jun 12, 2015; 102911 (May 2015).
481. **Berenson JR**, Cartmell A, Lyons R, Harb W, Tzachanis D, Boccia R, Rifkin R, Patel P, Dizon S, and Berdeja J, “Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858),” (Chinese Society of Clinical Oncology Annual Meeting) (September 2015).
482. Vardanyan S, Sanchez E, Li M, Wang C, Gillespie A, Spitzer M, Shvartsur A, Harutyunyan

NM, Garzio G, Tang G, Said J, Chen H, and **Berenson JR**, “Waldenstrom’s Macroglobulinemia Express B-Cell Maturation Antigen and Serum Levels Correlate with Disease Status and Conventional M-Protein and IgM Levels,” AACC Annual Meeting pS134 – Abstract A-384 (2015).

483. Sanchez E, Gillespie A, Harutyunyan NM, Tag G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang CS, Ben-Zvi J, Garzio G, Chen H, and **Berenson JR**, “Circulating BCMA Binding to its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients,” AACC Annual Meeting pS79 – Abstract A-222 (2015).

484. Vardanyan S, Ghermezi M, Harutyunyan N, Gottlieb J, Berenson A, Andreu-Vieyra C, Sanchez E, Swift R, Chen H, and **Berenson JR**, “Serum B-Cell Maturation Antigen Is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival,” AACC Annual Meeting pS126 – Abstract A-355 (2015).

485. Shah J, Niesvizky R, Stadtmauer E, Rifkin RM, **Berenson JR**, Berdeja J, Sharman J, Lyons R, Klippel Z, Chang Y, and Usmani S, “Oprozomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results of a Phase 1b/3 Study (NCT01999335),” Blood 126(23):378 (December 2015).

486. Shah J, Niesvizky R, Stadtmauer E, Rifkin R, **Berenson J**, Berdeja J, Sharman J, Lyons R, Klippel Z, Wong H, Chang Y, and Usmani S, “Oprozomib, Pomalidomide, and Dexamethasone (OPOMD) in Patients (PTS) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1B Study (NCT01999335),” Haematologica 2015; 100[suppl 1]:abstr P646; Hari, Haematologica 2015;100[suppl 1]:abstr P653.(May 2015).

487. Shah J, Niesvizky R, Stadtmauer E, Rifkin R, **Berenson J**, Berdeja J, Sharman J, Lyons R, Klippel Z, Wong H, Chang Y, and Usmani S, “Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858),” Haematologica 2015; 100[suppl 1]:abstr P269; Hari, Haematologica 2015;100[suppl 1]:abstr P269.(May 2015).

488. Vardanyan S, Meid K, Udd KA, Wang J, Li M, Sanchez E, Wang C, Gillespie A, Spitzer M, Spektor TM, Shvartsur, Harutyunyan NM, Garzio G, Tang G, Chen H, Treon SP, and **Berenson JR**, “Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenstrom’s Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels,” Blood 126(23):1778 (December 2015).

489. Udd KA, Rassenti LZ, David ME, Wang J, Vardanyan S, Linesch J, Li M, Sanchez E, Chen H, Spektor TM, Kipps TJ, and **Berenson JR**, “Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia,” Blood 126(23):2931 (December 2015).

490. Tang G, Li M, Sanchez E, Wang C, Vardanyan S, Lee T, Nosrati J, Cao J, Zahab M, Mehta P, Garzio G, Chen H, and **Berenson J**, “SNP rs34172460 (A258A) A in Gene CIP2A Correlates with Bortezomib Resistance in Multiple Myeloma Patients,” Blood 126(23):5333 (December 2015).

491. Chen H, Li M, Sanchez E, Gillespie A, Wang C, Lee T, Vardanyan S, Nosrati J, Cao J, Zahab M, Mehta P, Tang G, and **Berenson JR**, “Crosslinking of Fc Gamma-RIIb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway,” *Blood* 126(23):2995 (December 2015).
492. Chen H, Li M, Sanchez E, Gillespie A, Wang C, Lee T, Vardanyan S, Nosrati J, Cao J, Zahab M, Mehta P, Garzio G, Tang G, and **Berenson JR**, “Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization,” *Blood* 126(23):1011 (December 2015).
493. Sanchez E, Li M, Gillespie A, Mehta P, Vardanyan S, Garzio G, Tang G, Wang C, Chen H, and **Berenson JR**, “Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice,” *Blood* 126(23):5349 (December 2015).
494. Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang C, Ben-Zvi J, Garzio G, Chen H, and **Berenson JR**, “Soluble BCMA in Myeloma Serum Binds its Ligands BAFF and Prevents Normal Antibody Production in Multiple Myeloma Patients,” *Blood* 126(23):1799 (December 2015).
495. **Berenson JR**, Cartmell A, Lyons R, Harb W, Tzachanis D, Agajanian R, Boccia RV, Coleman M, Moss RA, Rifkin RM, Schupp M, Dixon S, Ou Y, Anderl J, and Berdeja JG, “Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion 1 (NCT01677858),” *Blood* 126(23):373 (December 2015).
496. Shvartsur A, Chatterjee D, Chen H, **Berenson JR**, Garban H, and Bonavida B, “A Bioinformatics Approach Revealed a Differential Expression of RKIP-related Genes in Premultiple Myeloma and Multiple Myeloma: Clinical Implications,” *Blood*. 2015. 126(23):5309 (December 2015).
497. Maglione PJ, Li M, Sanchez E, Chen H, Radigan L, **Berenson JR**, and Cunningham-Rundles C, “Reduced Serum BCMA Levels Distinguish Patients with Primary Antibody Deficiency,” *J Immunol* 196 (1 Supplement) 193.7 (May 1, 2016).
498. Sanchez E, Li M, Wang C, Mehta P, Tang G, Chen H, and **Berenson JR**, “Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Standard of Care Agents in Human Multiple Myeloma (MM) Cell Lines and Xenograft Models,” *AACR; Cancer Res* 2016;76(14 Suppl): Abstract nr 1339 (2016).
499. Sanchez E, Gillespie A, Harutyunyan N, Tang G, Gottlieb J, Vardanyan S, Li M, Andreu-Vieyra C, Ghermezi M, Wang C, Ben-Zvi J, Garzio G, Chen H, and **Berenson JR**, “Soluble BCMA in Serum Binds BAFF Causing Immune Deficiency in Multiple Myeloma,” *Clin Lab Sci* May-June 2016 46:315-333. (May 2016).
500. **Berenson JR**, Udd K, Spektor T, Wang J, Sanchez E, Tang G, Wang C, Li M, Chen H, Maglione PJ, and Cunningham-Rundles C, “Serum B-Cell Maturation Antigen is a Biomarker for Patients with B-cell Disorders,” *Ann Clin Lab Sci* May-June 2016 46:315-333. (May 2016).

501. **Berenson JR**, Sanchez E, Li M, Tang G, Wang C, and Chen H, “Soluble BCMA Binds its Ligand BAFF and Prevents Normal Antibody Production in Multiple Myeloma Patients,” (European Hematology Association 21st Congress Meeting) (Abstract release date: May 19,2016) EHA Learning Center. Berenson J. Jun 11, 2016; 133533.
502. **Berenson JR**, Udd K, Spektor T, Wang J, Sanchez E, Tang G, Wang C, Li M, Chen H, Maglione, P, and Cunningham-Rundles C, “Serum B-Cell Maturation Antigen is a Biomarker for Patients with B-Cell Disorders,” (European Hematology Association 21st Congress Meeting) (Abstract release date: May 19, 2016) EHA Learning Center. Berenson J; 132839 (Jun 9, 2016).
503. Udd K, Chen H, Li M, Soof C, Casas C, Etessami S, Gross Z, Ghermezi M, Wang J, Sanchez E, Wang C, Emmy-Sadr M, Swift R, and **Berenson JR**, “Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator for Patients with Multiple Myeloma,” Blood.; 128(22):5654 (2016).
504. Gross Z, Udd K, Ghermezi M, Etessami S, Chen H, Spektor T, Li M, Tang G, Wang CS, Sanchez E, Soof C, Casas C, Swift R, and **Berenson JR**, “Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels are Associated with Refractory Disease and Shortened Progression Free Survival,” Blood. 128(22):5652 (2016).
505. Chen H, Li M, Sanchez E, Wang C, Udd KA, Soof C, Casas C, Cao J, Wang J, Hekmati T, DeCorso K, Tang G, and **Berenson JR**, “Gene Expression of Gamma Secretase (GS) Complex-Related Proteins, the Enzyme That Sheds B-cell Maturation Antigen (BCMA), among Patients with Multiple Myeloma (MM) and Effects of the GS Inhibitor LSN424354 on Solubilized BCMA in MM and Chronic Lymphocytic Leukemia,” Blood. 128(22):5641 (2016).
506. Berdeja J, Rifkin R, Lyons R, Yang H, Zahlten-Kumeli A, Aggarwal, S, Iskander K, and **Berenson JR**, “Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure,” Blood. 128(22):2129 (2016).
507. Boccia R, Bessudo A, Agajanian R, Conkling P, Harb W, Hang H, Pinchasik D, Kimball A, and **Berenson JR**, “A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2),” Blood. 128(22):3325 (2016).
508. Ali SM, Leitzel K, Li M, Udd K, Wang J, Sanchez E, Chen H, **Berenson JR**, and Lipton A, “Reduced Serum B-cell Maturation Antigen Levels Predict Poor Outcome in Metastatic Breast Cancer Patients in a Phase 3 Randomized 2nd-line Hormone Therapy Trial,” Presented at: SABCS/CTRC/AACR Breast Cancer Symposium, Abstr P1-02-10 (Dec 7, 2016).
509. Berdeja JG, Rifkin RM, Lyons R, Cartmell A, Harb WA, Coleman M, Yang H, Zahlten-Kuemeli A, Iskander K, and **Berenson JR**, “Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma by Prior Lines of Therapy: Secondary Analysis from the CHAMPION-1 Study (NCT01677858),” International Myeloma Workshop, India, Abstract Book, p e19 (March 2017).

510. Udd K, Chen H, Li M, Soof C, Casas C, Etessami S, Gross Z, Ghermezi M, Wang J, Sanchez E, Wang C, Emmy-Sadr M, Swift R, and **Berenson JR**, “Changes in Serum B-Cell Maturation Antigen Levels are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma,” International Myeloma Workshop, India, Abstract Book, p e27 (March 2017).
511. Sanchez E, Porter A, Li M, Wang C, Smith E, Soof C, Director C, Tang G, Chen H, and **Berenson JR**, “Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents in Vitro and in Vivo,” International Myeloma Workshop, India, Abstract Book p e71 (March 2017).
512. Chen H, Li M, Wang C, Sanchez E, Soof C, Udd K, Director C, Cao J, Tang G, and **Berenson JR**, “Increase in M2 Macrophage Polarization in Multiple Myeloma Bone Marrow is Inhibited with the JAK2 Inhibitor Ruxolitinib Which Shows Anti-MM Effects,” International Myeloma Workshop, India, Abstract Book, p e133 (March 2017).
513. **Berenson JR**, “The Role of Serum BCMA in Monitoring, Predicting Outcomes and Immune Deficiency of Multiple Myeloma,” Third Annual Immuno-Therapy in Myeloma Scientific Workshop. Philadelphia, PA (May 2017).
514. **Berenson JR**, Cohen A, Spektor TM, Bitran T, Chen G, Moezi M, Bessudo A, Ye J, Hager S, Moss R, Cartmell A, Coleman T, Hrom J, Swift RA, and Lim S, “Replacement of Ixazomib for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Bortezomib or Carfilzomib-Containing Combination Therapy,” JCO. 2017. 35, no. 15 suppl 8013-8013 (May 2017).
515. **Berenson JR**, Cohen A, Spektor TM, Lashkari A, Mackintosh R, Bessudo A, Robinson M, Jhangiani H, Gabrail N, Nakhoul I, Kubba S, Neidhart J, Maluso T, Swift RA, and Vescio R, “Analysis of Efficacy and Safety of POM as a Replacement for Lenalidomide for Relapsed/Refractory Multiple Myeloma Pts Refractory to a Lenalidomide-Containing Regimen,” J Clin Onco. 35:e19528 (2017).
516. Bujarski S, Udd K, Soof CM, Chen H, Li M, Sanchez E, Stern J, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, and **Berenson JR**, “Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status among Multiple Myeloma Patients undergoing New Treatments,” Blood. 130:4371 (2017).
517. Sun C, Soof CM, Taneja A, Cook E, Udd K, Chen H, Sanchez E, Tian X, **Berenson JR**, and Wiestner A, “Serum B-Cell Maturation Antigen as a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib,” Blood. 130:4031 (2017).
518. Chen H, Li M, Sanchez E, Soof CM, Patil S, Udd K, Zhou M, Hekmati T, Wang EY, Tanenbaum EJ, Schlossberg R, Yashar MA, Wang CS, Tang GY, and **Berenson JR**, “Effects of the Gamma Secretase Inhibitors (GSI) DAPT (GSI-IX) and LSN424354 on Gene Expression and Shedding of BCMA from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells,” Blood. 130:5390 (2017).
519. Chen H, Li M, Sanchez E, Soof CM, Patil S, Udd K, Zhou M, Hekmati T, Wang EY,

Tanenbaum EJ, Schlossberg R, Yashar MA, Wang CS, Tang GY, and **Berenson JR**, “Serum sBCMA May Interfere with Anti-BCMA-CAR-Transduced T Cells or Other Anti-BCMA Antibody-Based Immunotherapy in Multiple Myeloma,” *Blood*. 130:4413 (2017).

520. **Berenson JR**, Cohen A, Spektor TM, Lashkari A, Mackintosh R, Bessudo A, Robinson M, Jhangiani H, Gabrail N, Nakhoul I, Kubba S, Neidhart J, Maluso T, Swift RA, and Vescio R, “Efficacy and Safety of Pomalidomide as a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen,” *Blood*. 130:3106 (2017).

521. Sanchez E, Li M, Wang C, Tanenbaum EJ, Patil S, Soof CM, Schlossberg R, Yachar MA, Hekmati T, Porter A, Tang G, Chen H, and **Berenson JR**, “Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the LAGk-1A Multiple Myeloma Xenograft Model,” *Blood*. 130:5393 (2017).

522. Mateos M-V, Moreau P, **Berenson JR**, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK, “Once-Weekly Versus Twice-Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma: Results of the Randomized Phase 3 Study Arrow (NCT02412878),” *The Lancet Oncology*. 19(7):953-964 (2015).

523. **Berenson JR**, To J, Spektor TM, Turner C, Swift RA, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, Vescio R, “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients,” *J Clin Oncol*. 36:8005 (2018).

524. **Berenson JR**, Cohen, A, Spektor TM, Lashkari A, Mackintosh R, Bessudo A, Robinson M, Jhangiani H, Gabrail N, Nakhoul I, Kubba S, Neidhart J, Maluso T, Swift RA, and Vescio R, “Efficacy and Safety of Pomalidomide as a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen,” *Journal of Clinical Oncology*. 36(15) (2018).

525. Bujarski S, Soof C, Chen H, Li M, Sanchez E, Wang CS, Emamy-Sadr M, Swift RA, Rahbari KJ, Patil S, Spektor TM, and **Berenson JR**, “Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Responses among Relapsed or Refractory Multiple Myeloma Patients Treated on the Phase I IRUX Trial,” *J Clin Oncol*. 36:e24313 (2018).

526. Mateos MV, Moreau P, **Berenson JR**, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, and Stewart AK, “Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing plus Dexamethasone (d) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W.,” *J Clin Oncol*. 36:8000 (2018).

527. Mateos MV, Moreau P, **Berenson JR**, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, and Stewart AK, “Once-Weekly vs Twice-Weekly Carfilzomib Dosing plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W.,” for ENCORE – Brazilian Congress of Hematology, Hemotherapy and Cell Therapy (HEMO), São Paulo (July 2018).

528. Mateos MV, Moreau P, **Berenson JR**, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, and Stewart AK, “Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing plus Dexamethasone (d) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W.,” *European Hematology Association*. 214544:s849 (2018).
529. Parameswaran H, Schroeder M, **Berenson JR**, Jakubowiak A, Kaufman JL, Voorhees PM, Fujii H, Yang Z, Galimi F, and Shain KH, “A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma,” *Blood*. 132:803 (2018).
530. Bujarski S, Soof C, Chen H, Li M, Sanchez E, Wang C, Enemy-Sadr M, Swift R, Rahbari K, Patil S, Spektor T, and **Berenson JR**, “Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone,” *Blood*. 132:1894 (2018).
531. **Berenson JR**, To J, Spektor TM, Turner C, Swift RA, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Bessudo A, Patel R, Lim S, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients,” *Blood*. 132:1988 (2018).
532. Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Cao J, Hekmati T, Tanenbaum EJ, Zahab B, Wang CS, Tang GY, Xu N, and **Berenson JR**, “The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids,” *Blood*. 132:1910 (2018).
533. Bensinger W, Raptis A, **Berenson JR**, Spira AI, Nooka AK, Chaudhry M, Elassaiss-Schaap J, Lo J, Nair N, Walling J, and Hari P, “Phase I/II Safety and Pharmacokinetics of BION-1301 Targeting APRIL, a Proliferation-Inducing Ligand, in Adults with Relapsed or Refractory Multiple Myeloma,” *Cancer Res* July 1, 2019 (79) (13 Supplement).
534. Soof CM, Parikh SA, Slager SL, Rabe KG, Ghermezi M, Spektor T, Kay NE, and **Berenson JR**, “B-Cell Maturation Antigen as a Prognostic Marker for Untreated Chronic Lymphocytic Leukemia,” *J Clin Oncol* 37, 2019 (suppl; abstr 7525).
535. **Berenson JR**, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift A, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Y, Patel R, Bessudo A, Lim S, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Lenalidomide, and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” *J Clin Oncol* 37, 2019 (suppl: abstr 8048).
536. Dispenzieri A, Soof CM, Rajkumar V, Gertz M, Kumar S, Bujarski S, Kyle R, and **Berenson JR**, “Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM),” *J Clin Oncol* 37, 2019 (suppl: abstr 8020).
537. **Berenson JR**, Martinez D, Spektor TM, Sanchez A, Matthew G, Swift RA, Eades B, Schwartz

G, Eshaghian S, Lim S, and Vescio R, “A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients,” American Society of Clinical Oncology Annual Meeting. June 2019. Chicago, IL. (accepted for publication only)

538. Moreau P, Stewart K, Dimopoulos MA, Siegel D, Facon T, **Berenson JR**, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, and Mateos MV, “Once-Weekly (70 mg/m²) Versus Twice-Weekly (56 mg/m²) Dosing of Carfilzomib for Patients with Relapsed and/or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 Trials,” *Hemasphere*. June 2019 (3:p260)

539. Jew S, Chang T, Bujarski S, Chen H, Safaie T, Mingjie L, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Saurabh P, Souther E, and **Berenson JR**, “Normalization of Serum B-Cell Maturation Antigen Levels Predicts Progression Free and Overall Survival in Multiple Myeloma Patients Starting Treatment,” 17th International Myeloma Workshop. September 2019. Boston MA. FP-206, pages 271-272 (2019).

540. Bujarski S, Udd K, Soof C, Chen H, Spektor T, Safaie T, Sanchez E, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, and **Berenson JR**, “Changes in Serum B-Cell Maturation Antigen Levels Rapidly Predict Progression Free Survival Among Multiple Myeloma Patients Undergoing New Treatment,” 17th International Myeloma Workshop. September 2019. Boston MA. FP-205, pages 270-271 (2019).

541. **Berenson JR**, Martinez D, Spektor T, Sanchez A, Ghermezi M, Swift R, Eades B, Schwartz G, Eshaghian S, Lim S, and Vescio R, “A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients,” 17th International Myeloma Workshop. September 2019. Boston MA. SP-087, pages 387-388 (2019).

542. **Berenson JR**, To J, Spektor T, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Y, Patel R, Bessudo A, Lim S, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” 17th International Myeloma Workshop. September 2019. Boston MA. SP-086, pages 386-387 (2019).

543. Chen H, Mingjie L, Xu N, Ng N, Sanchez E, Hekmati T, Wang C, Bujarski S, Tang G, and **Berenson JR**, “Ruxolitinib (RUX) Reverses Checkpoint Inhibition by Downregulating PD-L1 Expression in Both Multiple Myeloma (MM) Tumor and Stromal Cells,” 17th International Myeloma Workshop. September 2019. Boston MA. FP-179, pages 247-248 (2019).

544. Maglione PJ, Ko HM, Tokuyama M, Gyimesi G, Soof C, Li M, Sanchez E, Chen H, Radigan L, and **Berenson JR**, and Cunningham-Rundles C, “Serum B Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies,” European Society for Immunodeficiencies Meeting. September 2019 (2019).

545. Dispenzieri A, Soof C, Rajkumar V, Morie G, Kumar S, Bujarski S, Kyle RA, and **Berenson**

JR, “Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM),” 17th International Myeloma Workshop. September 2019. Boston MA. SP-187, pages 484-485 (2019).

546. **Berenson JR**, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Nassir Y, Patel R, Bessudo A, Greenwald D, Boccia R, Lim S, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” *Blood*. 134 (Supplement 1):1903 (2019).

547. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir I, Huang J, Daniely D, Wang C, Xu N, and **Berenson JR**, “The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma,” *Blood*. 134 (Supplement 1):4352 (2019).

548. Xu N, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir Y, Yu J, Huang J, Daniely D, Wang C, Chen H, and **Berenson JR**, “The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma,” *Blood*. 134 (Supplement 1):1824 (2019).

549. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang C, Xu N, and **Berenson JR**, “Ruxolitinib Reverses Checkpoint Inhibition by Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma,” *Blood*. 134 (Supplement 1):4402 (2019).

550. Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, Li M, Sanchez E, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, and **Berenson JR**, “Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status among Relapsed/Refractory Multiple Myeloma Patients undergoing New Treatments,” *Blood*. 134 (Supplement 1):1786 (2019).

551. Jew S, Chang T, Bujarski S, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Spektor TM, and **Berenson JR**, “Normalization of Serum B-cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients,” *Blood*. 134 (Supplement 1):4393 (2019).

552. Forslund A, Tang H, Duan C, Popa-Mckiver M, **Berenson J**, and Robbins M, “Comparative Analysis of sSLAMF7, sBCMA, and M-protein as Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Patients Treated with Pomalidomide and Dexamethasone +/- Elotuzumab,” *Blood*. 134 (Supplement 1): 1853 (2019).

553. **Berenson JR**, Silagan N, To J, Spektor TM, Martinez D, Sanchez A, Forouzan E, Swift R, Eades B, Schwartz G, Eshaghian S, Boccia R, Yang HH, Lim S, and Vescio RV, “Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM),” *Blood*. 136 (Supplement 1): 36 (2020).

554. Chen H, Li M, Goldwater M, Behare S, Cao J, Wallingford C, Hakmati A, Souther E, Xu Ning, and **Berenson JR**, “Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib,” *Blood*. 138 (Supplement 1): 4709 (2021)
555. Frenkel M, Alteber Z, Xu N, Li M, Chen H, Cojocaru G, **Berenson JR**, Ophir E, “Dominant Expression of DNAM-1 Axis Members in BM of MM Patients,” *Blood*. 138 (Supplement 1): 4717 (2021)
556. **Berenson JR**, Martinez D, Safaie T, Silagan N, To J, Spektor TM, Forouzan E, Swift R, Eades B, Eshaghian S, Schwartz G, Boccia RV, Yang HH, Moezi MM, Lim S, and Vescio R, “Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma,” *Blood*. 138 (Supplement 1):2727 (2021)
557. Yashar D, Regidor BS, Jew S, Bujarski S, Goldwater M, Swift R, Schwartz GE, Eshaghian S, Vescio R, and **Berenson JR**, “Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab,” *Blood*. 138 (Supplement 1): 3785 (2021)
558. Stampfer S, Goldwater M, Regidor BS, Jew SK, Bujarski SE, Chen H, Yashar D, Xu Ning, Li Mingjie, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Feinstein A, and **Berenson JR**, “Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients,” *Blood*. 138 (Supplement 1): 4393 (2021)
559. Chen H, Behare S, Li M, Goldwater M, Wallingford C, Hekmati A, Cao J, Levin R, Xu N, and **Berenson JR**, “Evaluation of Anti-Myeloma Effects of Selinexor Alone and in Combination with Duvelisib *In Vitro* and *In Vivo*,” *American Association of Cancer Research*. 82 (Supplement 12): 4195 (2022)
560. Frenkel M, Alteber Z, Xu N, Li M, Chen H, Cojocaru G, **Berenson J**, and Ophir E, “The Expression of PVRIG and TIGIT Pathway is Dominant in Multiple Myeloma Patients’ Bone Marrow,” *American Association of Cancer Research*. 82 (Supplement 12): 610 (2022)
561. **Berenson JR**, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Shahrooz Eshaghian, Swift R, Eades BM, Bujarski S, Regidor B, Kim C, Kim S, and Vescio R, “Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma,” *Blood*. 140 (Supplement 1): 12610-12611. (2022)
562. Xu N, Li M, Goldwater M, Behare S, Hekmati A, Yu H, Nassir I, Nassir A, Deighton CD, Chen H, and **Berenson JR**, “The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins PVRIG and TIGIT Expression on T cells in Multiple Myeloma Patients,” *Blood*. 140 (Supplement 1):12458 (2022)
563. Chen H, Li M, Goldwater M, Behare S, Hekmati A, Yu H, Nassir I, Nassir A, Deighton CD, Xu N, and **Berenson JR**, “Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-cells by Upregulating IFN γ and GZMB,” *Blood*. 140 (Supplement 1):12459 (2022)

564. Chen H, Souther E, Li M, Goldwater M, Behare S, Hekmati A, Yu H, Nassir I, Nassir A, Xu N, and **Berenson JR**, “Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity,” *Blood*. 140 (Supplement 1):12460-12461 (2022)
565. Chen H, Souther E, Li M, Goldwater M, Behare S, Hekmati A, Nassir I, Nassir A, Xu N, and **Berenson JR**, “Evaluation of Repotrectinib’s Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone *In Vitro* and *Ex Vivo*,” *Blood*. 140 (Supplement 1):4213-4214 (2022)
566. Richardson PG, Amatangelo M, **Berenson JR**, Cerchione C, Dimopoulos M, Toftmann Hansen C, Hwang SJ, Koo P, Kuroda J, Oriol A, Orlowski RZ, Quach H, Raab MS, Rocci A, Wang Y, White D, Yu B, Zhou Z, and Katz J, “A Phase 3 Two-Stage, Randomized Study of Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) versus Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma: SUCESSOR-2.” American Society of Clinical Oncology Annual Meeting, (presented as a poster at the 2024 meeting)
567. Richardson PG, Amatangelo M, **Berenson JR**, Cerchione C, Dimopoulos M, Toftmann Hansen C, Hwang SJ, Koo P, Kuroda J, Oriol A, Orlowski RZ, Quach H, Raab MS, Rocci A, Wang Y, White D, Yu B, Zhou Z, and Katz J, “A Phase 3 Two-Stage, Randomized Study of Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) versus Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma: SUCESSOR-2.” 7th International Congress of Blood and Marrow Transplantation (ICBMT), Busan, South Korea (in press and to be presented at the meeting from 31 August-2 September 2023).
568. **Berenson JR**, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi MM, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BE, Bujarski S, Sebat Y, Ray R, Kim S, and Vescio RA, “A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone,” *Blood*. 142 (Supplement 1): 4753 (2023)
569. Elsayed A, Mettias S, Kim S, Danis R, and **Berenson JR**, “Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis,” *Blood*. 142 (Supplement 1): 5092 (2023)
570. Danis R, Yashar, Bujarski S, Jew S, Swift R, and **Berenson JR**, “Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study,” *Blood*. 142 (Supplement 1): 3369 (2023)
571. Moore JT, Mettias SM, Swift R, Eades B, Eshaghian S, Schwartz G, and **Berenson JR**, “Clinical Outcomes for Unselected, Newly Diagnosed Multiple Myeloma Patients,” American Society of Clinical Oncology Annual Meeting (in press).
572. **Berenson J**, Swift R, Tellez V, Cheung J, Moore J, Pezzullo F, Gette A, Gillis L, Wright A, Gordon K, Hall J, Sayad P, and Morrison B, “mQOL, a Text-based Remote Therapeutic Monitoring (RTM) Platform for Symptom (Sx) and Quality of Life (QoL) Tracking in Multiple Myeloma (MM): Interim Results from a Prospective Observational Study,” International Myeloma Society Meeting 2025 (submitted for presentation).

573. Iliev V, Eliska Spalkova E, Birtwistle J, Howes S, van Heezik R, Malin G, Dutton I, **Berenson J**, Paul Moss S, and Harding S, “Biological variation of soluble B-cell maturation antigen in healthy donors,” Association for Diagnostics & Laboratory Medicine Annual Meeting 2025, Poster A-141, to be presented in July 2025.